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ABSTRACT
The major factor in the development of chronic obstructive airways disease (COPD)
is cigarette smoking, although not all smokers develop chronic obstructive
pulmonary disease. Inflammation and destruction has been shown in the lungs of
smokers with chronic obstructive pulmonary disease. Oxidative stress, both from
cigarette smoke and oxidants generated endogenously by cellular processes,
contribute to the inflammation that occurs in the lungs in chronic obstructive
pulmonary disease. It remains unclear why certain individuals appear susceptible to
the effects of cigarette smoke and go on to develop inflammation and airflow
limitation. The glutathione redox system is an important antioxidant protective
system within the lungs, and this system may play a critical role in the development
of inflammation. An alteration in the transcription of pro-inflammatory cytokines and
mediators is also likely to contribute to the inflammation within the lung. Nuclear
factor kappa-B (NF-kB) and activator protein-1 (AP-1) are both redox sensitive
transcription factors, and are involved in the regulation of the gene transcription of
many pro-inflammatory mediators. Activator protein-1 and nuclear factor kappa-B
have a close relationship with y-glutamylcysteine synthetase (y-GCS) (glutamate
cysteine ligase, GCL), the rate limiting enzyme in the synthesis of glutathione, with
the y-glutamylcysteine synthetase gene containing various elements including an
Activator protein-1 binding site. Susceptibility to the effects of cigarette smoke is
likely to explain why certain individuals develop chronic obstructive pulmonary
disease, and this susceptibility may arise from an earlier viral infection such as
adenoviral infection that lies dormant, but which in the face of an oxidant stimulus
such as cigarette smoke augments the inflammatory process.
The in vivo studies herein have examined glutathione and y-glutamylcysteine
synthetase, gene transcription, oxidant/antioxidant imbalance, the redox sensitive
transcription factors nuclear factor kappa-B and activator protein-1, and have
l
assessed for the presence of the early one adenoviral protein in human lung in
smokers and patients with COPD.
The results show similar levels of total glutathione in the lungs of patients with and
without airflow obstruction, and decreased y-glutamylcysteine synthetase activity in
patients with severe airflow obstruction who have undergone lung volume reduction
surgery for emphysema compared to those with no airflow obstruction. Local lung
oxidative stress as measured by malondialdehyde, and trolox equivalant antioxidant
capacity a marker of systemic oxidative stress did not correlate with lung function.
DNA binding of Nuclear factor kappa-B correlated with lung function as measured
by percent predicted forced expiratory volume in one second (FEVi), however no
such relationship was found with Activator protein-1 DNA binding. Examination for
early one adenoviral gene and protein in human lung tissue failed to reveal
conclusive results.
In conclusion levels of glutathione in human lung tissue, oxidative stress including
both lung and systemic oxidative stress, and the DNA binding of activator protein-1
in lung are not related to the degree of airflow obstruction present.
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1.1 Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a disease, associated with
progressive airflow limitation, which can ultimately lead to respiratory failure and
death. The clinical symptoms of COPD include cough with sputum production and
increasing breathlessness. Chronic bronchitis is defined in clinical terms as cough
with sputum production for most days for 3 months for at least 2 years (chronic
mucous hypersecretion). The symptoms of chronic bronchitis generally predate the
development of airflow obstruction and breathlessness.
The characteristic physiological feature of COPD is airway obstruction, which is
largely fixed (Pauwels et al., 2001). COPD includes emphysema, which is defined
anatomically by permanent, destructive enlargement of airspaces distal to the
terminal bronchioli without evidence of obvious fibrosis, bronchitis and bronchiolitis
(Snider., 1985; Snider., 1989). Airflow obstruction is determined by measuring the
forced expiratory volume in one second (FEVi) and the forced vital capacity (FVC).
The presence of airflow obstruction is defined by an FEVi < 80% predicted and an
FEVi / FVC ratio of < 70% predicted (BTS guidelines 1997). The natural history of
COPD has been described by Fletcher who showed that FEVi declines continuously
with age and that sudden large irreversible falls in FEV i are rare (Fletcher and Peto,
1977). Non-smokers lose FEVi at a slower rate than smokers. Their study identified a
group of smokers who lost FEVi at a faster rate, and in so doing identified a group of
smokers who appeared to be more susceptible to the effects of cigarette smoke.
Elowever, it is not known why certain individuals develop COPD.
The most important factor in the development of COPD is cigarette smoking (Doll et
al., 1994). Not all smokers will go onto develop COPD. The proportion of smokers
that go onto develop clinically significant COPD is approximately 15-20% (Tashkin
et al., 1984), however a more recent report suggests this is higher at around fifty
percent (Lundback et al., 2003). Smoking cessation is the only intervention that can
modify the natural history of COPD (Anthonisen et al., 1994). Traditionally cough
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and sputum have been considered to be less important, and that mortality and
morbidity in those suffering COPD is related to airflow obstruction rather than
mucus hypersecretion (Traver et al., 1979; Wiles et al., 1991; Vestbo et al., 1989).
However, this idea has been challenged in more recent work from the Copenhagen
City Heart Study which demonstrated an association between hypermucus secretion
and mortality and the development of exacerbations of COPD (Pistelli et al., 2003).
FEVi is a powerful predictor of mortality from COPD (Thomason et al., 2000;
Lange et al., 1990), and longitudinal population based studies have shown that
impaired pulmonary function is a strong predictor of increased mortality (Tockman
and Comstock 1989; Hole et al., 1996). Also, the effect that smoking cessation has
on reducing mortality is not just restricted to those with impaired lung function
(Pelkonen et al., 2000).
Clinical airflow obstruction develops from a lengthy and initially asymptomatic
process. In susceptible individuals that go on to develop COPD, a complex
interaction between genetic and environmental factors occurs. There are a number of
questions which remain unanswered with regard to the development of COPD.
Inflammatory responses may be different in susceptible smokers that go onto develop
COPD, or alternatively the protective mechanisms may be impaired.
1.2 The Anatomy of the Human lung
The function of the respiratory system is to extract oxygen from the inhaled air into
the pulmonary circulation, and to eliminate the waste gas carbon dioxide. The
respiratory tract is divided into an upper respiratory tract consisting of nose, pharynx
and larynx, and lower respiratory tract consisting of the airways and the lungs. The
larger, upper airways of the lungs consist of the trachea, main and lower lobe bronchi
and these airways progressively divide into smaller airways, and as they do so the
anatomical structure changes. The larger upper airways the trachea and bronchi
contain cartilage, but the more distal smaller airways or bronchioles are without
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cartilage. In the respiratory bronchiole there are increasing numbers of alveoli, and
the final lung unit is the acinus, in which gaseous exchange takes place.
Within the acinus, the alveolar wall is composed of type I (very thin) and type II
(more cuboidal in shape) alveolar cells, basement membranes, interstitial tissue and
capillary endothelial cells. Type I cells are fewer in number than type II, but because
of their flattened shape have a larger surface area. They are derived from type II cells
and do not undergo mitosis. The function of type I alveolar epithelial cells is for the
diffusion of gas from alveolus to capillary. Type II cells are more numerous than
type I and have microvilli on their surface. Their cytoplasm is rich in mitochondria
and endoplasmic reticulum, and lamellar bodies are present. They are the precursor
of type I cells and they tend to proliferate in acute alveolar injury. Endothelial cells
line the alveolar capillaries.
The bronchial wall consists of mucosa which is pseudostratified, the submucosa and
a fibrocartilaginous layer. Most of the mucosa is covered by ciliated cells (which
convey secretions towards the pharynx), interspersed with non-ciliated cells. Goblet
cells secrete mucin and their numbers reduce in the more distal as the airways. Clara
cells are found predominantly in the bronchioles and distal bronchi and their role is
secretory. The serous cell is a secretory cell and has microvilli present on its surface.
Alveolar macrophages are the main phagocytic cell of the acinus. They are derived
from bone marrow promonocyte stem cells, enter the circulation as monocytes and
reach the lung through the capillary endothelium and are able to penetrate the
alveolar epithelium into the alveolar space. They have phagocytic roles, secretory
and immunological functions.
The inner layer of the alveolar epithelium is separated from the alveolar gas by a thin
layer of surfactant. Surfactant consists of dipalmitoyl lecithin and dipalmotoyl
phosphatidyl ethanolamine and proteins.
The amount ofmucous secreting goblet cells present in the airways decreases as the
alveolus is approached. There are no goblet cells and hence no mucous in the
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alveolus, and the fluid within the alveolus is known as alveolar epithelial lining fluid.
The epithelial lining fluid (ELF) is an important area as it is in direct contact with the
type I and type II cells, and macrophages and may offer protection to these cells from
various stresses.
1.3 Pathological changes in the lungs in COPD
Effects of cigarette smoke on the lungs
In this section the pathology of the airway structure is described with particular
reference to cellular and morphological changes that occur in cigarette smoking and
clinical airflow obstruction.
Cigarette smoke is the major aetiological factor in the development of COPD.
Pathological changes can be found throughout the entire respiratory tract in response
to cigarette smoke (Jeffery, 1998; Cosio et al., 1980; Niewoehner et al., 1974), even
before the development of symptoms of chronic bronchitis or breathlessness.
Niewoehner examined the lungs of healthy people who had died in road traffic
accidents and found an inflammatory reaction in the peripheral airways of smokers
(Niewoehner et al., 1974). Cigarette smoke leads to increased numbers of
macrophages and neutrophils within the airway lumen (MacNee and Selby, 1993;
Kuschner et al., 1996). Chronic smoking leads to an increase in size of the
submucosal glands, an increase in the number of goblet cells in the surface
epithelium, and also the presence of goblet cells in the smaller more distal airways
(mucous metaplasia) (Ebert and Terracio, 1975). In smokers Clara cells are replaced
by mucus secreting cells with the potential for increased amounts of mucus in the
smaller peripheral airways (Ebert and Terracio, 1975). The mucociliary clearance
mechanism is affected by cigarette smoking (Wanner, 1985) with reduction in
numbers of ciliated cells and cilia length. In normal subjects the mucus is in discrete
flakes, but in smokers with bronchitis it is found in a more continuous layer over the
cells. These features lead to pooling of secretions and ultimately to an environment
that favours bacterial growth.
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The precise mechanism for increased mucus production remains unclear. IL-4 is
known to be important in the pathogenesis of asthma and also in airway wall
eosinophilia (Gross et al., 1993, Cho et al., 2005). IL-4 can also induce mucin
production and secretion (Dabbagh et al., 1999), and in smokers with chronic
bronchitis the IL-4 gene is strongly expressed in the inflammatory cell infiltrate in
the bronchial sub-epithelium and the submucous secreting glands (Zhu et al., 2001).
Oxidative stress has also been shown to promote mucus hypersecretion (Takeyama et
al., 2000). It is possible that in the early stages of lung inflammation there is
upregulation of IL-4 and this may be responsible for the clinical symptom of
increased mucus secretion in chronic bronchitis. No difference in m RNA expression
for either IL-4 or IL-5 is found in lung biopsy tissue from healthy non smokers,
patients with COPD and patients having an exacerbation of COPD (Zhu et al., 2001).
Th2 cytokines may have a role in the activation of proteolytic pathways and
contribute to the development of COPD. In an inducible transgenic animal model
with over expression of IL-13, the phenotype resembles that of human COPD (Zheng
et al., 2000).
The protease antiprotease hypothesis of the development of airway inflammation and
subsequent COPD and emphysema postulates that there is a defect in the protective
antiprotease shield. It has been suggested that emphysema is the product of an
abnormal increase in locally produced proteases and/or reduction in pulmonary
antiproteases and in the absence of normal repair, proteolysis leads to increased
tissue destruction and airspace enlargement. Human neutrophil elastase (HNE) is one
such protease, consisting of 267 amino acids and is capable of breaking peptide
bonds with catalytic activity against matrix substrates such as elastin which provide
the structural stability of the lungs. Certainly animal models have shown that
neutrophil elastase contributes to cigarette smoke-induced emphysema in mice
(Shapiro et al., 2003). In the human lung studies of the role of HNE have been
inconsistent with reports ofHNE localized in areas of diseased lung (Damiano et al.,
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1986) and others reporting an inverse relationship of HNE to airspace destruction
(Eidelman et al., 1990). HNE can induce mucin production (Voynow et al., 1999),
and this may occur by virtue of the proteolytic activation of an epidermal growth
factor receptor (EGFR) signaling cascade involving TGF-P (Kohri et al., 2002).
IL-13 may also have a role in the mucus hypersecretion, and increased expression of
IL-13 has been shown in bronchial wall cells of chronic smokers with chronic
bronchitis compared to asymptomatic smokers (Miotto et al., 2003).
The immune system plays a vital role in protecting the respiratory mucosa from
infection, but these systems need to be under tight control so that undesirable effects
do not ensue. The cells involved in this immune response are T cells, and there is a
network of T cells and dendritic cells that present antigen. CD8+ T cells are MHC
class I restricted whereas CD4+ cells respond to antigenic peptides presented to the
MHC class II cleft. MHC I pathway collects antigen present in the cytosol of the cell
such as viral or broken down self proteins. Soluble protein antigens enter the MHC
class II pathway. These two pathways are not completely exclusive when processing
antigen. CD4+ cells can be classified according to the cytokines produced, with
those that secrete interferon y (IFN-y), IL-2, and tumour necrosis-P (TNF-P), but not
IL-4, IL-5, IL-6, and IL-10 or p600 (IL-13) (Th 1) and those that make IL-4, IL-5,
IL-6, and IL-10 and IL13 (Th 2) (Mosmann et al., 1986). CD4+ T cells have a better
survival, less susceptibility to apoptosis and appear to be resistant to cytokine-
induced anergy compared to CD8+ T cells. Thl responses are associated with
infection with pathogenic organisms, but can go on to cause inflammation and
chronic tissue damage.
T Cell Sub-populations in COPD
The inflammatory reaction in COPD may be in part the result of uncontrolled Thl
responses leading to chronic tissue damage. Immunohistochemical examination of
human lung tissue has been helpful in attempting to define pathological changes, and
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T cell types, and inflammatory cell profiles in COPD; although some reports have
shown conflicting results (see table 1.1 for summary of findings).
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Bronchial biopsies from subjects with both mucus hypersecretion and airflow
obstruction have demonstrated significantly higher numbers of T lymphocytes and
macrophages in the bronchial submucosa, but no difference in lymphocyte
subpopulations or in neutrophil counts, compared to those with out airflow
obstruction (di Stefano et al., 1996). In severe airflow obstruction bronchial biopsies
have shown increased neutrophil, macrophage and NK lymphocyte numbers and an
increase in MlP-la positive epithelial cells, but within the subepithelium there was
no significant difference in the numbers of CD3, CD4 and CD8 T lymphocytes
compared to those with no obstruction (di Stefano et al., 1998). A later study by Di
Stefano et al in which bronchial biopsies from patients with severe airflow
obstruction were examined by immunostaining appears to show conflicting results
with reduced numbers of CD-8 and CD-3 lymphocytes compared to the groups with
mild or no airflow obstruction, and reduced CD-3+ cells expressing the chemokine
receptor CCR5 (Di Stefano et al., 2001).
O'Shaughnessy (O'Shaughnessy et al., 1997) examined the sub epithelial zone in
bronchial biopsies and showed an increased numbers of CD3+ T lymphocytes and
CD8+ cells in biopsies from subjects with airflow obstruction compared to normals.
No difference in number of neutrophils, mast cells, eosinphils or B lymphocytes was
found in those with and without airflow obstruction. Examination of bronchial
biopsies in exsmokers with and without airflow obstruction in another study failed to
show a predominance of CD8+ over CD4+ in the submucosa (Rutgers et al., 2000).
It is possible that cigarette smoke has a direct affect on airway CD8+ cells.
Peripheral blood lymphocytes are affected by cigarette smoking (Hughes et al.,
1985) and mild to moderate smokers have been shown to have increased CD4+ and
CD8+, and heavy smokers reduced CD4+.
The above studies have examined bronchial biopsies and so largely represent the
more proximal airways. The subject numbers that made up each of the groups have
also tended to be small with approximately 10 in each. A larger study by Amin and
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co-workers examined bronchial biopsies in 16 never smokers and 29 asymptomatic
smokers and found that asymptomatic smokers had increased CD68 (macrophage
marker) positive, IL-8 positive, human neutrophil lipocalin (neutrophil marker)
positive and eosinophil peroxidase (eosinophil marker) positive cells in the mucosa
compared to never smokers (Amin et al., 2003). Saetta (Saetta et al., 1998) examined
the more peripheral airways by using lung tissue from patients undergoing resection
for peripheral lung tumours. The numbers were small in each group, and immuno
staining showed no difference in numbers of CD 4+ T cells, macrophages or
neutrophils, but an increase in CD 8+ lymphocytes was found in those with airflow
obstruction. This finding conflicts with that of Bosken (Bosken et al., 1992) who
found that patients with airway obstruction had more B-lymphocytes in the airway
than control subjects and that the number of submucosal polymorphonuclear
leukocytes related to the amount smoked. Hogg and co-workers
have examined resected human lung tissue and have shown an increased absolute
volume of B cells and CD8 cells with increasing airflow obstruction (Hogg et al.,
2004).
Neutrophil and lung inflammation
It is likely that the neutrophil plays an important role in airway inflammation in
COPD. In response to cigarette smoke, peripheral blood neutrophils are less
deformable and so are more likely to be retained within the pulmonary circulation
(Drost et al., 1992). Increased neutrophils have been shown to be present in the lung
by immunostaining in those with severe airflow obstruction (di Stefano et al.t 1998),
however this has not been the case when airflow obstruction is mild or moderate
(Saetta et al., 1999; Saetta et al., 1998; O'Shaughnessy et al., 1997; di Stefano et al.,
1996). Cigarette smoke leads to increased numbers of neutrophils and macrophages
within the airway lumen (MacNee et al., 1993). Neutrophil function is altered in
COPD with increased chemotactic activity (Burnett et al., 1987) and enhanced
expression of adhesion molecules (Noguera et al., 1998). There is also enhanced
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peripheral neutrophil response to pro-inflammatory agents and enhanced respiratory
burst in patients with COPD, compared to non smokers (Noguera et al., 2001)
1.4 Free Radicals, Reactive Oxygen species
Oxidants are formed as a normal product of aerobic metabolism and biological
systems are continuously exposed to oxidants. Reactive oxygen species (ROS) are
metabolites of oxygen, and the lung is particularly susceptible to oxidant-mediated
damage because it is the site of gaseous exchange and hence is an environment of
high oxygen levels.
Oxidants can be produced at elevated rates under patho-physiological circumstances
and include partially reduced oxygen metabolites, free radicals which have an
unpaired electron in their outer orbit, and non-radical reactive oxygen species, which
are capable of subtracting an electron from another compound so changing the
oxidative state of both compounds. A free radical is a species capable of independent
existence with one or more unpaired electrons, is usually unstable and can react with
a wide range of compounds by extracting an electron, or more rarely donating an
electron (Halliwell., 1991). ROS are metabolites of oxygen, and many are also free
radicals. During respiration, bimolecular oxygen is reduced by 4 electrons, and
partial reduction generates the superoxide anion (02°").
O2 + e ► O2
Free radicals in cigarette smoke are derived from both the gas and tar phase. Short
acting oxidants such as 02°" and nitric oxide (NO) are predominantly found in the gas
phase. NO and 02°" immediately react to form the highly reactive peroxynitrite
(ONOO"). The tar phase is also a metal chelator and can bind ions and generate H2O2
Also the tar and lung epithelial lining fluid contain metal ions which take part in the
Fenton reaction to produce hydroxyl radicals ( OH). Hydrogen peroxide and
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hydroxyl radical ('OH) are formed from the superoxide anion by the action of
superoxide dismutases (SOD) on the superoxide anion. Hydrogen peroxide can also
be generated by the Haber Weiss reaction in which ferrous ion and superoxide anion
react together.
Fe3+ + 2H+ + 02* ► H202 + Fe2+
The Fenton reaction which involves the addition of an electron from a trace metal
such as iron (Fe2+) to hydrogen peroxide produces the hydroxyl radical (OH).
H202 + Fe2+ ► 02'"+ HO + Fe3+
This burden of oxidants in smokers lungs is enhanced further by the release of
oxygen radicals from the influx and activation of inflammatory leukocytes, both
neutrophils and macrophages. It has also been shown that leukocytes from smokers
release increased amounts of oxidants such as superoxide anion and hydrogen
peroxide compared to non smokers (Morrison et al., 1999).
Within the environment of the lung, activated neutrophils, macrophages and
eosinophils will generate ROS, with the formation of superoxide anion (02") which
is rapidly converted to hydrogen peroxide (H202). Circulating neutrophils from
cigarette smokers and patients undergoing an exacerbation of COPD release more
02"~ (Rahman et al., 1996). In animal models of lung inflammation, sequestered
neutophils in the pulmonary microcirculation release more ROS than circulating
neutrophils (Brown et al., 1995). Not only do infiltrating inflammatory cells produce
ROS, but the pulmonary epithelium can produce ROS (Rochelle et al., 1998; Kinnula
et al., 1992). Piotrowski has also shown that differentiation from type II to type I
alveolar epithelial cells is accompanied by an increase in hydrogen peroxide
production (Piotrowski et al., 2000). ROS can be generated intracellularly from the
NADPH oxidase system and xanthine/xanthine oxidase. The primary ROS-
generating enzyme system is NADPH oxidase which is present in phagocytes and
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epithelial cells. There is also evidence that airway smooth muscle cells, and vascular
smooth muscle and endothelial cells generate ROS from low activity NADPH
oxidases homologous to phagocytic NADPH oxidases which act as intermediates in
signaling in pathways (Brar et al., 2002; Griendling et al., 2000).
Detoxification of ROS occurs by a number of antioxidant defense systems which
detoxify reactive products or convert them to products that are easily quenched by
other antioxidants. Superoxide dismutate (SOD) is a cellular enzyme which forms
part of the antioxidant defense which catalyses the conversion of superoxide anions
(O2") to hydrogen peroxide (H2O2) (Fridovich and Freeman, 1986).
SOD
2 02" + 2H+ ► H202 + 02
Hydrogen peroxide is eliminated by the action of catalase (Chance et al., 1979).
Glutathione peroxidase also reduces hydrogen peroxide to water by oxidizing
glutathione to glutathione disulfide (Cohen and Hochstein, 1963). Free radical
scavengers are found in the tissues and serum and aid detoxification of oxidants.
Low molecular weight free radical scavengers found in the tissue include vitamin E,
vitamin C, reduced glutathione, a-tocopherol, taurine, uric acid and a-carotine.
Higher molecular weight scavengers are found in the serum and include a-
antitrypsin inhibitor, transferrin, albumin, caeruloplasmin, and amino acids
methionine and cysteine.
Oxidative Stress
Oxidative stress results from an imbalance in the oxidant-antioxidant equilibrium in
favour of oxidants. If the oxidant burden is so great these highly reactive oxygen
species are not be detoxified by the oxidant defense mechanisms and they will
damage cell components such as lipid membranes, proteins, carbohydrates and DNA.
15
Cell membranes are damaged by oxidative stress by virtue of their electron rich
environment due to the presence of multiple carbon-carbon double bonds, with
resultant lipid peroxidation. Reactive oxygen species including superoxide anion
radical ((V"), hydroxyal radical (OH), hydrogen peroxide (H2O2), and nitrogen
species, such as nitric oxide and peroxynitrite (ONOCT), can all affect cellular
function. Hydrogen peroxide is an important oxidant as it passes through lipid
membranes relatively easily, and in so doing can generate further oxidants both intra
and extracellularly. The local pH during the process ofmacrophage phagocytosis can
help the release of transition metals from their stores with enhanced hydroxyl radical
formation. Free iron in the ferrous form catalyses the Fenton reaction and also the
superoxide driven Haber-Weiss reaction, which generates the "OH, a very aggressive
oxidant capable of cellular damage with a half life of 10"9 seconds (Sies, 1991).
Oxidative stress can lead to an enhanced inflammatory process with generation of
ROS, which can increase activation of transcription factors (Schreck and Baeuerle,
1994; Adcock et al., 1994), alter chromatin remodeling and increase gene expression
of pro-inflammatory mediators (Iwata et al., 2002, Rahman et al., 2002).
1. 5 Inflammatory mediators in Chronic Obstructive Pulmonary Disease
Cytokines
Cytokines are pluripotent mediators of inflammation that are produced and secreted
by a wide range of cells including neutrophils, monocytes, macrophages, endothelial
cells and epithelial cells. Cytokines and the chemoattractant cytokines (chemokines)
act by binding to one or more cellular transmembrane receptors, and initiate
intracellular signaling pathways that are involved in recruitment of leucocytes to sites
of inflammation and injury (Strieter et al., 1996). Chemokines are divided into two
groups depending on the position of the first conserved cysteine residues at the
amino-terminus; those which are adjacent are termed C-C and those that are
separated by one amino acid are termed C-X-C. The cytokines associated with
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COPD include TNF-a, interferon (IFN)-y and (IL)-1|3 and IL-6 (Chung, 2001;
Majori et al., 1999).
Cellular and cytokine relationships in the lung
The alveolar and bronchial epithelium forms the first line of defence in the lungs to
inhaled environmental stimuli, allergens and microbes. Neutrophils and macrophages
are vital to the clearance of microbes, and it is well documented that there are
increased neutrophil numbers in the airway lumen in smokers with COPD
(Flunninghake and Crystal, 1983; Lacoste et al., 1993; Pesci et al., 1998). Cigarette
smoke leads to recruitment of alveolar macrophages and neutrophils into the lungs
(Kuschner et al., 1996), and these infiltrating inflammatory cells produce
endogenous factors such as TNF-a and interferon-y. These primary mediators can
provoke the production of secondary mediators in the local epithelium and also in
infiltrating cells, and include lipid mediators such as prostaglandins, leukotrienes and
platelet activating factor (PAF). These secondary mediators are chemotactic for
neutrophils and eosinophils and macrophages, and can also activate macrophages and
eosinophils and alter vascular and epithelial permeability (Rola-Pleaszczynski et al.,
1993; Cohn et al., 1997).
BAL from smokers show increased inflammatory mediators compared to non
smokers including IL-8, IL-1J3, IL-6 and MCP-1 (Kuschner et al., 1996). However
blood derived monocytes/macrophages from smokers show reduced levels of these
cyokines (Brown et al., 1989; Soliman et al., 1992; Yamaguchi et al., 1989; Ohta et
al., 1998). Such conflicting studies demonstrate the complexity of the
micropulmonary area and the likely contribution from surrounding cells and
inflammatory mediators.
TNF-a can stimulate the epithelium to produce secondary mediators such as lipid
mediators, reactive oxygen species (ROS), reactive nitrogen species (RNS), and
cytokines (Martin et al., 1997). These secondary mediators can affect epithelial cells
and other local cells and lead to further inflammatory responses. Neutrophils and
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macrophages can cause detrimental effects by causing airway wall damage and
remodelling via the actions of secreted proteases. It is still unclear whether the
macrophage or the neutrophil is the predominant cell implicated in the development
of smoking related lung disease and emphysema. Churg et al (Churg et al., 2003)
have demonstrated in a recent mouse model that macrophage metalloelastase
mediates acute cigarette-induced inflammation via TNF-a release.
Tumour Necrosis Factor alpha (TNF-a)
TNF-a interacts with two transmembrane receptors TNFR1 (TNFR p55) and TNFR2
(TNFR2 p75). In the majority of cells these receptors are co expressed, but there is
evidence to suggest that TNF-R55 is primarily found on the surface of cells of
epithelial origin and TNF-R75 on the cell surface of cells of myeloid origin
(Brockhaus et al., 1990). Proteolytic shedding of the extracellular cytokine binding
domains of the TNF-a receptors occurs in response to various inflammatory stimuli,
including endogenous TNF-a (Lantz et al., 1990), and have been used as a marker of
inflammation. Sputum obtained from COPD patients have increased neutrophils
(Vernooy et al., 2002; Peleman et al., 1999) and increased IL-8 levels compared to
healthy smokers (Keatings et al., 1996; Yamamoto et al., 1997). Keatings and co¬
workers (Keatings et al., 1996) have also shown increased TNF-a in induced sputum
in COPD, but Vernooy failed to confirm these findings in a later study; however
Vernooy did show increased soluble TNF-a receptor TNF-R55 in induced sputum
(Vernooy et al., 2002). The source of the s TNF-R55 is not clear, but it may originate
from neutrophils as activated neutrophils in vitro shed sTNF-R55 (Porteu and
Nathan, 1990) and the neutrophil is the predominant cell type within the airway
lumen (Keatings et al., 1996).
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Cultured bronchial epithelial cells secrete TNF-a in response to cigarette smoke
(Mio et al., 1997). Polymorphisms of the TNF-a gene result in constitutively higher
levels of TNF-a (Wilson et al., 1997). TNF-a can induce airway mucous cell
metaplasia in vitro and vivo (Takeyama et al., 2001), a reduction in interepithelial
binding and cell death (Kampf et al., 1999), deposition of collagen in alveolar walls
in murine models of emphysema (Sulkowska et al., 1997), and can also induce IL-1,
TNF-a, IL-8, and MCP-4 expression (Cromwell et al., 1992) and IFN-y receptors on
epithelial walls (Wu et al., 1996). IFN-y inhibits the proliferation of epithelial cells
and this may contribute to the loss of epithelial integrity that is present in
emphysema (Kampf et al., 1999). TNF-a has multiple pro inflammatory actions such
as neutrophil degranulation and associated release of proteolytic enzymes eg
lysozyme, and stimulation of the respiratory burst (Richter et al., 1989).
The importance of TNF-a in cigarette smoke induced emphysema is shown by the
observation that mice lacking TNF-a receptors do not develop smoke induced
inflammation (Churg et al., 2002).
Interleukin-8 and COPD
Interleukin-8 (IL-8) is a 16 kDa protein that is a member of the C-X-C family of
cytokines. The potential role of IL-8 in the development of COPD comes from
studies that have examined IL-8 levels in BAL, induced sputum and lung tissue
which have demonstrated increased levels of IL-8 (Pesci et al., 1998; Keatings et al.,
1996; Fuke et al., 2004) in the lungs of smokers with COPD. Tanino (Tanino et al.,
2002) has also shown that BAL IL-8 levels can be used to identify a population of
smokers with subclinical emphysema on CT scanning. Immunostaining and in situ
hybridization techniques for IL-8 have also shown that bronchiolar and alveolar
epithelium stains more intensely in smokers with COPD than those without COPD
(de Boer et al., 2000). There is in vitro evidence to suggest that large airway
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epithelium behaves differently to smaller peripheral airway epithelium in terms of
oxidative stress and chemokine release (Witherden et al., 2004; Mio et al., 1997;
Masubuchi et al., 1998). There is increased IL-8 release from bronchial epithelial
cells in response to cigarette smoke (Mio et al., 1997). However, type II bronchial
epithelial cells isolated from human lung tissue show inhibition of IL-8 release in
response to cigarette smoke extract (Witherden et al., 2004). Further, BAL obtained
from proximal airways contain higher concentrations of IL-8 compared to BAL from
more distal airways, and BAL IL-8 concentrations correlate with neutrophil counts in
BAL, suggesting that neutrophils may be the source of increased IL-8 release (Mio et
al., 1997). The presence of increased levels of IL-8 in large airways in COPD
exacerbations is suggested by elevated sputum levels of IL-8 (Aaron et al., 2001),
however BAL IL-8 levels in exacerbations of COPD are not altered compared to
baseline levels (Drost et al., 2005).
IL-8 is synthesised and released by bronchial epithelial cells (Nakamura et al., 1991),
macrophages, monocytes and neutrophils (Stieter et al., 1990; Chung, 2001). IL-8 is
a potent chemoattractant that is needed to recruit and activate neutrophils
(Baggiolini, 1998) and is fairly resistant to changes in pH and proteolytic degradation
compared with other chemoattractants (Steiter et al., 1996). It is regulated primarily
at the gene transcription level (Sica et al., 1990), although post transcriptional control
does occur (Yu et al., 2003). The cytokines TNF-a and IL-ip usually cause the most
expression of IL-8 within human cells (Brasier et al., 1998), but reactive oxygen
species (ROS) (Lakshminarayanan et al., 1997) and viral and bacterial infection can
also induce IL-8 production (Khair et al., 1994). Stimulation of cells leads to rapid
induction of IL-8, and there is evidence that production of IL-8 mRNA occurs within
60 minutes (Lakshminarayanan et al., 1997). Rapid induction of IL-8 gene
expression is mediated by transcription factors that bind to the IL-8 promoter region.
The IL-8 promoter area contains binding sites for inducible transcription factors
which are pro-inflammatory responsive elements important for IL-8 gene expression
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(Mukaida et al., 1994). In some circumstances there is both stimulus specific and cell
type specific expression of the IL-8 gene, and this is probably related to the
preferential activation and binding of transcription factors to the IL-8 promoter
region (Lakshminarayanan et al., 1998). There are two distinct promoter regions that
are important for IL-8; a distal promoter element comprised of an AP-1 binding site
and a proximal promoter area which has binding sites for both NF-IL-6 and NF-kB
(Brassier et al., 1998).
Relationship of IL-8 and NF-kB
The NF-kB binding site is the predominant cis acting element in the IL-8 gene
(Roebuck, 1999). For optimal IL-8 gene expression, cooperation of NF-kB with
either AP-1 or NF-IL-6 is needed (Mukaida et al., 1994). NF-IL-6 alone binds only
weakly to the IL-8 promoter, but in the presence of NF-kB the binding increases
(Kunsch et al., 1994). There is competition for the IL-8 NF-kB site and the classic
NF-kB site. These two sequences are different and IL-8 NF-kB binding site binds the
different NF-kB subunits Rel-A, NF-kB 1 and c-Rel. The classic NF-kB hetero
(p50/p65) is unable to transactivate the IL-8 site (Kunsch et al., 1993). IL-8 can be
down regulated through the NF-kB binding site, and IFN-(3, nitric oxide and
glucocorticoids inhibit cytokine induced IL-8 expression in cell lines (de Caterina et
al., 1995; Oliveira et al., 1994; Wertheim et al., 1993).
Oxidative stress can induce IL-8 expression, and this can occur through the
activation of an oxidant-responsive element in the IL-8 promoter. Genes that code for
protective antioxidant enzymes such as glutathione-S-transferase contain an ARE
within the promoter of the gene. The IL-8 gene promoter has a similar sequence to
the core ARE.
Oxidants increase the transcription of c-fos and c-jun genes, and the associated
proteins have a redox sensitive cysteine residue that must be in the reduced state to
permit DNA binding. This relationship has been demonstrated in an epithelial cell
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line where H2O2 induced IL-8 correlated with activation and binding of AP-1 to the
IL-8 promoter (Lakshminarayanan et al., 1997).
The role of RANTES, MlP-la, MIP-ip and MCP-1 and IL-8 lung inflammation
The neutrophil and the macrophage are central to the inflammatory process in
COPD. Important chemotactic and activating cytokines for neutrophil and
macrophage inflammatory cells include TNF-a, IL-8, Monocyte chemotractant
protein (MCP-1), and Macrophage inflammatory protein (MlP-la). MCP-1 and
MlP-la are both C-C chemokines.
MCP-1 is a chemoattractant for mononuclear phagocytes, T lymphocytes, B cells and
NK cells. MCP-1 has a role in monocyte migration across epithelial and endothelial
cell layers. Preferential release of MCP-1 and regulated on activation, normal T-cell
expressed and secreted (RANTES) from the apical compartment of the epithelial cell
with the creation of a chemotactic gradient across the epithelial cell and an increase
in monocyte traffic in the basal to apical direction has been shown in vitro in alveolar
type I and II cell lines (Rosseau et al., 2000). Human lung macrophages release IL-8,
MCP-1, and MlP-la (Goodman et al., 1998, Fuke et al., 2004). In vitro studies
examining leucocyte migration across an endothelial monolayer using fresh alveolar
type II epithelial cells also show constitutive basal MCP-1 levels which are
upregulated by TNF-a (Eghtesad et al., 2001). Type II alveolar cells isolated from
human lung produce detectable basal levels ofMCP-1, IL-8 and GRO-a, but low or
undetectable basal levels ofMlP-la and RANTES (Witherden et al., 2004). TNF-a
stimulated A549 cells release monocyte chemotactic factors with MCP-1 being the
predominant factor compared to GMCSF, RANTES or TGF-p (Koyama et al.,
1999).
The importance of these cytokines in smoking related lung disease is suggested by an
increase in cytokine expression within the lung environment. The expression of
TNF-a, IL-8, MCP-1 and MlP-la cytokines is increased in sputum (Keatings et al.,
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1996), BAL fluid (Capelli et al., 1999), plasma (Nguyen et al., 1999) and lung tissue
in patients with COPD (de Boer et al., 2000). Also cigarette smoke, even in healthy
individuals can lead to increased MCP-1 levels (Kuschner et al., 1996).
RANTES and MlP-la are both P chemokines that are involved in the migration of
inflammatory cells within the lungs. RANTES is a T-cell product and attracts
memory T-cells (Conlon et al., 1995) and is also a chemoattractant for moncytes,
basosphils and eosinophils (Schall et al., 1990, Bischoff et al., 1993). In stimulated
blood-derived lymphocytes, CD8+ lymphocytes are the predominant source of MIP-
la and RANTES (Conlon et al., 1995). There are however many other cellular
sources of RANTES including monocytes, platelets, epithelial cells, fibroblasts and
dendritic cells (Kameyoshi et al., 1994; Berkman et al., 1996; Rathanaswami et al.,
1993; Nagorsen et al., 2004). RANTES is released in the lung in response to noxious
stimuli such as bacteria and viruses (Fillion et al., 2001). In particular, respiratory
syncytial virus upregulates RANTES in-vitro in epithelial cell lines (Becker et al.,
1997), and this viral induction of RANTES within the lung may be important in
exacerbations of COPD.
Increased expression of mRNA RANTES is found in lung biopsies in subjects
undergoing an exacerbation of COPD, with strong mRNA RANTES expression in
the surface epithelium (Zhu et al., 2001). The expression of RANTES is under the
control of various transcription factors including the redox sensitive transcription
factor NF-kB (Song et al., 2000).
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1.6 Cell Membrane Lipid peroxidation
Within the cell membrane lipid peroxidation occurs in response to ROS, which are
generated in smoking related lung disease, and produce a chain reaction in which
unstable lipid hydroperoxides and secondary carbonyl compounds such as
malondialdehyde (MDA) are formed. As well as in lung disease lipid peroxidation
has been implicated in a number of other disease processes including atherosclerosis
(Palinski et al., 1989), diabetes (Shah et al., 1994) and genetic haemochromatosis
(Young et al., 1994).
Malondialdehyde and cigarette smoking
High levels of lipid peroxidation products are found in the blood and epithelial lining
fluid of patients with COPD compared to controls (Rahman et al., 1996; Morrison et
al., 1999). During exacerbations of COPD levels of peroxidation products are
increased (Rahman et al., 1997). It has also been shown that serum MDA levels
return to normal after the exacerbation of COPD has abated (Sahin et al., 2001).
Significantly higher levels of MDA are found in resected lung tissue from smokers
with a heavy smoking history compared to non smokers (Fahn et al., 1998). Lee (Lee
et al., 1999) measured MDA in lung tissue and found that MDA levels increased
with increasing age of the patient, and that MDA increased with cumulative smoke
exposure. Petruzzelli (Petruzzelli et al., 1990) found that the cumulative smoke
exposure (adjusted for age) did not correlate with the level of MDA in lung tissue,
but did find higher levels of MDA in patients who had smoked within 30 days of
their operation for lung resection.
4-HNE and Cigarette smoking related lung disease
Aldehydic end-products such as malonyldialdehyde (MDA), 4-hydroxy-2,3-nonenal
and 4-hydroxy-2,3-alkenals (HAKs) are generated from lipid peroxidation. 4-HNE, a
stable end product of lipid peroxidation, is highly reactive and capable of diffusion
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away from the original site of production (Esterbauer et al., 1991), and affects both
intracellular and extracellular biological targets. 4-HNE and other such aldehydic
compounds can affect cellular functions including signal transduction, gene
expression, apoptosis, cell proliferation and cell responses (Parola et al., 1999). 4-
HNE and MDA can modify proteins through covalent alkylation of lysine, histidine
and cysteine amino acid residues, and it is thought that these intermolecular
aldehyde-protein adducts are central to the cytotoxic events attributable to
uncontrolled lipid peroxidation. Removal of 4-HNE can be achieved by direct
interaction with glutathione (Canuto et al., 1994), transformation into the metabolite
4-hydroxy-nonenoic acid by alcohol dehydrogenase isoforms into 1,4-
dihydroxynonene, and the formation of conjugates between GSH and 4-HNE
catalysed by glutathione S-transferase (GST) (Ketterer et al., 1998) or with end
products of 4-HNE metabolism (Siems et ah, 1998).
In human lung tissue 4-HNE is found predominantly in the cytoplasm of airway
epithelial cells, endothelial cells, neutrophils and macrophages. Higher levels of 4-
HNE adducts are found in airway epithelial cells of smokers with COPD compared
to those without COPD (Rahman et al., 2002). There is a positive correlation
between levels of 4-HNE and y-GCS mRNA in alveolar epithelium (Rahman et al.,
2002). In murine models, acute cigarette exposure leads to increased levels of 4-
HNE, particularly in type II alveolar epithelial cells (Aoshiba et al., 2003). 4-HNE
induces cell signalling via the mitogen-activated protein kinase pathway leading to
the induction of AP-1 mediated genes (Uchida et al., 1999; Leonarduzzi et al., 2000).
4-HNE can also induce y-GCS mRNA in alveolar epithelial cells (Liu et al., 2001),
suggesting that 4-HNE is intimately related to redox sensitive genes controlled by
AP-1. In vitro work has shown that 4-HNE inhibits NF-kB activation in monocytes
by selectively blocking signalling events that are required for IkB phosphorylation
(Page et al., 1999). In emphysema in which there is destruction of alveolar walls and
permanent enlargement of distal airspaces, increased numbers of alveolar
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macrophages are retained within the alveolar interstitial space (Jeffery, 1998). Lipid
peroxidation products may have a role in retention of macrophages by virtue of
modification of the extracellular matrix. Kirkham (Kirkham et al., 2003) has shown
increased macrophage adhesion to both cigarette smoke modified collagen IV and
similarly collagen that has been modified with acrolein and 4-HNE. In vitro,
Kirkham and coworkers (Kirkham et al., 2004) have also shown that human
macrophages interacting with carbonyl or cigarette smoke modified extracellular
matrix proteins dramatically down regulates their ability to phagocytose apoptotic
neutrophils.
1.7 Glutathione
The glutathione redox system is the major antioxidant defence system within the
lungs. Glutathione is a low molecular weight tripeptide (L-y-glutamyl-L-
cysteinylglycine) which is synthesised from three amino acids (cysteine, glutamate
and glycine), and is found both intra and extracellularly (figure 1.1, molecular
structure GSH). GSH homeostasis is crucial to the maintenance of normal cellular
physiological processes. GSH reacts both enzymatically and non enzymatically with
cigarette smoke, highly reactive nitrogen oxides and electrophilic compounds such as
quinines, aldehydes, and peroxides, so rendering them less toxic to cells. By virtue of
strong nucleophilic properties, GSH can inactivate electrophilic reactive compounds
by the formation of GSH conjugates. GSH is also an important vehicle for
stabilizing, detoxifying and transferring cysteine.
The main source of GSH is the liver, which tends to export the majority of newly
synthesised GSH into the circulation. The kidney and the lungs also have a high
turnover of GSH, but the precise mechanism within the lung is not fully understood.
This is further complicated by the probability of individual cell types within the lung
differing in their GSH transport systems across the cell and may explain why
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Figure 1.1 Molecular structure ofglutathione
Glutathione Synthesis
Most GSH within the cell results from the transfer of its constituent amino acids
from outside the cell. The y-glutamyl cycle (figure 1.2) is a series of reactions in
which GSH is both synthesized, and degraded, and together with various key amino
acids is able to move into and out of the cell.
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Figure 1.2 The y-glutamyl cycle
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Extra-cellular GSH under the influence of the transmembrane enzyme y-glutamyl
transferase (y-GT), is broken down into a y-glutamyl moiety and L-cysteinylglycine.
Again under the influence of y-GT, y-glutamyl moiety with amino acids forms y-
glutamyl-amino acid. The y-glutamyl-amino acid is taken up into the cell, where it is
cleaved to free amino acids and glutamate. The L-cysteinylglycine at the cell surface,
under the influence of peptidases will release the amino acids cysteine and glycine.
These released amino acids will be free to move through the cell membrane utilizing
the amino acid transport system in a similar fashion to cysteine, glycine and
glutamate that are already present in the extracellular environment from the plasma.
There are also means for cellular uptake of intact GSH, intracellular GSH synthesis
and degradation and efflux of intact GSH and oxidized GSH (GSSG).
Cysteine, synthesized in the liver and found in low concentrations in plasma, is the
rate limiting substrate for GSH synthesis, particularly under conditions of oxidative
stress (Bannai, 1984; Deneke et al., 1992). Glutamate and glycine are rarely rate
limiting substrates in GSH formation (Bannai et al., 1984; Bannai et al., 1986). The
redox status of the extracellular area influences the cellular uptake of cysteine
(Bannai, 1984), and as extracellular GSH affects the redox status of the cell, then
extracellular GSH levels will also affect intracellular GSH levels. Cysteine uptake
into the cell is by a sodium dependent mechanism (ASC system) which is non-
inducible, and is not influenced by amino acid starvation or oxidative stress (Bannai,
1984). In a reduced extracellular environment, cystine is converted to cysteine which
is then taken up by the cell by the ASC amino acid system. Cystine is taken up into
the cell via the xc" system of amino acid transport which has both a sodium dependent
and non dependent system (Bannai et al., 1982). The xc" system is inhibited by
arginine, lysine and ornithine and competively inhibited by glutamate (Bannai and
Ishii 1982; Bannai and Kitamura, 1980). There may be species or cell type
differences in the xc~ cystine transport system as bovine pulmonary artery endothelial
cells have an inducible (by diethyl maleate DEM) sodium-independent system
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(Deneke et al., 1989). In type II epithelial cells only the non-inducible sodium
dependent cystine transport system is identified (Bukowski et al., 1995).
The liver is not able to uptake intact GSH directly, and GSH first undergoes
degradation by y-glutamyl tranpeptidase, and the constituent amino acids are taken
up and used for intracellular GSH synthesis. In the lung however, there is evidence
for direct cellular uptake of GSH, as addition of GSH to the perfusion media of rat
lungs maintains lung GSH levels. Also inclusion of GSH in the medium of type II
epithelial cell isolates gave protection against paraquat, and this protection persisted
even in the presence of a y-glutamyl tranpsptidase inhibitor (Hagen et al., 1986). An
active transport system for GSH uptake in rat type II epithelial cells has been
proposed by Bai (Bai et al., 1994). Others (Cheek et al., 1994; Joshi et al., 1986)
however have failed to show evidence of direct GSH uptake in lung cells.
Gamma glutamyltransferase (y-GT)
Gamma glutamyltransferase (y-GT) is an enzyme that has two subunits; a 55 kDa
membrane bound unit and a smaller (XXkDa) catalytic unit (Meister et al., 1981).
The active site of this enzyme is directed toward the outside of the cell (Griffith and
Meister, 1979), and it is involved in both synthesis and degradation of GSH. It can
break the y-glutamyl bond of GSH and so release cysteinyl-glycine and a glutamyl
moiety. The glutamyl moiety can be transferred to either an amino acid, a dipeptide
or GSH to produce a glutamyl derivative.
y-GT
GSH + amino acid ► y-glutamyl-amino acid + cysteinyl-glycine
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There is evidence that y-GT has a protective role against oxidative stress, as specific
y-GT inhibitors can prevent the protective effect afforded by extracellular glutathione
against added oxidants (van Klaveren et al., 1997).
In intracellular glutathione synthesis, the rate limiting enzyme y-glutamylcysteine
synthetase (also called glutamate-cysteine ligase-GCL) (Meister et al., 1985;
Grifffith et al., 1979), catalyses the bond between glutamate and cysteine, and is
inhibited by L-buthionine-[S,R]-sulphoximide (BSO). y-GCS (GCL) activity is
regulated by negative feedback inhibition from GSH, but not GSSG. High cellular
levels of cystine can stop the negative feedback of GSH production on y-GCS (Kang
et al., 1994). y-GCS (GCL) has 2 subunits, a modifier (GCL-M) and a catalytic
(GCL-C).
GSH can be exported out of the cell and this pathway is important in determining
final cellular GSH concentrations. This transport is affected by the thiol status of the
extracellular environment. In a more oxidised extracellular environment then the cell
retains GSH, and releases GSH in a more reduced environment (Lu et al., 1993; Lu
et al., 1994; Garcia-Ruiz et al., 1992). The origin of GSH in the ELF is not known. It
seems unlikely to be the result of simple diffusion from within the cell. Other cells
such as lymphocytes, macrophages, fibroblasts and endothelial cells can take GSH
from the ELF and effectively transport it to other areas. GSH exists in an oxidised
and reduced state. Usually there is only a tiny percentage of oxidised GSH (GSSG),
less than 0.01%, unless there is an oxidant stimulus. Under these conditions there is
export ofGSSG out of the cell, but the precise details of this transport system are not
clear. Some cells (type II cells, kidney cells and small intestine cells) have been
found to uptake intact GSH (Hagen et al., 1987; Hagen et al., 1988; Brown et al.,
1992; Bai et al., 1994; Jenkinson et al., 1994). In type II cells the uptake of intact
GSH is by an active mechanism that is sodium dependent. Type I cells do not have
the ability to take up intact GSH (Deneke and Fanburg et al., 1989). The total
glutathione level (GSH and GSSG) in plasma is low with levels of 3 ± 0.6 pM, and
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there is a 140 fold rise in the level found in the ELF with values of 429 ± 34 pM,
with the majority of the GSF1 being in the reduced form (Cross et al., 1994). Smokers
have 80% more GSH in the ELF compared to non-smokers and the majority of this
(98%) is in the reduced from (Cantin et al., 1987). The higher ELF GSF1
concentrations may be a protective mechanism for epithelial cells in the face of an
oxidant load. It is known that the erythrocytes from smokers have higher GSH
concentrations and give more protection to endothelial cells from hydrogen peroxide
than erythrocytes from non smokers (Toth et al., 1986). In pulmonary fibrosis the
ELF GSH is decreased four fold compared to normal individuals (Cantin et al.,
1989).
The glutathione depletion is not restricted to the lung. CT proven emphysema
patients have reduced muscle antioxidant capacity as demonstrated by reduced
resting muscle glutathione (Engelen et al., 2000). Reduced GSSG, lipid peroxidation,
y-GCS (GCL modifying or catalytic) heavy subunit mRNA have been measured in
muscle from COPD patients and healthy controls, both at rest and following an
exercise programme. Interestingly healthy subjects were able to adjust their redox
status, but this was not so in the COPD patients (Rabinovich et al., 2001)
1.8 Glutamate-cysteine ligase (GCL) (y-Glutamylcysteine Synthetase (y-GCS))
GSH is synthesised by two enzymes, y-GCS (the rate limiting enzyme) and
glutathione synthetase (Seelig and Meister 1984). The y-GCS enzyme is a
haloenzyme and exists as a dimer, which is composed of a heavy (y-GCS-HS; 73
kDa) and a light (y-GCS-LS; 28 kDa) subunit (Seelig et al., 1984). The heavy
subunit possesses all of the catalytic activity (Huang et al., 1993). y-GCS
nomenclature has changed and it is now referred to as glutamate-cysteine ligase
(GCL) with a catalytic subunit (GCLC) and a modifier subunit (GCLM). The GCLC
(y-GCS-HS) gene is induced in alveolar epithelial cells after stimulation with
oxidants, phenolic antioxidants and tumour necrosis factor (TNF-a) (Rahman et al.,
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1996; Rahman et al., 1996; Rahman et al., 1998; Rahman et al., 1999). In human
alveolar cells an oxidant stress in the form of cigarette smoke condensate results in
an initial depletion of intracellular GSH, followed by a rebound increase in
glutathione synthesis (Rahman et al., 1995). In chronic smokers there are elevated
levels ofGSH in the ELF, compared with non smokers (Cantin et al., 1987).
Down regulation of GCL (y-GCS) can occur in response to both TGF-(3 and oxidant
stress in vitro (Arsalane et al., 1997). GCL (y-GCS) expression has been localized
predominantly to bronchial epithelium (Soini et al., 2001), and Rahman et al have
demonstrated increased expression in the peripheral airways of COPD patients
compared to healthy smokers using in situ hybridisation (Rahman et al., 2000). Harju
and co-workers (Harju et al., 2002) performed immunohistochemical analysis of the
GCL (y-GCS) enzyme subunits in non smokers, smokers without COPD and smokers
with COPD. This group found that in all groups, staining for GCLC and GCLM (y-
GCS HS and LS) was stronger in central airways compared to peripheral airways. In
central and peripheral airways no difference in GCLC or GCLM (HS or LS) was
found within the groups, except that GCLC (y-GCS-LS) was increased in the central
airways in the non smoking group. In contrast to Rahman, no staining was
demonstrated in the alveolar epithelium. Harju and co-workers showed that alveolar
macrophages had significantly more GCLM and GCLC (HS and LS) in the non
smokers group. Rahman showed GCLC (y-GCS-HS) mRNA was localized to
bronchial, bronchiolar, and alveolar epithelial cells (Rahman et al., 2000), and it is
interesting that Harju et al (Harju et al., 2002) found that alveolar epithelium failed
to show any immuno-reactivity. Thus, although GCL (y-GCS) message appears to be
present in the alveolar epithelium, enzyme protein has not been demonstrated in the
alveolar epithelium.
Human GCL (y-GCS) is activated by the formation of reversible disulphide bonds,
with at least two of these bonds required for optimal enzyme activity. One pair of
disulphide bonds links the heavy and light subunits, and depletion of GSH promotes
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formation of this disulfide bond and ultimately optimal enzyme activity. The second
disulphide bond is intramolecular. GCL (y-GCS) is transcriptionally, post
transcriptionally and post translationally regulated (Soltaninassab et al., 2000). In
cell lines (human small cell line, lung, and Hep G2, hepatocytes) there is higher
constitutive expression of the GCLC (y-GCS light subunit) compared to that of the
GCLM (heavy subunit) (Kurokawa et al., 1995; Huang et al., 1993, Soltaninassab et
al., 2000). Similarly these studies have also demonstrated tissue specific differences
in the translational rates of these subunits. Stimuli that affect production of the heavy
subunit will there by affect the synthesis ofGSH. Certain stimuli produce signals that
not only induce transcription but also result in message stabilization. There are a
multitude of chemical, physical agents, and cytokines that are capable of inducing
the subunits ofGCL (y-GCS), and these are shown in table 1.2.
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Table 1.2 Compounds capable of inducing GCL (y-GCS) subunit activity


























GCLC and GCLM genes (y-GCS-HS and y-GCS-LS genes)
The genes for GCLC (y-GCS-HS) and GCLM (y-GCS-LS) are single copy genes
which have been mapped to 6pl2 and lp22.1 respectively (Griffith 1999; Wild and
Mulcahy 2000). Loss of 1 p21 -22 is associated with malignant mesothelioma, and
breast cancer and loss of this region results in loss of GCLM (y-GCS-LS) which
could limit GCL (y-GCS) activity (Lee et al., 1996); Vance et al., 1997).
Polymorphisms of the GCL (y-GCS) subunits may be important in susceptible
individuals who develop COPD.
As stated earlier, a multitude of agents can induce the subunits of GCL (y-GCS).
GCL (y-GCS) gene transcription is an extremely complex process that is not fully
unraveled. Groups interested in GCL (y-GCS) gene transcription have used various
cell lines including alveolar epithelial cells, Hep G2 cells, COS-1 cells, and mouse
endothelial cells, with the inherent problem of not knowing whether various
observations are cell or species specific. There is evidence of preferential DNA
binding of particular transcription factors with the whole, or part of the EpRE
sequence of the GCL (y-GCS) promoter in response to different stimuli.
Inducers of phase II protective enzymes such as P-napthoflavone that initiate a
protective response, the so called 'electrophile counterattack' have been useful in
understanding GCL (y-GCS) regulation (Prestera et al, 1993; Prestera and Talalay,
1995). This counterattack leads to increased intracellular glutathione and
upregulation of detoxification genes via antioxidant response elements
(ARE)/electrophile response elements (EpRE) located in the promoter region of the
respective genes. The EpRE core sequence is 5'(G/C)TGA(C/G)NNNGC(A/G)-3'
and often contains an AP-1 binding site and is often flanked by an AP-1 or an AP-1
like binding site. The sequence of the EpRE is similar to that of other response
elements such as the TRE-type Maf recognition elements (T-MARE) and the NF-E2-
binding sites (Kataoka et al., 1994). Thus transcription factors that work through
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these sites will, or may also bind to and regulate expression through EpRE
sequences. Such transcription factors are termed trans-acting factors.
Glutamate cysteine Ligase (GCL) and AP-1 binding sites
There is a close association between GCL (y-GCS) and the redox sensitive
transcription factors activator protein-1 (AP-1) and nuclear factor kappa B (NF-kB).
The 5'-flanking region of the y-GCS-HS gene contains various elements (antioxidant
response element (ARE), metal response element (MRE)), and putative transcription
factors (AP-1, NF-kB, AP-2, SP-1). Functional AP-1 elements have been identified
in the heavy and light subunits of y-GCS, and these AP-1 elements are important for
constitutive and inducible GCLC (y-GCS-HS) and GCLM (y-GCS-LS) activity
(Moinova and Mulcahy 1998; Wild et al., 1998). Cho has shown that oxidised low-
density lipoprotein induced GCLC (y-GCS-HS) expression, and that this was
regulated by an AP-1 binding site located at -365 and -241 base pairs (Cho et al.,
1999). Rahman et al have also demonstrated in an epithelial cell line that an AP-1
element located between -269 and 263 base pairs is required for the oxidant mediated
(menadione and hydrogen peroxide) regulation of GCLC (y-GCS-HS) promoter
activity ( Rahman et al., 1998).
Glutamate Cysteine Ligase (GCL) and electrophile response element (EpRE)
The promoter of GCLC (y-GCS-LS) contains an electrophile response element
(EpRE), which is located 0.3 kb upstream of the translational start site, and this has
an AP-1 element within it, and in Hep G 2 cells it has been shown to direct
constitutive and P-naphthoflavone induced y-GCS-LS activity (Moinova et al.,
1998). There is also an apparent redundant AP-1 element located more distal to the
EpRE on the GCLM (y-GCS-LS) gene that is also able to direct p-naphthoflavone
induced GCLM (y-GCS-LS) activity. Similarly, the GCLC (y-GCS-HS) gene has an
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EpRE, designated EpRE4 (Mulcahy et al., 1997) and this is located approximately
3.1 kb upstream of the translational start site.
Glutamate Cysteine Ligase (GCL) and relationship with other nuclear proteins
It has been shown that in COS-1 cells, the bZIP transcription factors TCF11/Nrfl and
Nrf2 cause increased expression of GCLC (y-GCS-HS) by interacting with AREs
within the GCLM (y-GCS-HS) gene (Myhrstad et ah, 2001).
Jeyapaul and co-workers showed that there is competition between antioxidant
response elements of different genes for the DNA binding of the nuclear proteins Nrf
and jun (Jeyapaul et al., 2000). This group also demonstrated that over expression of
Nrfl, Nrf2 and jun proteins caused a significant up regulation ofGCL (y-GCS) ARE-
mediated basal and beta-naphthoflavone induction of the CAT gene transfected hep
G2 cells. Also the c-Jun level within cells was shown to determine the level of ARE
mediated GCL (y-GCS) gene expression (Jeyapaul et al., 2000).
Wild (Wild et al., 1998) has postulated that the binding of the transcription factor
Nrf2 to the EpRE site in the promoter is critical to transcriptional upregulation of
GCLC (y-GCS-HS) gene. This group has shown that xenobiotic exposure of HepG 2
cells does not lead to an increase in Nrf2 protein levels and that it is likely that this
transcription factor merely translocates from the cytosol to the nucleus under the
influence of oxidative stress. Wild et al has also suggested that small Maf proteins
dimerise with jun or fos proteins and this dimerisation is essential for the DNA
binding of the Nrf2 to the EpRE site, but that Jun proteins were not required for the
inducible response. This group has also postulated that the enzyme protein product is
likely to exert both a negative and positive effect. The negative effect is mediated by
the inhibition of the dimerisation of the jun-maf proteins, and the positive effect on
the actual gene transcription. Binding at the ARE-4 promoter area may stimulate
dimerisation of small maf proteins that exert a negative effect on the DNA binding of
Nrf2 at the ARE-4 site. It is possible that there are multiple putative transcription
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sites in the promoter of GCL (y-GCS) gene that are involved in response to different
stimuli. The depletion of GSH in human alveolar epithelial cells in response to TG-
Fp has been shown to involve the AP-l/ARE-4 DNA binding site and that the AP-1
complex consists of c-Jun and Fra-1 dimers (Jardine et al., 2002). Although Jardine
and co-workers have failed to identify Nrf2 DNA binding by Supershift experiments
in resting alveolar cells (and TGF-P stimulated), this does not preclude Nrf2
promoter binding at the ARE in human alveolar epithelial cells in response to
oxidative stress.
It is thus possible that certain stimuli lead to preferential binding of a particular form
of AP-1 complex, and some of these complexes, although binding may not cause
gene transcription.
Constitutive and basal Glutamate cysteine Ligase (GCL) gene transcription
There is both constitutive and inducible GCL (y-GCS) gene transcription, with
possible differences in the associated pathways. There is evidence in HepG cells to
suggest that basal expression of GCL (y-GCS) subunit genes are under the influence
of AP-1 binding sites in the promoter region (Moinova et al., 1998; Wild et al.,
1998). Rahman and co-workers (Rahman et al., 1998) have shown that in alveolar
epithelial cells, the -511 to +82 of the 5'- flanking region of the GCLC (y-GCS-HS)
promoter is involved in the constitutive expression, and that the -303 to -201 base
pair sequence of the promoter is involved in oxidant induced transcriptional
upregulation of GCLC (y-GCS-HS) gene. Rahman et al (1998) used menadione,
which induces oxidative stress by the generation of oxygen radicals, and hydrogen
peroxide in a series of CAT reporter deletion constructs. In contrast Mulcahy, who
used P-napthoflavone and HepG2 cells, has reported an ARE present in the area -
3147 to -3137 base pairs that is involved in GCLC (y-GCS-HS) gene transcriptional




NF-kB is likely to play a pivotal role in the development of inflammation within the
lungs. This section aims to discuss the complex relationship that exists between the
transcription factor NF-kB and pro-inflammatory cytokine production, and
antioxidants within the lung. There is evidence that the pathways for NF-kB
activation may be different depending upon the stimulus, the presence of associated
antioxidants in the local cellular environment, and also on the type of cell (Janssen-
Heininger et al., 2000; Brennan et al., 1995; Bonizzi et al., 1999; Korn et al., 2001).
Nuclear factor kappa (NF-kB) is a member of the Rel family of transcription factors
which all share a sequence homology over a 300 amino acid sequence (the NF-
kb/Rel domain) (Baldwin, 1996), and can exist as hetero or homo dimmers. The
classical activated form of NF-kB is a heterodimer consisting of a 65 kD heavy
subunit and a 50 kD light unit. NF-kB can be formed from other subunits such as
p 105, p50, plOO, p52, c-Rel, and Rel B. Although dimers formed from these
subunits will have the same 300 amino acid homology, they are likely to activate
different genes and have different stimuli for translocating to the nucleus from the
cytoplasm. NF-kB that is found in the cytoplasm is in an inactive form (unable to
bind to DNA) in association with an inhibitory protein, IkB.
Inhibitory kappa B (IkB)
There are several isoforms of IkB such as hcB-a, IkB-P, IkB-y, IkB-5, and IkB-s,
but the most abundant is IkB-cx (Baldwin, 1996; Baeuerle, 1998). An appropriate cell
stimulus such as a cytokine will allow the inhibitory protein IkB-cc to be
phosphorylated at specific serine residues by specific IkB Kinases (IKK). This leads
to the transfer of an ubiquitin molecule to the IkB-oc and NF-kB complexes. In the
case of IkB-cc, ubiquitination serves as a signal to proteolytic enzymes to degrade
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IkB-oc, and so releasing the NF-kB (pl05/p65 complex) from the inhibitory affect of
IkB-cx (Karin and Ben-Neriah, 2000). In the case ofNF-kB (pl05/p65 complex) the
ubiquitination of the pi05 subunit leads to it increasing the rate at which pi05 is
processed to p50 and thus the formation of the p50/p65 complex, which can then
translocate to the nucleus where it binds to specific areas on the promoter of target
genes. The p50/p50 homodimer can bind to the NF-kB binding site, but will inhibit
transcription rather than stimulate it. The IkB-cx gene (MAD-3) has several kB
sequences in its promoter region, so that when NF-kB translocates to the nucleus it
also induces the synthesis of IkB-cx. The newly formed IkB-cc then moves into the
nucleus and binds to the activated NF-kB and induces the export of NF-kB into the
cytoplasm, thus rendering it inactive once again (Arenzana-Seisdedos et al., 1995).
Both IkBoc and IkBP in the post induction phase can enter the nucleus and repress
NF-kB DNA binding, but only IkBcx can cause nuclear export of NF-kB. Changing
the N-terminal region of IkBP to that of the IkBcc sequence allows the nuclear export
of NF-kB (Huang and Miyamoto, 2001) and this property of IkBoc allows for rapid
reactivation ofNF-kB within cells.
IKK is composed of two catalytic subunits IKKa and IKKp and a regulatory subunit,
IKKy (Zandi et al., 1999; Rothwarf et al., 1998), see figure 1.3 NF-kB activation
pathways. Negative and positive NF-KB regulator pathways converge at the level of
IKK. There are a number of upstream Kinases including Mitogen-activated protein
kinase/Extracellular signal-regulated kinase Kinase Kinase 1 (MEKK1), NF-kB
Inducing Kinase (NIK) and protein Kinase B (Akt) that activate IKK by leading to
the phosphorylation of a critical number of serine residues (phosphorylation of IkB
on serines 32 and 36) in the IKKa and IKKp subunits. The IkB Kinase (IKK)
complex and its activation is a crucial component of the activation of NF-kB in
response to various stimuli.
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Phosphatidylinositol 3- kinase (PI-3K) pathway for NF-kB activation
There is however another pathway for NF-kB activation via oxidants such as
hydrogen peroxide, pervanadate, hypoxia and ultraviolet light which involves release
of NF-kB complex by tyrosine phosphorylation of IkBoc (Li et al., 1998; Imbert et
al., 1996; Janssen-Heininger et al., 1999). The phosphorylation involves tyrosine 42
instead of serines 32/36 as is the case for IKK dependent pathway of
phosphorylation. In this the PI-3K/Akt pathway is able to activate NF-aB by
dissociating tyrosine 42 phosphorylated IkBcx from NF-kB without degrading hcBa.
This alternative (PI-3K) pathway in which there is no activation of IKK has been
associated with both degradation and lack of degradation of IkB (Imbert et al., 1996;
Beraud et al., 1999).
Using a myeloid cell line Takada (Takada et al., 2003) has shown that H2O2 induced
tyrosine phosphorylation of IkBoc occurs via syk protein kinase. Cells that do not
express syk kinase do not activate NF-kB, and this may explain why there are
conflicting reports when different cell types are used.
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There are many stimuli that can activate NF-kB (Rahman et al., 1998), table 1.3. The
cytokines interleukin-1P (IL-ip), interleukin-2 (IL-2), interleukin-6 (IL-6),
interleukin-8 (IL-8), tumour necrosis factor a and P (TNF-a and TNF-P) can trigger
activation ofNF-kB (Siebenlist et al., 1994; Barnes and Karin, 1997). Oxidant stress
such as hydrogen peroxide, ozone and hyperoxia all activate NF-kB (Schreck et al.,
1991). The ability of ROS to activate transcription factors and therefore induce gene
expression, has been described by many workers (Schreck and Baeuerle, 1994;
Adcock et al., 1994; Meyer et al., 1993). ROS can activate NF-kB by oxidation of
the cysteine-SH group or by ubiquitination and proteolytic breakdown of hcBa
(Shang et al., 1997). Oxidative stress, lipid peroxidation and increases in cytosolic
oxidized GSH (GSSG) lead to increased ubiquitination of NF-kB. TNF-a, IL-ip,
LPS and ultraviolet irradiation can also cause a cellular increase in ROS by
mitochondria (Richter et al., 1995). The reactive oxygen species signaling that
regulates the transcription of IL-4 (Jeannin et al., 1995), IL-6 and TNF-a (Gosett et
al., 1999) is mediated through a thiol dependent mechanism.
NF-kB may not be exclusively required in the redox mediated pathways governing
pro-inflammatory cytokines in the alveolar epithelium. Haddad (Haddad., 2001) has
examined LPS-induced TNF-a and IL-6 production in vitro in an alveolar epithelial
cell line. Pretreatment of the cells with BSO (inhibitor of y-GCS) prior to stimulation
with LPS augmented the TNF-a and IL-6 levels, and this was associated with
induction of intracellular accumulation of reactive oxygen species. BSO inhibited the
phosphorylation/degradation of hcB-a, but BSO also upregulated cytokine
biosynthesis, and this suggests again that NF-kB is probably not exclusively required
in the redox mediated pathways governing pro-inflammatory cytokines in the
alveolar epithelium. It has also been shown that BSO blocks the oxyexcitation
(delta/?02)-dependent nuclear localization of RelA (p65) the major transactivating
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member of the Rel family (Haddad et al., 2001). It is possible that the IkP-oc/NF-kB
pathway is independent of, or at least partially independent of the redox-dependent
regulation of pro-inflammatory cytokines. Antioxidants (Matsumota et al., 1998) and
glutathione precursors have been shown to down regulate cytokine synthesis and
down stream processes (Reimund et al., 1998), but depletion of GSH is associated
with augmentation of an inflammatory signal and exacerbation of inflammation
(Haddad et al., 2001).
Agents Capable of Activating NF-kB Inhibitors of NF-kB Activation
Tumour necrosis family N-acetyl-L-cysteine






















Table 1.3 Agents that can activate NF-kB and agents that inhibitNF-kB activation
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The cell type appears to influence the pathway for H2O2 induced NF-kB activation,
and there is also some variability within a cell type (Bonizzi et al., 1999; Bonizzi et
al., 2000). This is demonstrated in T cell lines where Wurzburg T cells, but not
Jurkat T lymphocytes are responsive to H2O2 (Anderson et al., 1994). Similarly a
different response to H2O2 is found in rat alveolar and mouse alveolar cell lines
(Janssen-Heininger et al., 1999, Korn et al., 2001). The inter-relationship of NF-kB
with antioxidants, antioxidant enzymes and cytokines is complex and not fully
understood. Oxidants not only have an effect on IKK activity, but oxidants also
influence NK-kB dependent gene transcription. Reactive oxygen species may act as
second messengers leading to NF-kB activation (Schreck et al., 1991; Flohe et al.,
1997). It is still unclear whether the redox nature of the environment is crucial to the
activation ofNF-kB or not, and this is further complicated, as work by Flayakawa et
al (Hayakawa et al., 2003) has shown that the antioxidants N-acetyl-L-cysteine and
pyrrolidine dithiocarbamate inhibit NF-kB independently of their anti-oxidative
action. Korn in contrast has shown that hydrogen peroxide inhibits the activity of
activated IKK (Korn et al., 2001). Undoubtedly epithelial cells of the lung will be
exposed to both oxidants and inflammatory cytokines, and these in vivo situations are
difficult to imitate in vitro.
Infectious agents such as bacteria and viruses, and in particular rhino virus are
known to activate NF-kB (Zhu et al., 1996). Inhibitors of NF-kB include
corticosteroids (dexamethasone), antioxidants such as GSH, thioredoxin, N-
acetylcysteine (NAC), vitamin E and the cytokines interleukin-4 and interleukin-10
(Scheinman et al., 1995; Schenk et al., 1994; Wang et al., 1994). GSH and NAC act
by inhibiting the inducible decay of IkB-oc (Oka et al., 2000). There have also been
conflicting reports where thiols such as NAC and thioredoxin have been shown to
activate NF-kB by the generation of ROS in particular circumstances, and this is
thought to be due to the reduction of a cysteine residue on the NF-kB protein
(Fernandez et al., 1999).
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NF-kB and Pro-inflammatory genes
NF-kB regulates the expression of a number of genes involved in the inflammatory
process within the lungs, including pro-inflammatory cytokines and adhesion
molecules (table 1.4).




































The genes controlling production of some inflammatory mediators are known to be
upregulated in inflammatory lung diseases. Also, the products of some genes that are
regulated by NF-kB, can also cause activation of NF-kB. This is well demonstrated
by IL-ip and TNF-a which can both activate NF-kB, and be activated by NF-kB.
Section 1.5 has already examined the role of TNF-a in lung inflammation.
In TNF and IL-1 induced NF-kB activation pathways, there are individual upstream
processes that occur prior to the degradation of h<Ba. Cell surface receptors and
protein-protein interactions occur, in which the two pathways of NF-kB activation
both utilise members of the TNF receptor associated factor (TRAP) family of adaptor
proteins and both converge at the level of the protein kinase NIK (Malinin et al.,
1997). TNF dependent trimerisation of the TNF receptor leads to recruitment to the
cell membrane of the following: adaptor protein which is a TNF-R associated death
domain protein (TRADD), receptor interacting protein (RIP) which is a death
domain containing serine/threonine kinase and subsequently TRAF2, and NIK
(Rahman and MacNee, 1998). TRAF2 and RIP have been shown to be required for
NF-kB and IKK activation (Devin et al., 2000). With regard to IL-1, an IL-1 receptor
interacts with TRAF6 and NIK with subsequent activation of IKK complex. Another
signaling pathway is that of MEKKI or MAPKKK because MEKKI is recruited to
the TNF-a activated IkB complex (Lee et al., 1997).
Activator Protein-1 (AP-1)
AP-1 is a collection of related transcription factors belonging to the Fos (cFos, FosB,
Fral, Fra2) and Jun (c-Jun, JunB, JunD) families that dimerise in various
combinations through their leucine zipper region. Dimerisation of fos-jun or jun-jun
is a prerequisite for DNA binding via a 'leucine zipper' domain (Karin et al., 1997).
A leucine zipper domain is an area that regulates the expression of a number of
genes. Fos/Jun heterodimers bind with the greatest affinity and are the predominant
form of AP-1 in most cells. Jun/Jun homodimers bind with a low affinity. Activation
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of the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) response
element (TRE) is a prerequisite for AP-1 induced transcriptional regulation. Any
agents that activate TRE such as serum responsive factor also activate AP-1 by a
protein kinase C mediated pathway (Rahman et al., 1998). Depletion of intracellular
GSH in airway epithelial cells following exposure to cigarette smoke free radicals
leads to increased AP-1 DNA binding and release of IL-8 (Rahman et al., 1996; Mio
et al., 1997). Rahman has shown that the AP-1 binding site on y-GCS gene that is
present at -269 to -263 base pairs, is involved in transcriptional up-regulation of y-
GCS-HS gene under oxidative stress (Rahman et al., 1998).
1.10 Chromatin remodeling and Gene Transcription
A key requirement in gene transcription is the accessibility of DNA to regulatory
transcription factors. DNA is packaged into chromatin to facilitate storage of large
quantities of this nucleic acid within the nucleus. Chromatin consists of the coiling of
DNA around four core histone (El) proteins: H3, H4, H2A, and H2B. H3 and H4 are
organized into a tetramer, whereas H2A/H2B is assembled as two dimmers (Beato,
1996). Chromatin remodeling occurs through the action of histone acetylases (E1AT)
and histone deacetylases (E1DAC). E1AT proteins transfer an acetyl group from
coenzyme A onto lysine, resulting in the unwinding of DNA from the histones and
increasing greater accessibility of transcription factors to genes, which in turn
enhances gene transcription (Imhof and Wolffe, 1998).
Gene repression is associated with reversal of acetylation by a process of
deacetylation which is controlled by histone deacetylases (ElDACs). Histone
deacetylases catalyse hydrolysis of the acetyl groups from the amino terminal lysine
residues of the nucleosomal core histones, thereby causing chromatin condensation
and displacement of transcription factors from gene promoters (Narlikar et al., 2002;
Fischle et al., 2001). Histone acetylation is a dynamic process and so changes in
acetylases or deacetylases can have dramatic effects on the overall histone
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acetyltransferase activity (HAT). Thus increased gene activity may result from
















(AcH = acetylated histones)
Figure 1.10 Histone acetylation and deacetylation
Acetylation of Transcription factors
Transcriptional coactivators such as CREB binding protein (CBP), and p300/CBP-
associated factor (PCAF) have intrinsic HAT activity (Ogryzko et al., 1998) and this
acetylation activity is activated by binding of transcription factors such as AP-1 and
NF-kB.
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In unstimulated cells transcriptionally inactive nuclear NF-kB consists of
homodimers of either p65 or p50 complexed with the histone deacetylase HDAC-1.
The p50-HDAC-l complexes bind to DNA and suppress NF-kB dependent gene
expression. In the face of an appropriate stimulus there is nuclear localisation ofNF-
kB together with phophorylation of p65 that associates with CBP and displaces the
p50-HDAC-l complexes. Phosphorylation of p65 appears to be critical in
determining whether p65 associates with CBP or HDAC-1, so that only p65 enters
the nucleus (Zhong et al., 2002)
Control of the duration of the NF-kB effect is influenced by histone deacetylation
and its effect on inhibitory IkBoc in the cytoplasm. Chen (Chen et al., 2001) has
shown that the acetylated RelA subunit of NF-kB becomes deacetylated through an
interaction with FIDAC-3 and this deacetylation promotes effective binding to IkBoc
and there is IkBcc dependent nuclear export through a chromosomal region
maintenance-1 (CRM-Independent pathway. Deacetylation of RelA by HDAC3 acts
as an intranuclear molecular switch that controls the duration of the NF-kappaB
transcriptional response, and contributes to the replenishment of the depleted
cytoplasmic pool of latent NF-kB-IkBoc complexes.
Glucocorticoids and Histone acetylation/Deacetylation
Glucocorticoids are an effective treatment for inflammatory diseases such as asthma,
and act by repressing the activation of transcription factors and induction of
proinflammatory mediators. In addition corticosteroids stimulate the expression of
some anti-inflammatory genes such as SLPI and IL-ip receptor antagonist (Levine et
al., 1996). However it has been postulated that repression of HAT activity, and
consequent repression of inflammatory genes, is the predominant mode of action of
corticosteroids in asthma. Ito et al (Ito et al., 2002) have demonstrated more HDAC
activity and less HAT activity in bronchial biopsies obtained from mild asthmatics
receiving inhaled corticosteroids. Reductions in HDAC activity and HDAC2
expression have also been detected in mild asthmatics compared with normal
controls (Ito et al., 2002). Similarly, mechanistic studies conducted in vitro have
provided evidence that the corticosteroid, dexamethasone enhances HDAC activity
and expression while decreasing HAT activity, responses that do not appear to be
mediated through NF-kB (Newton et ah, 1998) Different patterns of histone
acetylation are known to occur in response to dexamethasone and IL-ip stimulation
(Ito et al., 2000). In alveolar epithelial cells, IL-ip causes acetylation of histone H4
K8 and K12 and dexamethasone acetylates K5 and K16 with no effect on K8 and
K12. These differences may occur because activated GR complex inhibits acetylation
of K8 and K12 by acting both as a direct inhibitor of CBP-associated histone
acetylation, and by recruiting HDAC2 to the p65-CBP HAT complex.
Role of Histone Acetylation/Deacetylation in Proinflammatory gene induction
The hydroxamic acid, trichostatin A, is an HDAC inhibitor that has been used to
explore the role of histone deacetylases in vitro. Kagoshima (Kagoshima et al., 2001)
examined IL-ip stimulated GM-CSF release in A549 cells, following
dexamethasone and trichostatin A. Incubation with dexamethasone resulted in
inhibition of the GM-CSF release, and this inhibition was partially lost following
incubation with trichostatin A. Over expression of CBP resulted in inhibition of the
GM-CSF release. The implication being that the mechanism of glucocorticoid action
in suppressing interleukin-1 beta-stimulated GM-CSF release in A549 cells may
involve modulation of CBP-mediated histone-acetylase activity and DNA
methylation.
Further evidence for the importance of chromatin remodeling in modulation of the
inflammatory response in the lungs has come from examining IL-8 release in in vitro
systems in response to HDAC inhibitors. IL-8 cytokine release is increased in A549
cells in response to particulate air pollution Pmio (particles <10 microns in diameter)
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and hydrogen peroxide stimulation. Co-incubation of these A549 cells with
trichostatin A leads to an increase in IL-8 cytokine production (Gilmour et al., 2003),
increased HAT activity, and increased levels of acetylated histone 4. PM 10 mediates
IL-8 transcription via enhanced HAT activity and acetylation of H4 on the gene
promoter. Pretreatment of epithelial cells with trichostatin A, followed by stimulation
with LPS, TNF-a, and hydrogen peroxide leads to hyperacetylation and increased
IL-8 (Iwata et al., 2002; Rahman et al, 2002). Marwick et al (Marwick et al., 2004)
have also shown evidence of disruption of the histone acetylation/ deacetylation
balance in response to cigarette smoke in vivo in the rat.
1.11 Early One Adenovirus Protein (ElA)
Childhood Respiratory Tract Infection and the Development of COPD
The critical question of, why only 15-20% of cigarette smokers go onto develop
COPD (Tashkin et al., 1984), remains unanswered. An environmental or genetic
factor in these smokers may be important in the susceptibility to the development of
COPD. It is likely that clinical airflow obstruction results from a lengthy and initial
asymptomatic process, and a possible candidate for such an initial process or insult is
an infectious agent.
In infants, children, adults, and animal models, acute viral respiratory infection leads
to airway hyper-responsiveness (Sly and Hibbert 1989; Weiss et al., 1985; Empey et
al., 1976; Laitinen et al., 1991; McDonald et al., 1988; Huang et al., 1989; Robinson
et al., 1996; Piedemonte et al., 1990). Viruses including respiratory syncytial virus
(RSV), parainfluenza, rhinovirus and adenovirus are commonly identified in infants
and young children with a lower respiratory tract infection (Avila et al., 1989).
Korppi and co-workers have shown that twenty years after children were hospitalised
for RSV respiratory infections, lung function was found to be abnormal compared to
a control group (Korppi et al., 2004). Post-mortem lung tissue secretions obtained
from fatal asthma, asthma suffers who died from non-asthma causes and non-asthma
53
controls all show a similar viral profile using the technique of PCR, and suggest that
the lower respiratory tract acts as a reservoir for viruses (Macek et al., 1999). Macek
has also shown the presence of adenovirus capsid protein in lung tissue of children
with steroid resistant asthma that developed after childhood bronchiolitis, and in
some cases they were able to culture adenovirus (Macek et al., 1994). Some
epidemiological studies have implicated earlier childhood adenoviral infections as an
independent factor in the development of adult asthma and COPD (Samet et al.,
1983). Also, there is a reduction in mean FEVi adjusted for age and height in men
who had pneumonia in their first 2 years (Shaheen et al., 1995). It may be that the
timing of an insult (viral infection) with respect to the stage of child lung
development is the critical factor to the final outcome (in terms of airflow obstruction
development). Lower respiratory tract infection in childhood leads to impaired lung
function as measured by FEV) in adulthood and it has been suggested that this
reflects impaired lung growth. Low birth weight, and birth weight at 1 year is
associated with worse lung function in adult life and death from COPD in adult life
(Barker et al., 1991; Edwards et al., 2003).
There is evidence of chronic bacterial infection in patients with COPD (Moller et al.,
1998: von Hertzen et al., 1997). Chronic Haemophilus influenzae infection in
explanted human lung is more common in those with underlying COPD (Moller et
al., 1998) and there is a higher presence of Chlamydiae pneumoniae in patients with
COPD (von Hertzen et al., 1997). Chronic colonization with Chlamydiae
pneumoniae is also associated with increased frequency of COPD exacerbations
(Blasi et al., 2002).
Adenoviral Protein and cigarette smoke
A possible additive effect of adenoviral protein and cigarette smoke in lung
inflammation is demonstrated by adeno 5 virus infected guinea pigs where there
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were increased numbers of macrophages and T-lymphocyte helper cells in response
to cigarette smoke (Vitalis et al., 1998). Further, there is in vivo evidence in humans
that latent adenoviral infection may be important in the pathogenesis of COPD as
Matsuse showed that in resected lung tissue increased amounts of the ElA region of
the viral genome is present in patients with COPD (Matsuse et al., 1992). ElA viral
protein has also been detected in human lung sections (Elliott et al., 1995).
Adenoviral E1A Protein and susceptibility to COPD
Hogg has postulated that an earlier adenoviral infection may render the respiratory
tract more susceptible to damage in the face of an oxidant stimulus such as cigarette
smoke (Hogg et al., 2001). Adenoviral DNA can integrate itself into the human
genome and this can lead to the amplification of viral proteins (oncoptroteins). One
such viral protein is the early one adenoviral protein (El A). Human adenovirus type
5 (Ad5) produces early ElA messenger RNAs (mRNAs) of 13S and 12S that encode
proteins of 289 and 243 residues (Perricaudet et al., 1979). The major role of E1A is
to induce cell entry into the S phase of the cell cycle so that the conditions are
optimal for viral replication (Shenk et al 1996).
E1A and Proinflammatory Cytokines
The possible role of El A in lung disease (inflammation) comes from the influence
ElA can have on inflammatory cytokines and molecules. Metcalf (Metcalf et al.,
1996) found that stimulating ElA transfected cell lines (THP-1 and Jurkat) lead to
increased production of TNF-a, compared to cells transfected with a control plasmid.
ElA transfected A549 alveolar like epithelial cells when stimulated with endotoxin
produce an increased amount of IL-8 (Keicho et al., 1997). This group has also
shown that the expression of the adhesion molecule ICAM-1 is increased in ElA
transfected cells in response to LPS (Keicho et al., 1997) and that E1A may
modulate the activity of the ICAM-1 promoter in epithelial cells (Higashimoto et al.,
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1999). Furthermore, it has been shown that LPS, and not TNF-a or PMA,
stimulation of A459 ElA transfected cells leads to increased IL-8 expression (Keicho
et al., 1999). In addition E1A transfected cells, LPS stimulation fails to induce other
inflammatory mediators, such as monocyte chemotactic and activating factor, TGF-
P, IL-ip, IL-6, granulocyte-macrophage colony stimulating factor (GMCSF) and
granulocyte colony-stimulating factor (Keicho et al., 1997). It is thus possible that the
mechanism of ElA enhanced epithelial IL-8 cytokine release and ICAM-1
expression is exclusive for IL-8 and ICAM-1. It has also been demonstrated that the
NF-kB binding nucleotide sequence of the IL-8 promoter region favours binding of
the Rel-A containing homodimer rather than p50 homodimer (Keicho et al., 1999;
Brasier et al., 1998). It is likely that the ElA protein does not bind directly to NF-kB
and that its effect is through binding to co-activators. EIA transfected epithelial cells
stimulated with PMio release more IL-8 and ICAM-1 (both mRNA and protein)
compared to non transfected, and such cells also show increased DNA binding of
NF-kB (Gilmour et al., 2001; Fujii et al., 2003). Flowever Fujii also showed that the
monocyte chemoattractant MCP-1 levels were reduced in the cell supernatant of
PMjo stimulated EIA transfected A549 cells.
EIA and Relationship with NF-kB and transcriptional co-activators
The EIA 13S splice variant binds and activates NF-kB (Paal et al., 1997). EIA 13S
mediated activation ofNF-kB occurs via 2 separate pathways (Schmitz et al., 1996).
One pathway is the activation ofNF-kB containing the p65 subunit from cytoplasmic
NF-kB-IkB complex and involves reactive oxygen species, phosphorylation of IkB
and IkB degradation. The other pathway involves EIA 13S stimulation of the
transcriptional activity of the C-terminal 80 amino acids of p65 at a core promoter
with either a TATA box or an initiator (INR) element. After NF-kB has been
activated by EIA 13S there is upregulation of the transcription of pro-inflammatory
genes such as TNF-a and IL-8 (Metcalf et al., 1996; Keicho et al., 1997).
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Trancriptional coactivators p300 and CREB-binding protein (CBP) have common
domains and functions, and are ubiquitously expressed and regulate a broad spectrum
of biological activities such as cell differentiation. p300/CBP is able to recruit further
trancriptional coactivators such as p300/CBP-associated protein (PCAF) (Yang et al.,
1996), NF-kB (Perkins et al., 1997) and p53 (Avantaggiati et al., 1997). The
transcriptional coactivators p300/CBP and PCAF possess histone acetyltransferase
activity (Bannister and Kouzarides, 1996). It is thought that CBP activates
transcription by bridging the gap between DNA-bound transcription factors and
components of the general transcriptional machinery. It is likely that CBP is central
to different signaling pathways, and that sequestration of CBP by particular
transcription factors results in a particular set of genes being expressed (Chakravarti
et al., 1996). There is evidence that ElA subverts cellular processes by displacing
cellular transcription factors from CBP (Bannister and Kouzarides, 1995; Lee et al.,
1996).
ElA protein can interact with several different DNA binding domains and so can be
recruited to different gene promoters and thus can regulate the transcription of
numerous different genes that do not share the same promoter sequence (Liu and
Green, 1994). The p53 tumour suppressor gene product can activate and repress
transcription, depending upon which domain is bound (amino terminal domain and
carboxy terminal domain). p53 binds to DNA sequences called p53 response
elements, and these response elements may be present within or near the promoter of
genes, and in these cases will affect transcription. p53 binds to the TATA-binding
protein (TBP) and binding of the carboxy terminal domain of the p53 to TBP
represses gene transcription. ElA may act by reducing transcriptional repression by
displacing p53 from TBP, and in vitro EIA 13S can displace the carboxy terminal
bound p53 and so release the gene from repression (Horikoshi et al., 1995).
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1.12 Summary and rationale of thesis
Cigarette smoking, in a proportion of susceptible individuals will lead to chronic
obstructive pulmonary disease (COPD) and ultimately death from respiratory failure.
Oxidative stress from cigarette smoke and endogenously produced oxidants by
cellular processes contributes to the inflammation that occurs in the lungs in COPD.
The glutathione redox system is one of the central antioxidant defence systems in the
human lung. The altered transcription of pro-inflammatory cytokines and mediators
also contributes to the inflammatory process. NF-kB and AP-1 are both redox
sensitive transcription factors which are involved in regulation of gene transcription
ofmany pro-inflammatory mediators
The general premise though out this thesis, has been that lung tissue obtained from
subjects with airflow obstruction would show alterations in glutathione and related
enzymes, and changes in the DNA binding of the redox sensitive transcription factors
NF-kB and AP-1, and that early one adenoviral protein would be identifiable in the
lung.
HYPOTHESIS
1. There is increased glutathione levels and increased y-GCS gene transcription
in the lungs of patients with COPD and a generalised oxidant/antioxidant
imbalance in favour of oxidants.
2. The altered redox status associated with airflow obstruction leads to
activation of redox regulated transcription factors in human lungs and there is
increased DNA binding of the transcription factors AP-1 and NF-kB.
3. Latent adenoviral infection is present and can be detected in the lungs of
patients with airflow obstruction.
58
AIMS
The studies described herein were designed to measure glutathione levels, the
activity and expression of y-GCS, activation of redox transcription factors (AP-1 and
NF-kB) and to examine for the presence of EIA, and to illustrate their relationship to
the presence of COPD in vivo using human lung tissue.
Specific objectives
1. To measure GSH levels in human lung tissue obtained from smokers with
and without COPD
2. To measure the activity of y-GCS activity in human lung tissue from smokers
with and without COPD
3. To perform semi-quantitative analysis of y-GCS expression by in situ
hybridisation
4. To measure levels of lipid peroxidation products in human lung tissue from
smokers with and without COPD
5. To measure levels of 4-HNE by Western blotting
6. To measure levels of antioxidant capacity in plasma obtained from smokers
with and without COPD
7. To measure the DNA binding ofNF-kB and AP-1 in human lung tissue from
smokers with and without airflow obstruction
8. To identify the presence of EIA protein in human lung tissue
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CHAPTER 2




The glutathione reductase system is probably the most important antioxidant
defence system within the lung. In vitro studies using alveolar type II like cells have
shown alterations in GSH and y-GCS gene in response to an oxidant stimulus
including cigarette smoke (Rahman et al., 1995). In an attempt to understand the
inflammatory process that is occurring in smoking related lung disease, we
hypothesised that in lung tissue obtained from smokers with severe airflow
obstruction there would be enhanced GSH levels and increased activity of the rate
limiting enzyme y-GCS by way of a protective response to smoking related oxidant
attack. In this study systemic and local oxidative stress, glutathione, glutathione
peroxidase activity, and y-GCS activity were measured in lung tissue, and y-GCS
gene expression was examined, in patients with normal lung function, airflow




2.2.1 Methods for lung tissue collection
Lung tissue was obtained from patients who were undergoing resection for suspected
peripheral bronchial carcinoma, lung volume reduction surgery (LVRS) and lung
biopsy on the Thoracic Surgical Unit, Royal Infirmary Edinburgh between May 1998
and June 2001. The study was approved by Lothian Research Ethics Committee and
also had approval from the Research and Development Unit of the Edinburgh Hospital
Trust. Patients gave written consent for the use of lung tissue and a blood sample in
the research project. A smoking history was obtained from the patient the day before
the operation, and on the morning of the operation a blood sample was taken in an
EDTA coated tube and carried on ice back to the laboratory. On the morning of the
operation the patient was questioned as to the timing of their last cigarette and an
estimate made as to whether this was within 24 hours of the surgery.
Lung tissue was taken from the thoracic surgical theatres immediately after it was
resected, and taken on ice to the pathology department where it was examined
macroscopically by the pathologist who then removed a piece of macroscopically
normal tissue from the resected lung. The tissue was placed in cold phosphate
buffered saline (PBS) and taken to the laboratory on ice. The lung tissue was then
washed several times in PBS, gently dried in sterile gauze, and then cut into
approximately 0.5g pieces before being stored at -70°C. The first fifteen lung tissue
samples collected were placed directly into the -70°C freezer, but the later samples
were snap frozen in liquid nitrogen first and then placed in the -70°C freezer. The
EDTA collected samples were centrifuged at 6000 rpm, 4°C for 6 minutes and the
supernatant stored at -80°C.
The majority of patients had pre-operative spirometry performed in the lung function
laboratory at the Royal Infirmary Edinburgh and this data was obtained. In those who
had not had lung function performed in Edinburgh, the referring hospital was
contacted to obtain spirometry. In a proportion of patients it was not possible to obtain
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lung function data. The final histological diagnosis of the resected tissue was obtained
from the pathology department of the University ofEdinburgh.
A pool of lung tissue was created which consisted of four groups, and which included
severe airflow obstruction (LVRS), moderate airflow obstruction, no airflow
obstruction and never smokers. Twenty patients had undergone lung volume reduction
surgery. Of these nineteen, two patients had undergone LVRS bilaterally, and two
patients had LVRS trimmings taken from different lobes of the lung.
The definition of COPD used in this study was based on that of the global strategy for
the diagnosis, management and prevention of chronic obstructive pulmonary disease
(GOLD), (Pauwels et al., 2001). Moderate airflow obstruction consisted of subjects
with an FEVj/FVC ratio of less than 70%, and a percent predicted FEVi of less than
80% and greater than or equal to 30%. The presence of no airflow obstruction was
defined as normal spirometry. The non smoking group consisted of subjects with no
smoking history and no previous lung disease besides the current problem
necessitating lung resection. The fourth subject group were those with clinical and CT
evidence of airflow obstruction and emphysema who were undergoing lung volume
reduction surgery and were considered to have severe airflow obstruction, although
technically a number of these subjects did not fulfil the GOLD criteria for severe
COPD based on spirometric data.
141 patients had a histological diagnosis of bronchial carcinoma, although there was a
wide range of histological diagnosis including TB, benign hamartoma and suppurative
lung disease. Two patients who had undergone resection for suspected bronchial
carcinoma were found to have histological evidence of tuberculosis, and four patients
were suffering from a supurative lung disease. Two patients had a benign hamartoma,
one patient had a chronic scaring process present, and one patient had chronic
interstitial pneumonia. Eight patients had interstitial lung disease and one patient had
bronchiolitis organising pneumonia.
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2.2.2 Trolox Equivalent Antioxidant Capacity (TEAC)
All reagents used in this thesis were obtained from Sigma Aldrich Co Ltd., Poole, UK
unless otherwise stated.
Blood samples were collected in EDTA coated tubes on the morning of the operation.
Seventy two subjects were included and comprised patients undergoing thoracic
surgery for suspected bronchial carcinoma or lung volume reduction surgery (LVRS)
for severe emphysema. Plasma was obtained by centrifugation of the blood samples at
6000 rpm for 6 minutes. TEAC was measured by the method of Rice-Evans and
Miller (Miller et al., 1993). TEAC was calculated by defining the concentration of the
vitamin E analogue Trolox that had the equivalent antioxidant capacity to lmmol/L of
the plasma sample under investigation. Solutions of 0.5mM 2,2' Azino-bis (3-
ethylbenz-triazoline-6-sulfonic acid) diammonium salt (ABTS), 450pM hydrogen
peroxide and metmyoglobin (70pM) were prepared. A solution of metmyoglobin was
prepared by making a 740 pM solution of potassium ferricyanide (K3 FE (CN)6 in
PBS. Myoglobin (7.5 mg/ml horse heart Sigma) was added to the ferricyanide solution
to give a 400 pM solution of metmyoglobin. The ferricyanide and myoglobin were
allowed to react for five minutes with occasional shaking, and the solution placed in a
dialysis tube and dialysed in PBS in the cold room for 6 hours. The metmyoglobin
concentration was calculated using the equation:
Metmyoglobin cone = 146 x (Abs 490) - 108 x Abss6o + 2.1 x Abssgo-Abs7oo
Absorbances were read in a spectrophotometer using 1ml plastic cuvette with 0.1 ml
metmyoglobin and 0.9ml PBS and read against 1ml PBS blank.
A 70 pM working solution ofmetmyoglobin was used for the assay.
The reagents (497 pi (PBS + plasma/Trolox), 300 pi 0.5 mM ABTS, 36 pi 70 pM
metmyoglobin, and 167 pi 450pM hydrogen peroxide} were added to a 1ml plastic
cuvette, and the change in absorbance at 734 nm over 6 minutes was recorded. A
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standard curve was produced by using increasing concentrations of trolox (0, 2.5
nmole-12.5 nmole) and measuring the absorbance at 734 nm after 6 minutes. The
results reported were the mean ± SEM of one experiment performed in quadruple.
2.2.3 Lipid Peroxidation
Malondialdehyde was measured using a Calbiochem calorimetric assay kit, EMD
Biosciences, Inc, an Affiliate ofMerck K GaA, Darmstadt, Germany.
Frozen lung tissue was weighed and then homogenised on ice in 2 mis Tris CI pH 7.4
in 15 ml size falcon tubes. The homogeniser probe was cleaned between each sample
with 75% alcohol and distilled FLO. Six hundred pi of lung homogenate was placed in
1.5 ml eppendorf and centrifuged at 13000 rpm, 4°C for 10 mins. Two hundred pi of
supernatant was used in the assay.
The assay is based on the reaction of reagent Rl(10.3 mM N -methyl-2-phenylindole
in acetonitrile) with malondialdehyde (MDA) at 45°C, in which the reaction yields a
stable chromophore with a maximal absorbance at 586 nm. The reagent R1 is diluted
in methanol with 3 parts R1 to 1 part methanol to give R1 mix. The assay was carried
out in clean glass tubes. MDA standards 0.5 pM, 1 pM, 1.5 pM, 2 pM, 4 pM and 6
pM (in the final volume of reaction of 1ml) were produced using 5, 10, 15, 20, 40,
and 60 pi of the standard (standard concentration 0.1 mM). Reagent Rlmix and the
standard or sample were added together with an appropriate volume of 20 mM TrisCl
pH 7.4 to bring volume to 850 pi and vortexed for 5 seconds. One hundred and fifty pi
of 12 N HCL was added to the glass tube which was vortexed again. Plastic bungs
were inserted into the tubes before incubation at 45°C for 1 hour in a water bath, and
then cooled on ice for 10 minutes. The glass tubes were centrifuged at 3000 rpm for
10 mins at room temp. The supernatant was placed in 1ml plastic cuvettes and read
against the standard blank at 586 mn. A standard curve was produced and values for
the samples calculated using the standard curve. Lipid peroxidation was expressed in
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pinoles per gram of lung tissue. The results reported were the mean ± SEM of one
experiment performed in duplicate.
2.2.4 GSH and GSSG assays
Approximately 0.5 g of lung tissue was homogenized on ice in 0.1 M phosphate
buffer pH 7.5 with 5 mM EDTA (KPE buffer) and the supernatant was used in the
assay. Glutathione levels were measured using an assay described by Tietze (Tietze
et al., 1969). This assay detects the oxidation of GSH by the sulfhydryl reagent
DTNB (5,5'-dithiobis[2-nitobenzoic acid]) in the presence of NADPH, following the
conversion of GSSG to GSH by glutathione reductase to form the yellow derivative
2-nitro-5-thiobenzoic acid which can be detected spectrophotometrically. This assay
measures total glutathione and does not distinguish between oxidized (GSSG) and
reduced glutathione (GSH). 20 pi of supernatant, 680 pi of phosphate buffer with
EDTA, 100 pi DTNB (5mM) and 100 pi glutathione reductase (1 unit/1 OOpl) were
added to a 1 ml plastic cuvette. 100 pi of 2.4 mM NADPH was added and the rate of
change of the absorbance measured for 1 minute at 410 nm. The total glutathione
concentration was obtained using linear regression from a standard curve using
reduced GSH in the range of 0.33 to 1.35 nmol. The results were expressed in nmole
of GSH per mg of total protein. To measure GSSG, the supernatant (100 pi) and
standards were treated with 2-vinylpyridine (10 pi) for 30 minutes, followed by the
addition of 30 pi triethanolamine and thereafter used in the assay for GSH as
described above, but with GSSG standards (0.165 nM -1.65 nM). The results are
expressed nmole/mg protein, and as mean ± SEM. The results reported were the
mean ± SEM of one experiment performed in triplicate.
0.1 M Phosphate Buffer with 5mM EDTA, Ph 7.5 (KPE)
Solution A 6.8g KH2PO4 in 500 mis dH20 stored at 4°C
Solution B 8.5g K2HPO4 in 500 mis dH20 stored at 4°C
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0.1M phosphate buffer made by adding 16mls of solution A to 84 mis solution B and
diluting with 100 mis dH^O, adjusting pH to 7.5 and adding 0.327g EDTA
2.2.5 y-Glutamyl cysteine Synthetase (y-GCS) Activity
y-GCS activity was measured using the technique of Seelig and Meister (Seelig and
Meister, 1985). The enzyme activity was measured in a reaction mixture containing L-
glutamate, L-oc-Aminobutyrate, and ATP by a coupled enzyme procedure in which the
rate of formation of ADP, in the presence of pyruvate kinase, lactate dehydrogenase,
phosphoenolpyruvate, and NADH, is obtained from the decrease in absorbance of
NADH at 340 nm. The determination of y-GCS activity is based on the oxidation of
NADH which is assumed to be equal to the formation of ADP following addition of
all the necessary reagents.
The reactions are:-
y-GCS
L-glut. + ATP ► ADP + glutamylbutyrate + amino phosphate
a-aminobutyric acid
ADP + PEP ► pyruvate + ATP
LDH
Pyruvate + NADH ► lactate + NAD+
Approximately 100 mg lung tissue was homogenised on ice in lml of 0.1 M Tris HCL
pH 8, and y-GCS measured immediately after homogenisation without freezing the
homogenate as the y-GCS enzyme is very unstable.
Briefly Tris HCL (0.1M), pH 8 with 150 mM KC1, lOmM L-glutamate, lOmM L-
aminobutyrate, 20 mM Mg CI, and 2 mM sodium EDTA were prepared in advance
and stored at 4°C. On the day of the experiment Na2ATP, phosphoenolpyruvate and
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NADH at concentrations of 5 mM, 2 mM, and 0.2 mM respectively were added to this
buffer solution and this y-GCS buffer was brought to room temperature. The reaction
was carried out in 1ml glass cuvettes. y-GCS buffer (880 pi), 100 pi lung supernatant,
17 pg of pyruvate kinase enzyme (in 10 pi ) and 17 pg of lactate dehydrogenase
enzyme (lOpl) were added, mixed and the decrease in absorbance at 340nm recorded
over 1 minute. A blank was created using 100 pi water was used for comparison, y-
GCS activity was measured using the molar coefficient of 6.22 in the following
equation:
(AAbs of sample- AAbsorbance of blank) x total cuvette volume(mls) = units/ml
6.22 x sample volume (mis)
pmoles ofNADPH oxidised per minute per ml of sample (units/ml).
All results were expressed per mg protein. The results reported were the mean ±
SEM of one experiment performed in triplicate.
2.2.6 Glutathione Peroxidase (GPx) Activity Assay
This method is based on the assay described by Paglia and Valentine (Paglia and
Valentine, 1967). The GPx reaction involves the reduction of hydroperoxides
(ROOH) to water using glutathione (GSH) as a reducing substrate with the




2GSH + ROOH * GSSG + ROH + H20
GSSG + 2NADPH ► 2GSH + 2NADP+
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The assay measures the rate of disappearance of NADPH at 340 nm. Using cumene
hydroperoxide as the hydroperoxide, results in the selenium dependent form of GPx
activity being assessed.
For this assay approximately 100 mg lung tissue was homogenised in 1 ml 0.2 M
potassium phosphate buffer, pH 7 (39 mis 0.2 M KH2PO4 and 61 mis 0.2M
K2HPO4 3H20) with 2mM Na2EDTA (0.2 M KPE buffer) and supernatant used to
measure GPx activity. The reaction buffer consisted of 35 mis KPE buffer with 57
mg reduced GSH and 10 mg NADPH. A solution of cumene hyroperoxide (70 pi
cumene and 50 mis d H20) was prepared fresh and heated in water bath to 30°C.
Nine hundred pi of the precombined buffer was mixed with 100 pi of sample and
lunit of glutathione reductase (in volume of 5 pi d H20, heated in a heating block to
30°) in a quartz cuvette and allowed to stand at room temperature for 5 minutes.
Twenty five pi of cumene solution at 30°C was added and the decrease in absorbance
at 340 nm recorded over 1 minute. The activity of each sample was determined using
a bovine erythrocyte standard (Sigma). Glutathione peroxidase activity was
expressed as the pmoles of NADPH oxidised per min per ml of sample and the
results were expressed in pmoles/min/mg protein. The results obtained represented
the mean ± SEM of one experiment performed in duplicate.
2.2.7 Protein Measurement
Protein was measured using the BCA protein assay reagent kit by Pierce, Rockford,
USA. This technique utilizes bichinchoninic acid (BCA). Protein in an alkaline
environment causes the reduction of Cu to Cu , and the cuprous cation is detected
calorimetrically using BCA. A purple coloured product is formed by chelation of two
molecules of BCA with one cuprous ion and this soluble complex exhibits a linear
absorbance at 562 nm with regard to protein concentration. Ten pi of appropriately
diluted supernatant was added to each well of a 96 well plate, followed by the
addition of 200 pi of a solution composed of 50 parts solution A and 1 part solution
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B. A standard curve for the protein was generated using concentrations of bovine
albumin 0.1 -1 mg diluted in PBS. The 96 well plate was incubated at 37°C and then
read in a spectrophotometer at 570 nm
2.2.8 Statistical analysis
Results were analysed using the computer programe GraphPad Instat, and the results
expressed as mean ± SEM. ANOVA was used for comparison between several
groups, unpaired t test for comparisons between two groups and Pearson correlation
for the assessment of correlation with lung function.
An assessment of the power of the study and determining the sample size was not
undertaken prior to undertaking the study, and this will be addressed in the
discussion section.
2.2.7 In situ Hybridisation for y-Glutamylcysteine Synthetase (y-GCS)
Hybridisation is the base pairing that takes place between complementary pieces of
DNA or RNA. It allows the localisation ofDNA or RNA sequences (genes) within a
mixed population of cells within a tissue. This is achieved by the annealing of
labelled complementary nucleic acid probes to DNA or RNA sequences within tissue
sections.
Synthesis of y-GCS-HS digoxigenin riboprobe
The y-GCS-HS digoxigenin riboprobe was prepared by Dr Irfan Rahman. The 1.679
kilobase complementary DNA insert of human y-GCS-HS in pBluescript 11 SK
(ATCC 79023) was used to derive the complementary sense and anti sense probes.
The plasmid containing y-GCS-HS complementary DNA was digested using Pstl,
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resulting in a 760 base pair fragment, and was recloned into pBlue-script II SK. The
plasmid was linearised by restriction enzymes Bam HI and Hind III. T7 and T3 RNA
polymerases were used to make antisense and sense probes respectively.
Digoxgenin-labelled cRNA probes were synthesised using digoxigenin-11-UTP
(Boehringer Manheim).
Paraffin embedded sections of 4pm thickness were placed on Superfrost slides with
two sections per slide, separated using a Dako paraffin pen. Sections were
deparaffinised by heating at 60°C for 45 minutes, and washed in xylene, followed by
a 100% ethanol wash. The slides were allowed to dry at room temperature, following
which they were immersed in 0.2 N hydrochloric acid (HCL) for 20 minutes and then
washed twice in a PBS/5 mM MgCL2 solution for 10 minutes. Following this the
slides were soaked in a detergent 0.3% Triton X-100 in PBS for 15 minutes. The
tissue was made porous to the incoming probe by using proteinase K (5pg/lml
buffer) (buffer 20 mM Tris CL/5mM EDTA), and incubating at 37°C for 15 mins.
The action of proteinase K was stopped by soaking the slides in 0.2% glycine/PBS
for 10 mins. Sections were then fixed by washing in 4% formaldehyde in PBS. The
non specific sites were then blocked using 10 mM DTT in PBS at 45°C for 10
minutes, followed by x2 washes in PBS for 1 min. The slides were soaked in
triethanolamine with acetic anhydride, followed by washing with 2x SSC. Slides
were then preheated to 62°C (the hybridisation temperature) for 30 minutes prior to
hybridisation.
Hybridisation mix and slides were heated at 62°C for 10 minutes. 20ng of DIG-y-
GCS probe per 200 pi hybridisation mix were added and 200 pi of the probe/mix
was placed on each section and hybridisation was allowed to take place overnight.
The following morning the slides were washed twice in 50% formamide in 2x SSC at
50°C, followed by a 30 minute wash at 50°C, followed by a 45 minute wash in 0.1 x
SSC /20 mM P-mercaptoethanol at 62°C. The slides were incubated with 2 units
RNAse T1 (Boehringer Mannheim) per ml in ImM EDTA pH 7.8/2x SSC at 37°C
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for 30 minutes. The slides were rinsed in buffer 1 at room temperature and then
blocked using normal sheep serum 1:2000 in buffer 2, at room temperature for 30
minutes. The immunohistochemical detection of digoxigenin-labelled hybrids was
performed using sheep antibody against digoxigenin (Boehringer Mannheim) at a
concentration of 1:2000 in buffer 2 for 60 minutes. The slides were then rinsed in
buffer 1 and then buffer 3. Colour development was achieved using nitroblue
tetrazolium as a chromogen and bicholyl-indolyl phosphate as a coupling agent
(Boehringer Mannheim).
Semiquantitative Analysis
Paraffin embedded lung tissue sections from 4 patients with airflow obstruction and
4 patients with no airflow obstruction were included.
The slides were reviewed by Dr Donald Salter (Consultant pathologist, University of
Edinburgh) and cell types within the airways and alveoli were scored for the
presence of y-GCS-HS staining. The scoring system consisted of < 5% of cells
staining score 0, 5-30% score 1, 30-90% score 2, > 90% score 3.
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Hybridisation Mix
Reagents per 5ml of mix in 4x SSC
salmon sperm DNA 125 pi
t RNA 25ng/ml 200 pi
1 MDTT 49 pi
lOOx Denhardt's 50 pi
50% Dextrane sulphate 1000 pi
20x SSC 1000 pi
formamide 2500 pi
water 67 pi






made up to 500 mis with RNAse free autoclaved milliQ water
1 M Tris Ph 7.4 and pH 9.5
60.6 g Tris (NH2C(CH2OH)3)
made up to 500mls with RNAse free autoclaved milliQ water
20 x SSC
175.3 g NaCl
88.2 g sodium citrate (H0C(C00Na)(CH2C00Na)2.2H20)
made up to 1000 mis with RNAse free autoclaved milliQ water
Buffer 1 (2x buffer 1)
17.5g NaCl
23.2 g maleinezuur
made up to 800 mis RNAse free milliQ water
Bring pH to 7.5 using NaOH
Make up to 1000 mis with RNAse free autoclaved milliQ water
Buffer 2
5 g blocking-reagents in 500ml buffer 1
Buffer 3
10 ml Tris-buffer (IM Ph 9.5)
2 ml NaCl (5M)
5 ml MgCl2(lM)
made up to 1 OOmls with RNAse free autoclaved milliQ water
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2.3 Results Oxidant Imbalance
2.3.1 Markers of systemic Oxidative stress
Trolox Equivalent Antioxidant Capacity (TEAC)
System oxidative stress was assessed by measuring the plasma trolox equivalent
antioxidant capacity (TEAC) in 72 patients. The characteristics of the patients are
shown below in table 2.1, and the mean TEAC levels are shown in table 2.2. No
significant difference in mean plasma TEAC was found in patients with normal lung
function, airflow obstruction or those with severe airflow obstruction, p=0.093, ns.
Normal lung function was defined as FEVi > 80% predicted and FEV,/ FVC > 70%.
The majority of plasma samples were obtained from patients undergoing surgery for a
suspected malignant condition. Table 2.3 shows the levels of TEAC in current
smokers and acute smokers, and those with malignant and non-malignant lung
histological diagnoses.









Smoking History pack yrs 45.4(1-112)
FEV, litres (±SD) 2.57 ± 0.76
FEVi % pred 95 ± 10.5
FVC litres 3.47 ± 0.95













61.2 ±10.01 31.42 ±10.4
Table 2.2 TEAC measurements in subjects with normal lung function, COPD and
those with severe COPD who had undergone lung volume reduction surgery
Normal Lung COPD Severe
Function COPD
n=28 n=36 n=8
Mean TEAC (mM) (±SD) 0.68 ±0.12 0.75 ±0.12 0.68 ±0.11
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Mean TEAC ± SD (mmole)
smoking within 24 hrs (n=22) no smoking within 24 hrs (n=16)
Current smokers n=38 0.73 ±0.12 0.69 ±0.13




Tabic 2.3 TEAC measurements in current smokers and acute smokers, and those with
malignant and non-malignant lung histological diagnoses.
The severity of airflow obstruction assessed using percent predicted FEVi did not
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Plasma TEAC (mmole)
1.2
Figure 2.1 The relationship ofserum TEAC, a marker ofsystemic oxidative stress with
lung function as measured by % predicted FEVi. There is no significant correlation
between TEAC and % predicted FEVi (p=0.57, ns). Each point represents the mean
values obtainedfrom quadruple plasma samples.
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To assess whether acute cigarette smoking had an effect on plasma TEAC, current
smokers were divided into those who had smoked within 24 hours of the blood sample
being obtained and those who had not. There were 38 current smokers and 22 of these
had smoked a cigarette within 24 hours, 13 had not smoked in 24 hours, and smoking
history regarding last cigarette smoked was unavailable in three patients. There was no
difference in plasma TEAC levels in current smokers who had smoked acutely
compared to current smokers who had not smoked acutely (mean TEAC in acute
smokers 0.73 ±0.12 nmole, and mean TEAC in current smokers with no cigarette
smoking within 24 hours 0.69 ±0.13 nmole). A higher level of plasma TEAC was not
found in those who had smoked acutely, p=0.3, ns, figure 2.2.
1
p= 0.3
cigs within 24 hours no cigs within 24 hours
Figure 2.2 Comparison of serum TEAC levels in current smokers who had, or had
not smoked within 24 hours of the sample being taken. The histograms represent the
mean value and the bars the SEM. No difference in plasma TEAC level was
demonstrated in these two populations (p=0.3, ns).
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The effect of chronic cigarette smoking with respect to systemic oxidative stress was
examined, and no correlation was found between pack years of smoking and serum

































Figure 2.3 The relationship ofserum TEAC levels with pack years ofsmoking. There
is no significant correlation between TEAC and amount smoked as measured by pack
years ofsmoking, (r=-0.13, p=0.32 ns).
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2.3.2 Local Oxidative stress:MalondiaIdehyde in lung tissue
To investigate local lung oxidative stress, the lipid peroxidation product
malondialdehyde (MDA) was measured in human lung tissue from 46 subjects (18
smokers with normal lung function, 20 with COPD, and 8 with severe COPD having
undergone LVRS). Table 2.4 shows the characterstics of the patients in whom lung
tissue was obtained to study lipid peroxidation. Table 2.5 shows the levels of lipid
peroxidation products and figure 2.4 shows a graph of the mean MDA levels in lung
tissue obtained from patients with no airflow obstruction, airflow obstruction and
those with severe airflow obstruction who had undergone LVRS, and no significant
difference in mean MDA levels within these three groups was found, p=0.6 ns.
Table 2.4 Patient characteristicsfor MDA (lipidperoxidation)
Normal Lung COPD Severe
Function COPD
n=18 n=20 n=8
Age 62(43-77) 60(21-73) 54(42-66)
Male:female 9:9 13:7 3:5
Smoking History pack yrs 44.3 ± 12.6 3715.9 54126.9
FEVi litres (±SD) 2.910.11 1.910.08* 0.610.09*
FEV, % pred 9813.4 67.5 12.0* 22.312.4*
FVC litres 3.910.17 2.9 + 0.15 2.410.31
FEV,/ FVC % 80.412.3 62.912.4* 26.5 12.0*
MDA pmole/g tissue 49.3 18.28 40.416.34 50.919
(mean ±SEM)
* p<0.0001 versus normal lung function group
able 2.5 Levels ofMDA (lipidperoxidation) in human lung tissue
Normal Lung COPD Severe
Function COPD
n=18 n=20 n=8
















Figure 2.4 MDA (malondialdehyde) levels in lung tissue from patients with no airflow
obstruction, moderate COPD, and severe COPD. The histograms represent mean
values and the bars SEM. No significant difference in MDA levels in these three
groups ofpatient is found, p=0.6 ns. Results are reported as the mean ± SEM ofone
experiment performed in duplicate.
2.3.3 Relationship of Glutathione levels, y-Glutamylcysteine synthetase activity
(glutamate cysteine ligase) and glutathione peroxidase with lung function in
human lung tissue
Table 2.6 shows the characteristics of the 90 patients from whom lung tissue was
obtained to make measurements of total GSH and y-GCS (GCL) activity, and the
levels of GSH are shown in table 2.7. Thirty five patients had normal lung function,
thirty eight patients had airflow obstruction and seventeen patients had severe airflow
obstruction and had undergone lung volume reduction surgery. Measurements were





were found to have interstitial lung disease and so could not fulfill the criteria of
normal lung tissue, one patient had tuberculosis and lung function data was
incomplete in six patients. Ninety patients were therefore included in the final
analysis.
Table 2.6 Patient characteristics for measurements ofglutathione and y-GCS activity
Normal Lung COPD Severe COPD
Function (lung volume
reduction surgery)
n=35 n=38 n=l 7
GSH mnole/mg protein 9.57±5.67 8.08±5.51 9.84±5.57
(mean ± SD)
Age (mean ± SD) 63.3±9.2 65.417.6 55.916.5
Male: female 11:24 30:8 4:13
Smoking History (pack yrs) 38.8130.9 44.81 27.9 58141.6
Current:Ex:Never:Unknown 20:10:3:2 19:16:3:0 6:10:0:1
FEVi 2.2810.67 2.010.46 0.6810.32
FEVi % pred 96.5 ±13.1 62.91 10.8 30.9118.7
FVC 3.1±0.89 3.3 ±0.73 2.310.68
FEVi/ FVC % 72.716.5 60.7110.7 33114.2
Table 2.7 Levels ofglutathione and y-GCS activity




GSH nmole/mg protein 9.57±5.67 8.08±5.51 9.84±5.57
(mean ± SD)
Out of the 90 patients included in the study, 45 were current smokers, 36 were ex-
smokers, 6 had never smoked and there was incomplete smoking history in 3
patients. Three of the current smokers had an inaccurate smoking history recorded
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with regard to timing of their last cigarette. Of the current smokers, twenty two
patients had smoked within 24 hours of the surgery and 20 patients had not smoked.
Mean total glutathione levels were not significantly different in lung tissue obtained
from patients with severe airflow obstruction (9.57 ± 5.67 nmole/mg protein),
airflow obstruction (8.08 ± 5.51 nmole/mg protein) and the non obstructed group












no airflow obstruction airflow obstruction severe airflow
obstruction
Figure 2.5 Mean total glutathione levels in human lung tissue in patients with no
airflow obstruction, moderate airflow obstruction, and severe airflow obstruction
(LVRS). Histograms represent the means and the bars the SEM. There is no
significant difference in these groups p=0.41, ns. Results are reported as the mean ±
SEMofone experimentperformed in triplicate.
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The level of total glutathione in current (mean GSH 9.61 ± 0.77 nmole/mg protein) and
ex-smokers (mean GSH 8.36 ± 0.99 nmole/mg protein) was not significantly different
p=0.22, ns, and similarly acute cigarette smoking (within 24 hours of surgery) did not
influence GSH levels with similar levels being found in smokers who had (mean GSH
10.56 ± 1.15 nmole/mg protein) and who had not smoked (mean GSH 8.72 ± 1.17














Figure 2.6 Glutathione levels in current and ex smokers. Histograms mean and bars









cigs within 24 hours no cigs within 24 hours
Figure 2.7 Glutathione levels in lung tissue of smokers who have smoked within 24
hours of surgery and those who have not. Histograms represent means and bars the
SEM. No significant difference is demonstratedp=0.24, ns.
Measurements of reduced glutathione (GSSG) in lung tissue supernatants revealed
negligible amounts ofGSSG.
Although no difference in total GSH was found in patients with severe airflow
obstruction, we were interested to know if there was a difference in the activity of the
rate limiting enzyme in GSH production, y-GCS (GCL). In contrast to the GSH data, y-
GCS (GCL) activity in lung tissue obtained from smokers with severe airflow
obstruction was significantly lower that of smokers without airflow obstruction,
p<0.01, figure 2.8.
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No airflow Airflow obstruction
obstruction
LVRS
*p< 0.05 airflow obstruction versus no airflow obstruction
** p< 0.001 LVRS versus no airflow obstruction
Figure 2.8 y-GCS activity in human lung tissue from patients with no airflow
obstruction, airflow obstruction, and severe airflow obstruction (L VRS). Histograms
represent the means and the bars the SEM. There is a significant difference in y-GCS
activity in the group undergoing LVRS compared to the group with no airflow
obstruction, p<0.01, and there is a significant difference in y-GCS activity in the
group with airflow obstruction compared to the group with no airflow obstruction
p<0.05. Results are reported as the mean ± SEM of one experiment performed in
triplicate.
The relationship of chronic cigarette smoking as measured by pack years of smoking







































(units per mg protein)
Figure 2.9 The relationship ofg-GCS with smoking history (pack years). This graph
shows that there is no significant correlation between pack years of smoking and
levels ofy-GCS in human lung tissue, (r=0.1, p=0.18, ns).
Glutathione peroxidase activity was measured in a representative sample (46) of the
81 patients who had measurements of GSH made in lung tissue. There was no
difference between this group of 46 patients and the group as a whole (81 patients).
Table 2.7 shows the characteristics of the 46 patients, and the levels of glutathione
peroxidase are shown in table 2.8.
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Tabic 2.7 Characteristics of the 46 patients in whom glutathione peroxidase activity
was measured in human lung tissue.
Normal Lung COPD Severe COPD
Function
n=18 n-21 n=7
Age (range) 64.3 (37-75) 64.5 (21-73) 55.9 (42-66)
Male:female 4:14 13:7 3:4
Smoking History (pack yrs) 35.9 ±4.8 45.1 ±6.4 74.4 ±23.9
FEVi litres (±SD) 2.1 ± 0.16 1.9 ±0.09 0.61 ±0.15
FEVi % pred 94.8 ±3.2 64.6 ±2.1 27.7 ±0.9
FVC litres 2.9 ± 0.2 3.2 ±0.18 1.7 ±0.3
FEVi/FVC% 71.6 ±5.9 61 ±2.4 39 ±5.9
Table 2.8 Levels ofglutathione peroxidase in human lung tissue
Normal Lung COPD Severe COPD
Function
n=18 n=21 n=7
Glutathione Peroxidase 0.076± 0.018 0.07 ± 0.018 0.077 ± 0.019
Activity (units/mg protein)
Mean ± SD
No significant difference in glutathione peroxidase activity level was found in
smokers without obstruction (mean GPx 0.076 ± 0.018 units/mg protein), with
airflow obstruction (mean GPx 0.07 ± 0.018 units/mg protein), and with severe
86



















Figure 2.10 Shows glutathione peroxidase activity in human lung tissue from the
patient groups no airflow obstruction, moderate airflow obstruction, and severe
airflow obstruction (LVRS). Histograms represent the means and the bars the SEM.
No significant difference in glutathione peroxidase activity was found, p= 0.77, ns.
Results are expressed as the mean ± SEM ofone experiment performed in duplicate.
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Levels of glutathione peroxidase in human lung tissue did not correlate with pack
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Glutathione peroxidase
Figure 2.11 The relationship of lung glutathione peroxidase levels with packyears of
smoking. There is no significant correlation between TEAC and amount smoked as
measured by pack years ofsmoking, (r=0.01-, p=0.95 ns).
3.3.4 In-situ hybridization for y-Glutamylcysteine Synthetase expression in
human lung (GCL)
Expression of y-GCS-HS was examined in human lung tissue sections from eight
subjects with and without airflow obstruction using in situ hybridization. Table 2.9
summarises the data concerning age, lung function and smoking history for the two
groups of patients examined. All patients were current smokers (having smoked
regularly within the last 6 months). Only one patient in the no airflow obstruction
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group had smoked within 24 hours of the lung surgery, whereas three of those with
airflow obstruction had smoked within 24 hours of the surgery. Mean pack years of
smoking was lower in the airflow obstruction group with a large standard deviation
compared to the no airflow obstruction group.
Table 2.9 Clinical characteristics ofsubjects
Age FEVj FEVi/VC Pack years
n (years) % predicted (0/
No airflow obstruction 4 61.5+ 5.3 89+ 1.8 75.2+ 3.5 61.5+ 11.9
Airflow obstruction 4 63.3+ 8.6 65.9+5.9 59.5+ 5.4 48.7+ 18.9
Figure 2.12 Figure 2.13
Figure 2.12 and 2.13 Photomicrograph examples of staining using antisense and
sense m RNA probes for y-GCS-HS in lung tissue from a patient with no airflow
obstruction. In figure 2.12 there is strong dark blue staining in a cytoplasmic
distribution in the bronchial epithelial cells and also the alveolar epithelial cells. The
sense probe in figure 2.13 shows no staining.
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Table 2.10 Staining scoresfor y-GCS-HS expression in epithelial cells in lung tissue
Bronchial type I type II
Epithelium Alveolar Alveolar
Epithelium epithelium
No airflow 3 3 3








Table 2.11 Staining scores for y-GCS-HS expression in smooth muscle cells in lung
tissue
Vascular smooth muscle Airway smooth vascular endothelium
bronchial alveolar muscle bronchial alveolar
No airflow 3 0 2 1 0
obstruction 3 0 3 0 0
2 0 2 2 0














Tables 2.10 and 2.11 are the staining scores for y-GCS-HS expression in epithelial
cells and smooth muscle cells. The epithelial cells of all types in airflow obstruction
and no airflow obstruction stain consistently for y-GCS-HS expression, where as in
smooth muscle this is more variable, with virtually no staining in alveolar smooth
muscle and alveolar vascular endothelium.
The predominant cell types that expressed y-GCS-HS mRNA in lung tissue from
smokers with and without airflow obstruction were epithelial cells, including
bronchial, and type I and type II alveolar epithelial cells. Figure 2.12 and 2.13 show
photomicrographs of the staining obtained using anti-sense and sense RNA probes.
Strong dark blue staining in a cytoplasmic distribution is shown with the antisense y-
GCS-HS probe. Tables 2.10 and 2.11 show the scores for the y-GCS-HS gene
expression in different cell types. No difference in y-GCS-HS mRNA expression in
epithelial cells is shown in the score for subjects with and without airflow
obstruction. In both groups alveolar vascular smooth muscle, bronchial, and alveolar
endothelium stained poorly suggesting that there is very little expression of y-GCS-
HS in these cell types.
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2.4 Discussion Antioxidant imbalance
Chronic obstructive pulmonary disease is characterised by an abnormal
inflammatory response in the lungs to inhaled particles and gases usually in the form
of cigarette smoke (Pauwels et al., 2001). The mechanism by which inflammation is
'abnormal' or enhanced in smokers who develop COPD is unknown but is the focus
of intensive study. Enhanced oxidative stress is proposed as a mechanism by which
inflammation is amplified in the lungs of COPD patients. Several studies have
measured enhanced markers of oxidative stress in breath/breath condensate in COPD
patients as an indication of increased airspace oxidative stress (Kharitonov and
Barnes, 2001). The studies in this thesis have used fresh human lung tissue in an
attempt to provide evidence for an altered overall oxidant/antioxidant imbalance in
favour of oxidants in the lung tissue of smokers who have developed COPD
compared to smokers with a similar smoking history, that have normal lung function.
Reactive oxygen species are generated in smoking related lung disease from
inflammatory leucocytes, the normal process of aerobic metabolism and exogenous
sources such as cigarette smoke. Protective antioxidant systems including the
GSH/redox system, SOD and catalase operate to balance the oxidant attack. Free
radical scavengers within the blood and tissues such as vitamins C and E, a-
tocopherol, albumin and amino acids can help detoxification of these oxidants. Free
radical activity can be assessed by measurements of lipid peroxidation, levels of
plasma antioxidants such as albumin, and measurements of total antioxidant capacity
in the systemic circulation. There are various methods of assessing free radical-
scavenging activity in plasma including the total peroxyl radical-trapping antioxidant
parameter (TRAP) assay (Wayner et al., 1987) which is based on the constant
production of water-soluble peroxyl radicals by the spontaneous decomposition of an
initiator such as 2,2'-azobis(2-amidopropane) hydrochloric acid (ABAP), enhanced
chemiluminescent (ECL) assay (Whitehead, 1992) and the use of the ABTS assay, of
which TEAC is a variant. Measurements of total antioxidant activity are highly
dependent on the assay used, with each assay having its own specific oxidative stress
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and index marker of oxidation. Different assays tend to be more influenced by one
particular antioxidant component than others. In the case of TEAC the major
antioxidant component is plasma proteins (albumin 43%, urate 33%, ascorbate 9%
and vitamin E 3%). Urate contributes 70% of the plasma antioxidant capacity by the
ECL method and 58% in the TRAP assay.
In this study the trolox equivalent antioxidant capacity (TEAC), a marker of
systemic oxidative stress, was measured in plasma obtained before patients
underwent surgery for suspected bronchial carcinoma or LVRS. No significant
difference in mean plasma TEAC level was found in the three groups, and levels of
TEAC did not correlate with the degree of airflow obstruction. Rahman also failed to
demonstrate a correlation between degree of airflow obstruction and systemic
oxidative stress as measured by TEAC in the peripheral blood of smokers with and
without airflow obstruction, and a healthy control population (Rahman et al., 2000).
However, Rahman has also shown that BALF TEAC is elevated in healthy smokers
compared to healthy non-smokers, and that both smokers and non smokers with IPF
have reduced BALF TEAC compared to healthy smokers and non smokers (Rahman
et al., 1999). Acute smoking and also exacerbations of COPD have been associated
with a reduction in serum TEAC compared to controls (Morrison et al., 1999;
Rahman et al., 1997). However, we found that in chronic smokers, smoking within
24 hours of collection of the sample did not affect TEAC levels, and the presence of
a malignant or non malignant diagnosis did not influence the TEAC levels. It is
likely that changes in TEAC in response to acute cigarette smoking occur earlier
(than 24 hours) and that levels have returned to baseline by 24 hours. Tumour cell
lines generate constitutively high levels of hydrogen peroxide (Szatrowski and
Nathan, 1991), and reduced plasma peroxyl radical trapping capacity has been found
in lung cancer patients compared to controls (Erhola et al., 1997). It is therefore
possible that reductions in serum TEAC in patients with severe airflow obstruction
were masked as the comparison groups (no airflow obstruction and moderate airflow
obstruction) may have had a reduced serum antioxidant capacity by virtue of the lung
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cancer. However it has also been shown that patients undergoing thoracotomy for
both malignant and non malignant processes have the same baseline TRAP levels
(antioxidant capacity) before surgery, which rises several months after surgery
(Erhola et al., 1998). Our study aimed to determine if there was increased systemic
oxidative stress in patients with severe airflow obstruction compared to those with
normal lung function, and so a control group of normal healthy volunteers was not
included. However previous data indicate higher levels of TEAC in a control group
of healthy non smokers of 1.31 mmol/L (Rahman et al., 2000).
The lipid peroxidation product MDA was measured in resected human lung
tissue. The levels of MDA in human lung tissue, were not significantly different in
the three patient groups. Others have demonstrated higher levels of lipid peroxidation
products in the epithelial lining fluid of patients with COPD compared to controls
(Morrison et al., 1999). However in lung tissue there have been conflicting reports
with regard to the level of lipid peroxidation products in smokers lungs compared to
non smokers (Fahn et al., 1998; Petruzzelli et al., 1990).
The GSH redox system plays a critical role in maintaining the intra- and
extra-cellular oxidant/antioxidant balance, particularly in the lungs. The purpose of
the experiments reported in this chapter was to identify differences in GSH and its
enzyme system in lung tissue from patients with airflow obstruction, compared to
those without airflow obstruction. The hypothesis was that alterations in the GSH
redox system may be related to the enhanced oxidative stress and hence the
susceptibility to the effects of cigarette smoke, which may be a factor leading to the
development of airflow obstruction in susceptible smokers.
We found no difference in lung total GSH levels in smokers with and without
airflow obstruction, decreased levels of y-GCS (GCL) activity in patients with severe
airflow obstruction, and no alteration in GPx activity in the airflow obstruction
group.
The response of the GSH redox system to cigarette smoke has been studied
by Rahman et al (Rahman et al., 1995) who showed in the A549 human alveolar
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type II-like cell line that cigarette smoke condensate leads to an initial depletion of
intracellular GSH, followed by a rebound increase in GSH synthesis. The in vivo
corollary of these experiments show that epithelial lining fluid GSH is increased two
fold in chronic smokers, but is decreased in the face of acute smoking (Morrison et
al., 1999). Linden found that airflow obstruction as measured by percent predicted
FEVi, showed a correlation with BALF GSH (Linden et al., 1993). However, in an
earlier study BALF GSH levels were found to be similar in chronic smokers with and
without airflow obstruction (Linden et al., 1989). In my study, the levels of total
glutathione in whole lung tissue from smokers with severe COPD, moderate COPD
and normal lung function were not significantly different between these three groups.
Measurement of GSSG (oxidised GSH) were virtually undetectable in the vast
majority of samples analysed using the method based on Tietze (Tietze, 1969). It is
possible that if a different method with a greater sensitivity to detect GSSG had been
employed then the GSH:GSSG ratio could have been calculated and this may have
been altered indicative of increased oxidative stress. High performance liquid
chromatography (HPLC) developed by Reed et al (Reed et al, 1980) has been used to
measure GSH/GSSG in the nanomole range, and liquid chromatography/mass
spectrometric methods are also able to detect levels of GSH and GSSG as low as 3.3
pmol (Guan et al., 2003). Due to limitations in the amount of lung tissue available, it
was not possible to undertake repeated measurements of glutathione in lung tissue
using another method.
Human lung tissue consists of numerous cells types, connective tissue and
blood vessels which contain red blood cells. Red blood cells contain GSH, and it was
hoped that a correction for haemoglobin GSH could be included. We attempted to
measure haemoglobin levels in the supernatant from the homogenised samples using
an haemoglobin measuring kit from Sigma, however the levels in the samples were
below the detection range of the kit suggesting haemoglobin contamination was not a
problem. Moreover, the levels ofGSH that we found were similar to previous reports
(Cook et al., 1991; Blair et al., 1997). Both these previous studies included much
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smaller numbers of lung tissue samples than the experiments presented in this thesis.
Blair (Blair et al., 1997) used a flourometric method using supernatant from lung
tissue homogenised in 5% trichloroacetic acid, and did not use a correction for
haemoglobin. Cook (Cook et al., 1991) used the Tietze method (Tietze et al., 1969)
to determine GSH levels in cell suspensions obtained from enzymatic digested lung
tissue, and removed red blood cells from the cell suspensions by lysis.
Degraded tumour biopsies show cell population variations in thiol stains,
suggesting that subpopulations within tumour cells have different GSH levels (Cook
et al., 1991). Homogenised lung tissue, may not reflect more subtle changes that are
occurring in individual cells such as macrophages and bronchial epithelial cells and
may therefore give the false impression that there is no alteration in GPx, and GSH
levels. Alternatively it could be argued that the initial assault on the
oxidative/antioxidative balance from cigarette smoke occurs in the epithelial lining
fluid, where the protective response is to increase ELF GPx and GSH to protect the
valuable epithelial cells, and GPx and GSH is therefore not altered within the cells.
In cell lines acute exposure to cigarette smoke condensate decreases the levels of
GSH (Rahman et al., 1995), and so details of smoking history including the time of
the last cigarette in relation to the surgery was recorded. We also examined whether
there was a difference in GSH in smokers compared to ex-smokers, and also whether
smoking a cigarette within 24 hours of obtaining the lung tissue had an effect on
GSH levels. No difference in GSH levels was found in any of these groups.
In our work patients with severe airflow obstruction had undergone LVRS, a
surgical procedure for a non malignant process, whereas the majority of the other
pieces of lung tissue specimens were obtained from subjects with an underlying
malignant process affecting the lungs. Melloni et al has examined GSH levels in ELF
and found higher levels in the ELF from patients with non small cell lung cancer
compared to non smokers, and smokers without lung cancer (Melloni et al., 1996).
To examine whether the presence of malignancy influenced GSH or y-GCS levels, a
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comparison was made between malignant and non malignant histological diagnoses,
and no significant differences were identified.
Extracellular antioxidants are the initial defence against inhaled ROS, which
subsequently become utilised in the epithelial lining fluid of the lungs. Glutathione
peroxidase is an important enzyme and is found intracellularly (cGPx) as well as
extracellularly (eGPx). The airway epithelium expresses and secretes GPx into the
epithelial lining fluid. There is increased eGPx expression in bronchial epithelial
cells and macrophages from chronic smokers compared to non smokers (Comhair et
al., 2000), and increased GPx acitivity is present the ELF of patients with chronic
berrylium disease compared with healthy controls and healthy smokers (Comhair et
al., 1999). I found no significant increase in GPx activity in human lung tissue from
patients with airflow obstruction, or current smokers versus ex-smokers, and nor did
the timing of the last cigarette influence the GPx levels.
In epithelial cell lines cigarette smoke and also other oxidant stress leads to
an initial decrease in GSH followed by a rebound increase in GSH, and these
changes are mirrored by changes in y-GCS mRNA (Rahman et al., 1996) and also y-
GCS activity (Ray et al., 2002). After examining GSH levels in lung tissue, we
studied the activity of the rate limiting enzyme y-GCS. Interestingly, there was a
significant correlation between lung function as measured by percent predicted FEV i
and y-GCS activity, and more specifically that the lung tissue from patients with
severe COPD undergoing LVRS had significantly lower levels of y-GCS activity
compared to smokers without airflow obstruction. These y-GCS results in some
respect appear to be in conflict with the GSH results in which no association with
lung function was found. However, it could be that a real association of GSH with
lung function was masked due to inaccuracies in the measurement of GSSG, or
contamination in the tissue homogenate from red blood cell glutathione. y-GCS is the
rate limiting enzyme in the synthesis of GSH and so it would be expected that
decreased y-GCS activity would be associated with decreased levels of GSH. In our
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studies the fact that y-GCS activity is decreased in lung tissue of smokers with
reduced FEVi and lower levels of y-GCS activity did not result in lower lung GSH in
COPD patients, suggests post transcriptional / translational modification of y-GCS.
The premise has been that a difference in GSH levels in smokers with and without
airflow obstruction would support the theory of susceptibility to development of
airflow obstruction in the severe airflow obstruction group. However the converse
may be true, with no difference in GSH levels in patients with and without COPD,
suggesting a failure to mount an appropriate response to an enhanced oxidant burden
in smokers with COPD.
Rahman et al (Rahman et al., 2000,) examined human lung tissue using in situ
hybridisation and found that there was increased expression of y-GCS in the alveolar
epithelium in smokers with COPD. Similarly animal work has also shown
localisation of y-GCS protein and message to the alveolar epithelium in response to
an oxidant stimulus (Shukla et al., 2000).
To investigate if there were more subtle changes in y-GCS expression in individual
cellular components of lung tissue, in-situ hybridisation was performed on lung
sections from patients with and without airflow obstruction. Although small numbers
were used, a consistent finding in both groups was that the predominant cell types
expressing y-GCS mRNA were epithelial cells, both bronchial and alveolar, and
there was a general lack of staining in alveolar endothelium. My work, although on
smaller numbers of tissue sections, is in agreement with others (Rahman et al., 2000)
and has shown localisation of y-GCS expression to be predominantly in the
epithelium of the lung.
Inaccuracies may have been present in this study. The use of resected lung
tissue inevitably carries the risk of intraoperative factors influencing the results. Also
the use of homogenised lung tissue, as is the case in this thesis, may not reflect more
subtle changes that are occurring in individual cells such as macrophages and
bronchial epithelial cells. The blood samples were collected in EDTA coated tubes
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and then centrifuged to yield plasma. Collection in heparin coated tubes may have
been better as heparin does not interfere with the TEAC assay, and EDTA coated
tubes can give lower values. The mean results obtained for TEAC in our population
of severe airflow obstruction and moderate airflow obstruction, 0.68 nmole and 0.75
nmole respectively, is lower than that reported by Rahman who collected blood
samples in heparin coated tubes, were levels of 0.81 were found. Haem proteins will
promote the formation of ABTS+ and give falsely elevated TEAC levels, and so
careful separation of whole blood is important. This was not a problem in our study
as the whole blood was collected in 4 separate EDTA coated tubes which were
centrifuged, and samples with inadequate separation were discarded, without
contamination of the remaining samples. The smoking history may not have been
accurate as the majority of patients were undergoing surgery for a lung malignancy
and so may not have disclosed their true smoking history or time of their last
cigarette. Also we did not use an objective measurement of the smoking status such
as urinary cotinin or carboxy haemoglobin to aid confirmation of ex-smokers. Drugs
may influence systemic oxidative stress and inflammation and no details of the drugs
the patients were receiving were included in this work.
Before embarking on the various studies documented in this thesis, an assessment of
the power of the study should have been undertaken. This is particularly important as
a large number of the studies included in this thesis failed to show sufficient
evidence to reject the null hypothesis. One possible reason for this is that the sample
size could have been too small to detect any statistically significant differences
between the groups of interest.
A key component of the power of a research study is determining the sample size.
The sample size will be influenced by the size of the clinically relevant expected
difference in the measurement that is being investigated in the different groups. If the
expected size of the difference in the measurement is small, and also if the
measurements show a lot of variability then the sample size will need to be larger.
The variability of the measurement under observation can be obtained from
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previously published work or by performing a pilot study. Certainly there is previous
published work (Cook et al., 1991; Blair et al.t 1997) that has examined levels of
GSH in human lung. However, the earlier work did not examine GSH levels in the
specific patient groups that we were interested in and so details of the expected
difference in the measurements were not readily available. However, data presented
in this thesis could now be used to help determine the power of a future study.
In summary no difference in local or systemic oxidative stress, and no difference in
lung total GSH or GPx levels were found in patients with or without airflow
obstruction, although y-GCS activity was reduced in patients with severe airflow
obstruction. It is possible that the epithelial lining fluid is the site that manages
oxidative stress inorder to minimise intracellular changes, and this may explain our
findings in lung tissue.
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CHAPTER 3
THE ASSESSMENT OF NF-kB AND AP-1 DNA BINDING IN HUMAN
LUNG TISSUE IN PATIENTS WITH AND WITHOUT
AIRFLOW OBSTRUCTION
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3.1 Introduction Transcription factors
Increased inflammatory cytokine production is evident in the lungs of smokers with
COPD, and this may initiate or contribute to the inflammation and damage that
occurs, and the subsequent development of airflow obstruction. Cytokine expression
is under the influence of transcription factors such as NF-kB and AP-1. NF-kB and
AP-1 are both considered to be redox sensitive transcription factors, although there is
evidence that the pathways for NF-kB activation may be different depending up on
the stimulus, the presence of associated antioxidants in the local cellular
environment, and also on the type of cell (Janssen-Heininger et al., 2000; Brennan et
al., 1995; Bonizzi et al., 1999; Korn et al., 2001). Reactive oxygen species may also
act as second messengers leading to NF-kB activation (Schreck et al., 1991; Flohe et
al., 1997).
We hypothesized that lung tissue obtained from smokers with airflow obstruction
would demonstrate increased DNA binding of the transcription factors NF-kB and
AP-1 compared to lung tissue obtained from smokers without evidence of airflow
obstruction. We also examined the subunits ofNF-kB and AP-1 in lung tissue.
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3.2 Methods
Transcription Factor Nuclear Binding in lung tissue
Lung collection and processing was as previously described in chapter 2 methods.
The DNA binding of the transcription factors NF-kB and AP-1 was assessed in lung
tissue obtained from thirty five patients who had undergone surgery for suspected
bronchial carcinoma or who had undergone LVRS. In this group lung tissue was
obtained from three individuals who had never smoked, four subjects who had severe
airflow obstruction and who were undergoing LVRS for emphysema, and twenty
eight smokers who were undergoing resection for suspected bronchial carcinoma (14
with airflow obstruction and 14 without airflow obstruction). In the case of surgery
for suspected tumour, macroscopically normal tissue away from the tumour was
used. Lung tissue was stored at -80°C until the experiments were carried out.
3.2.1 Extraction of Nuclear Protein
Samples of approximately 0.5 g of frozen lung tissue was homogenised on ice (using
a polytron homogeniser) in 1 ml ice cold buffer A (10 mM HEPES pH 7.8, 10 mM
KC1, 2 mM MgCL, 0.1 mM EDTA, 0.2 mM NaF, 0.4 mM PMSF, leupeptin 1 pg/pl
and 0.2mM Na orthovanadate). Pieces of fibrous material within the homogenate
were discarded. The homogenised sample was left to stand on ice for 15 minutes,
after which 200 pi of buffer B (10% Nonidet-P40 solution in distilled water) was
added to the homogenate and vortexed hard for 15 seconds. The sample was
centrifuged at 13000 rpm, 4°C for 20 seconds, the supernatant discarded and the
pellet retained. Depending on the size of the pellet remaining then 50 pi or 100 pi of
buffer C (50 mM Hepes, 50 mM KC1, 300 mM NaCl, 0.1 mM EDTA, 1 mM EDTA,
1 mM DTT, 0.4 mM PMSF, 10%glycerol, 0.2 mM NaF and 0.2 mM NaVCL) was
added and the mixture pipetted up and down using a wide bore pipett tip. The sample
was agitated on ice for 30 minutes and centrifuged 13000 rpm 4°C for 5 mins. The
supernatant fraction (nuclear protein extract) was stored at -80°C.
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3.2.2 Total Protein Assay
Nuclear protein was measured using a BCA protein assay by Pierce, Rockford, USA.
In brief standard concentrations of bovine serum albumin (BSA) were made up of
0.05 mg/ml - lmg/ml. The nuclear protein samples were either used in their
concentrated form or in an appropriate dilution. lOpl of sample and lOpl of the
standards were added to a 96 well plate. Reagents A and B were mixed together in
1:50 ratio. 21 Opil of (A&B) mix was added to samples and standards and incubated
for 30 minutes at 37°C, and then the absorbance was read at 570 nm using a
spectrophotometer. Standard curves were drawn and sample protein concentrations
calculated.
3.2.3 Electromobility Gel Shift Assay (EMSA)
This is a technique in which nuclear proteins are incubated with a radio labelled
oligonucleotide sequence and then resolved on an acrylamide gel. In this technique
proteins that bind specifically to an end-labelled DNA fragment (probe) retard the
mobility of the fragment during electrophoresis and result in discrete bands that
correspond to the protein-DNA complex. The density of the bands reflects the
affinity of binding and gives a quantitative assessment of the DNA binding.
Preparation and radioactive labelling of lung tissue nuclear extracts
Ten pg of nuclear extract was incubated on ice for 20 minutes in a 500 pi eppendorf
with 4 pi of loading buffer (50 mM Tris CI pH 7.5, 500 mM KC1, 2.5 mM MgCh, in
40% glycerol and water solution) and 0.5 pi of poly dl-dC, Promega, Southampton,
UK and made up to a final volume of 19 pi with distilled H2O. One pi of labelled
oligonucleotide probe was added to the mix and incubated for 20 minutes at room
temperature.
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Cold competitor: 2pl of the same unlabelled oligonucleotide sequence was added to
the mix, together with the labelled probe.
Cold non-competitor: 2pl of a different oligonucleotide sequence was added to the
mix, together with the labelled probe.
Negative Control: Distilled water replaced the sample volume.
Positive control:HeLa Extract (Promega)
Radioactive labelling of consensus oligonucleotide probe
(y-32 P) ATP (Amersham Pharmacia Biotech, Buckinghamshire, UK) within the
second half life of decay was used and 2p 1 (1.75 pmol/p 1) of consensus
oligonucleotide of interest was used.
Consensus sequence ofNF-kB-DNA binding site:
5' AGT TGA GGG GAC TTT CCC AGG C-3' (Promega)
Consensus sequence of AP-1 -DNA binding site:
5'-CGC TTG ATG AGT CAG CCG GAA-3' (Promega)
Consensus sequence ofOct-1 (Promega)
5'-TGT CGA ATG CAA ATC ACTAGA A-3'
1 jlxI lOx T4 polynucleotide kinase buffer, lp 1 T4 polynucleotide kinase (5010u/pl),
5pl d H2O2, and lp 1 (y-32 P) ATP (3000Ci/mmol at lOmCi/ml) were added to a 500pl
eppendorf tube and incubated at 37°C for 10 minutes. The reaction was stopped with
lpl 0.5 M EDTA and 89 p 1 of lx TE buffer was added. The labelled probe was
stored at -20°C.
Loading buffer (DNA protein binding buffer)
50 mM Tris CL, 500 mM KC1, 5 mM DTT, 5 mM EDTA, 2.5 mM MgCh and 40%
glycerol.
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Electromobility mobility shift assay (EMSA)
The protein-DNA complexes were resolved on a nondenaturing 6% acrylamide gel
(10 mis lx TBE buffer, lOmls acrylamide bis, 10 mis d H2O2 , 700 pi fresh 25%
ammonium persulphate and 20 pi tetramethylethylemediamine
(TEMED) in lx Tris-borate-ethylenediamine tetraacetic acid (TBE) running buffer
for 4 hours at 100V. The polyacrylamide gel mixture was poured immediately into
the prepared gel plates and the comb inserted for creation of the wells. The gel plate
system was loaded into the tank with approx 500 mis lx TBE buffer and the
apparatus checked to identify leaks, before electrophoresis was commenced. Prior to
loading the samples in the wells, the gel was pre run for 30 minutes at 150 volts.
Samples were added to the wells and the gel continued to be run at 150 volts until the
samples had passed through the wells, and the voltage was then reduced to 100 volts.
The gels were removed from the glass plate apparatus, vacuum dried onto Whatman
paper and autoradiographed at -70°C using Kodak film.
DNA binding was assessed by autoradiography and quantitative analysis was
performed by densitometry measurements of the bands using UVP Grab and Gelplate
program (UltraViolet Products, Limited, Cambridge, E1K). The HeLa nuclear extract
was used as the positive control and all other bands were measured relative to this.
An arbitary value of 100 was assigned to the HeLa band and all other bands were
graded relative to this. To combat any inaccuracies in gel loading, a normalization
technique was used. The process of normalisation was achieved by using the
universal transcription factor, Octamer-1 (Oct-1) and expressing the amount of
transcription factor DNA binding as a ratio to Oct-1 binding.We were thus able to
compare bands on different EMSA gels.
Data was expressed as mean ± SEM. GraphPad Instat statistical package was used to
analyse the data. Spearman Rank correlation was used to analyse the data with regard
to the correlation of the DNA binding with lung function, and Mann-Whitney test to
compare DNA binding within the groups with and without airflow obstruction.
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3.2.4 Supershift Assay
EMSAs for NF-kB and AP-1 gave more than one band. This is because NF-kB and
AP-1 have several homo and heterodimers, all of which share a similar amino acid
sequence. The classical activated form ofNF-kB is a heterodimer consisting of a 65
k D heavy subunit and a 50 k D light unit. Using the same technique as an EMSA,
but using an antibody to the NF-kB subunit to be identified, the supershift technique
allows identification of the different subunits that are represented by particular bands
on the gel shift. Antibodies are available for c-fos, c-jun, p50 and p65.
For the NF-kB supershift a mix consisting of lOpg nuclear protein, 4 pi of loading
buffer, 0.5 pi poly dl/dC, 8pg p50 or p65 antibody (NF-kB p65 rabbit polyclonal
200pg/0.1ml Santa Cruz SC-109X, p50 rabbit polyclonal 200pg/0.1ml Santa Cruz
SC-114X, Santa Cruz Biotechnology, CA, USA) was made up to 20pl with distilled
water and incubated at room temperature for 1 hour. A control of non specific rabbit
IgG , cold competitor and non competitors were included.
For the AP-1 supershift 2pg of c fos, c jun and Nr-f2 (rabbit polyclonal IgG S, mouse
monoclonal IgG, and rabbit polyclonal IgG, Santa Cruz Biotechnology, CA, USA)
were used and the mix was incubated overnight at 4°C. Non-specific rabbit IgG, and
mouse IgG were included as controls and cold competitor and non competitors were
also included. Labelled probe was added and allowed to incubate for 20 minutes at
room temperature before the samples were loaded into the wells and the acrylamide
gel resolved.
3.2.5 Western Blotting for c-jun
The Supershift technique for the subunits ofAP-1, using antibodies against c-fos and
c-jun failed to demonstrate retarded bands. We therefore used the technique of
Western blotting to identify c-jun protein. Nuclear protein was extracted and
quantified as previously described from four lung samples (two with, and two
without airflow obstruction). Control proteins were included which consisted of
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nuclear extract from A549 cells treated with TNF-a which had previously been
shown to demonstrate c-jun on Western blotting. Bio-rad biotinylated high range
SDS-PAGE standards were used, with lOpl (standard diluted 1:4 with sample
loading buffer, heated to 98°C for 5 minutes) loaded on the gel. A standard Western
procedure was performed (see methods section 4.2. for detailed Western protocol)
using 10pg of nuclear protein, resolved at 200 volts for 40 minutes on (6% and 10%
stacking and running) an acrylamide gel. Transfer of protein was as per the
previously documented method using 100 volts for lhour. The primary antibody
used was c-jun (200pg/ml), Santa Cruz, CA, USA and this was diluted 1:500 in
TBS/0. l%Tween/Marvel and incubated with the nitrocellulose membrane for one
hour hour at room temperature. The secondary antibody was Sapu HRP antimouse
IgG, SAPU, in lOmls TBS/0. l%Tween (without Marvel) with 6.6pl streptavidin and
this was incubated for one hour hours at room temperature. Bands were detected
using enhanced chemiluminescence (ECL Western blotting detection system,
Amersham Biotech, Buckinghamshire, UK).
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3.3 Results
Transcription factor DNA binding in human lung tissue
3.3.1 Patient Characteristics
Table 3.1 shows the characteristics of the 35 patients included in the study. Lung
tissue was obtained from three subjects who had never smoked cigarettes, four
subjects who had severe airflow obstruction and who were undergoing lung volume
reduction surgery for emphysema, and twenty eight smokers who were undergoing
resection for suspected bronchial carcinoma (14 with airflow obstruction and 14
without airflow obstruction). The mean percent predicted forced expiratory volume in
one second was 67% in the never smokers, 39% in the LVRS group, and 60% and
94% respectively in the smokers with and without airflow obstruction. The severe
airflow obstruction group and the airflow obstruction group had a mean smoking
history of 73 pack years, and 55 pack years respectively which was significantly
higher than that of the group with no airflow obstruction (mean pack years 35).
Table 3.1 Patient characteristics of the groups in which the DNA binding of
transcription factors AP-1 andNF-kB were measured in lung tissue
Smokers
Never Smokers Normal Lung COPD Severe COPD
Function
n-3 n=14 n=14 n=4
Age 55 (21-73) 60 (37-73) 51(57-70) 57(49-59)
Male:female 0:3 2:12 11:3 2:2
Smoking History pack yrs 0 35 ± 3.2 55 ± 6.5* 73 ± 36.9*"
FEV, litres (±SD) 1.5 ±0.12 2.1 ±0.2 2 ± 0.09 0.9 ±0.21*
FEVi % pred 67 ±6.7** 94 ±2.1 60 ±1.5*** 39 ±11.9*"
FVC litres 2.1± 0.32 2.9 ± 0.27 3.5 ±0.16 2.6 ± 0.42
FEV!/FVC% 73.3 ±5.9 72.7 ± 1.2 56.6 ±1.5*" 35 ± 6.6***
Values are mean ± SEM
* p<0.01 versus normal lung function group
** p<0.001 versus normal lung function group
*** p<0.0001 versus normal lung function group
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Table 3.2 shows the normalised DNA binding for the transcription factors AP-1 and
NF-kB in human lung tissue and this NF-kB data is also presented graphically in
figure 3.2, and the AP-1 data presented graphically in figure 3.5. There is no
significant difference in the mean normalised NF-kB DNA binding in never smokers
(239 ± 40), those with normal lung function (153 ± 41.1), airflow obstruction (178 ±
25.6), and those with severe airflow obstruction who have undergone LVRS (265 ±
32.4), p=0.061.
Table 3.2 Normalised DNA binding for NF-kB and AP-1 in the four groups of
subjects never smokers, smokers with normal lung function, smokers with airflow
obstruction and patients with severe emphysema who had undergone lung volume
reduction surgery
Smokers
Never Smokers Normal Lung COPD Severe COPD
Function












3.3.2 Negative correlation of NF-kB DNA binding with lung function
A significant negative correlation between the DNA binding of NF-kB and lung
function (as measured by percent predicted FEVi) was found using a non parametric
Spearman Rank Correlation (r=-0.4, p=0.015), figure 3.1. A representative EMSA
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Figure 3.1 Relationship between normalised NF-kB DNA binding and lung



















Figure 3.2 Normalised NF-kB DNA binding in human lung tissue from patients with
severe airflow obstruction (LVRS), airflow obstruction, and no airflow obstruction.
Histograms represent the means and the bars the SEM. The difference in normalized
DNA binding ofNF-kB in the group undergoing LVRS compared to the group with
no airflow obstruction is not quite significant, p=0.061.
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Figure 3.3 A representative electromobility shift assay for NF idB in different groups
ofpatients is shown in figure 4. Lane 1 negative control, lane 2 positive HeLa, lanes
3-7 nuclear extract obtained from lung tissue from subjects without airflow
obstruction, lanes 8,9 and 11 nuclear extract obtained from patients with severe
airflow obstruction undergoing LVRS. Lane 10 and 12 nuclear extract from never
smokers, and lanes 13 &14, nuclear extract incubated with a non competitor and
cold competitor respectively. Bands were analysed using the UVP Grab A and
Gelplate. Variability of the DNA binding is demonstrated between the patient groups.
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To confirm that the band was NF-kB, a Supershift was performed to identify the
subunits of the NF-kB. In figure 3.4 two retarded bands are identified in lane 6, and a
single retarded band in lane 7. The upper retarded band is the heavier p65 subunit,
and the lower retarded band is the p50 subunit.
1 2 3 4 5 6 7
p65 sub unit ofNF-kB
p50 sub unit NF-kB
Figure 3.4 Supershift for NF-kB using nuclear protein extracted from human lung
tissue. LanelHeLa positive control, lane 2 negative (ddH20), lanes 3-7 nuclear
protein from lung tissue samples incubated with the following: lane 3 cold
competitor using excess of the oligonucleotide NF-kB, lane 4 non competitor, lane 5
a nonspecific antibody in the form of rabbit serum, lane 6 p50 antibody, lane 7 p65
antibody. There are two retarded bands in the upper part ofthe gel in lanes 6 and 7,
which indicate the presence of the p50 and p65 subunits of the transcription factor
NF-kB in nuclear extractfrom human lung tissue.
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3.3.3 Relationship of AP-1 DNA binding and lung function
No significant correlation was found for AP-1 DNA binding and lung function as
measured by percent predicted FEVi (r= -0.21, p=0.21, ns). Similarly there was no
significant difference in the normalised DNA binding of the transcription factor AP-1
in the groups (never smokers 48.8 ± 15.3, normal lung function 30.4 ± 3, COPD 39.6
± 4.8, and severe COPD 24.9 ± 9.5), p=0.15, ns. The relationship between AP-1
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Figure 3.5 Relationship between normalisedAP-1 DNA binding and lungfunction as
measured by percent predicted FEVi r=-0.21, p=0.21 ns.
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I was unable to demonstrate the c-fos and c-jun subunits of AP-1 using human lung
nuclear extract using the Supershift technique. Western blot was therefore performed
using a monoclonal antibody to c-jun, and a band in the expected region of
approximately 97 kDa was seen. A representative Western blot is shown in figure
3.6.
Figure 3.6 This shows a Western blot using antibody to c-jun and using nuclear
extractfrom 2 patients with airflow obstruction (lanes 1 and 2) and two patients with
no airflow obstruction (lanes 2 and 3). A protein band is visible at around 97kDa
suggestive ofc-jun.
3.3.4 DNA binding of the transcription factors NF-kB and AP-1 and smoking
history
We examined whether the DNA binding of AP-1 and NF-kB in human lung tissue
correlated with smoking history in terms of pack years of smoking. In human lung
there was no significant correlation demonstrated between AP-1 DNA binding and
pack years of smoking, p= 0.84, ns, or NF-kB and pack years of smoking, p=0.92,
ns. Figure 3.7 and 3.8 show the relationship between pack years of smoking and the
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Figure 3.7 The relationship between pack years ofsmoking and the DNA binding of
AP-1 in human lung tissue. This graph shows that there is no correlation between































Figure 3.8 The relationship between pack years ofsmoking and the DNA binding of
NF-kB in human lung tissue. This graph shows that there is no correlation between
smoking history and the DNA binding ofNF-kB in human lung tissue, p=0.92, ns.
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3.4 Discussion
I was able to demonstrate a significant negative correlation between NF-kB DNA
binding and the degree of airflow obstruction as measured by the percent predicted
FEVi, however no significant correlation between AP-1 DNA binding and lung
function was found. The DNA binding of AP-1 and NF-kB did not correlate with
pack years of smoking. I was also able to show that the NF-kB subunits represented
in lung tissue are p50 and p65. Using supershift to identify the subunits of AP-1, no
c-fos or c-jun subunits were found in lung homogenate, however c-jun was identified
in nuclear extract by Western blotting.
NF-kB is known to play an important role in the upregulation of a number of pro¬
inflammatory genes (Barnes and Karim, 1997; Rao et al., 1997; Akira and
Kishimoto, 1997), and may be the pivotal factor in the inflammatory process in
COPD. I have demonstrated variability in the DNA binding of the transcription
factors AP-1 and NF-kB in fresh human lung tissue obtained from smokers, and that
increased DNA binding ofNF-kB is associated with more severe airflow obstruction.
Previous studies have shown evidence of increased DNA binding of NF-kB in
pooled nuclear extracts from bronchial biopsies obtained from asthmatic patients
(Hart et al., 1998). The p65 subunit of NF-kB has also been examined in bronchial
biopsies by Western blot and immunostaining techniques, and increased expression
of p65 in bronchial epithelium of smokers with airflow obstruction has been
demonstrated (Di Stefano et al., 2002). In an animal model of lung reperfusion
injury, Ross has demonstrated increased NF-kB activation in lung tissue which peaks
at 30 minutes after reperfusion (Ross et al., 2000). In vitro studies have examined the
activation of NF-kB in cell lines in response to pro-inflammatory stimuli (Janny et
al., 2000, Karim and Ben-Neriah, 2000), however this study demonstrates changes
in NF-kB nuclear binding in human lung tissue, and in particular in smokers with
and without airflow obstruction. Although a relationship was shown between NF-kB
DNA binding and lung function, as lung tissue contains numerous cells it is
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impossible to know whether an individual cell or group of cells is responsible for this
observation.
NF-kB is a member of the Rel family of proteins and can exist in a dimeric state,
either as a homodimer or a heterodimer. In order to identify which components of the
NF-kB complex were present in the lung nuclear extract supershift assay was
performed. We have demonstrated by supershift that the retarded bands in nuclear
extract from human lung are composed of both the p50 and p65 subunits of NF-kB.
Our findings are in keeping with Hart et al who have shown p50 and p65 subunits of
the NF-kB complex in bronchial biopsies of asthmatics (Hart et al., 1998). The NF-
kB complex may be species dependent as the NF-kB complex in pig lung with
reperfusion injury has been shown to be a homodimer of p65 alone (Ross et al.,
2000).
It is possible that intra-operative factors or ex-vivo handling of the lung tissue
affected the levels ofDNA binding of the transcription factors, however these factors
were present in all the patients. The time from removal of the resected lung from the
thoracic cavity to being frozen in liquid nitrogen was not constant, and this may have
affected transcription factor DNA binding. However Ross et al found no difference
in NF-kB DNA binding in ex-vivo lung tissue which had undergone 6 hours of
ischaemic organ storage (Ross et al., 2000). Certainly my fresh lung samples were all
carried on ice and processed well within six hours of being removed from the body.
The lung tissue was removed from macroscopically normal tissue from one area only
of the lung. Ideally lung tissue from multiple areas of the lung should have been
examined to assess if there was variability of the DNA binding depending on the site
within the lung in an individual. Although thirty five patients were included in this
study of the transcription DNA binding, only three were non smokers and only four
had severe airflow obstruction. The inclusion of more samples from these groups
would have improved the results. Interestingly the group of never smokers had a
mean FEVi % predicted of 67, demonstrating airflow obstruction, and so this group
was not 'normal'. Included in this group was a 21 year old woman, who had airflow
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obstruction demonstrated on lung function testing, and at surgery was noted to have a
tumour that was behaving as a ball and valve effect, leading to airflow obstruction.
The histology of this tumour was a low grade muco-epidermoid tumour, which is in
contrast to all the other malignant pathologies included in this study, which were all
the more standard lung cancers (10 squamous cell, 12 adenocarcinoma, 4 large cell, 2
small cell carcinoma, 1 carcinoid, and 1 non small cell with neuroendocrine features).
A large number of lung samples (35) were assessed for transcription factor DNA
binding and so a method of comparing samples from different gels had to be used.
This was done by giving the HeLa positive control an arbitary value of 100 on each
individual gel radiograph, and grading the samples relative to this. A normalisation
process was also included so that errors in gel nuclear extract loading could be
controlled for. The process of normalisation was achieved by using a universal
transcription factor, Octamer-1 (Oct-1); a technique similar to using a housekeeping
gene in RNA polymerase chain reaction. The transcription factor Oct-1 is a member
of the POU homeodomain family and is ubiquitously expressed. This protein binds to
the specific-octamer sequence ATGCAAAT, and plays a role in transcription of
genes that contain an Oct-1 binding motif. This normalisation method has also been
used by Hart who examined pooled nuclear protein DNA binding in asthmatics (Hart
et al., 1998).
AP-1 is a transcription factor and the promoters of many inflammatory response
genes, especially those encoding cytokines and chemokines, have AP-1 binding sites
(Kracht and Saklatvala, 2002). In this study we failed to show a correlation of AP-1
DNA binding with lung function. This is particularly interesting as AP-1 is
intimately involved in the upregulation of the important antioxidant enzymes y-
Glutamylcysteine synthetase (y-GCS) and hemoxygenase-1 (Oguro et al., 1996), and
chapter two of this thesis has shown that there is a significant reduction in y-GCS
activity in patients with severe airflow obstruction. It therefore may have been
expected that increased AP-1 DNA binding would be associated with better lung
function. Studies in human epithelial cell lines show that AP-1 is acutely sensitive to
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oxidant stimuli such as cigarette smoke (Rahman et al., 1996; Rahman et al., 1996).
There are also cell type specific responses to cigarette smoke with regard to AP-1
subunit expression. Cigarette smoke exposed A549 cells show enhanced AP-1
binding (Rahman et al., 1996), but there is no increased AP-1 DNA binding in
cigarette exposed U397 cells which are a premonocytic cell line (Favatier and Polla,
2001). It may be that a relationship between AP-1 DNA binding and lung function
does exist in particular cells within lung tissue and the use of whole lung tissue may
mask changes in individual cells.
Another explanation may be that in the human lung after a prolonged oxidant insult
(cigarette smoke), there is loss of the acute cigarette-induced affects on cells. The
timing of an acute oxidant stimulus may therefore be important in the DNA binding
of these transcription factors.
AP-1 is a dimeric protein composed of members of the jun (c-jun. jun-B, and Jun-D)
and fos (c-fos, fosB, fra-1 and fra-2) family that can bind to the promoter region of
various genes. Using supershift, it was not possible to demonstrate c-jun or c-fos in
whole lung nuclear extract, but using Western blot a band in the region of 97 kDa,
highly suggestive of c-jun was found. The same c-jun antibody was used in the
Supershift and Western experiments and this suggests that the conditions for the
Supershift were not correct. It is possible that the c-jun and c-fos antibodies used in
the Supershift were not immunoreactive to human antigen, however this seems
unlikely given that the Western technique was successful for c-jun. In a rat model of
acute inflammation conflicting results using Supershift and Western have been also
been found (Guo et al., 2002). Guo et al failed to demonstrate c-jun in whole lung
nuclear extracts from rats by Supershift and identified c-fos, jun-B and jun-D.
However, using Western identified a band suggestive of c-jun. The work by Guo also
showed time related changes in levels of the AP-1 subunits in response to IgG related
acute lung injury and also that there is increased c-jun protein expression in
macophages compared to lung. This group has also reported that the AP-1 complex
in nuclear extract from alveolar macrophages from these same animals does not
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supershift with c-fos antibodies. It therefore appears likely that there are different
heterodimeric patterns of AP-1 in alveolar macrophages and lung tissue.
Maturational differences in AP-1 protein subunit predominance have been shown in
rat lung in response to hyperoxia with a relative lack of c-jun and abundance of junB
in neonatal rats compared to older rats (Yang et al., 2000). Recent in vitro work has
shown that there is upregulation of c-fos and fra-1 in IL-1 induced IL-8 production
and that Fra-1 is a negative regulator of IL-8 (Hoffmann et al., 2004).There is
therefore a complex relationship between AP-1 and NF-kB in inflammation as fra-1
counteracts the positive regulatory effects of c-fos and p65 NF-kB on IL-8 gene
expression. Our work concentrated on c-fos and c-jun and we should have extended
this work to include Supershift and Western blotting to examine for other subunits
including jun-B andjun-D and fra-1.
The expression of jun and fos proteins varies in different cell lines and also in
malignantly transformed versus non transformed cell lines. For example high levels
of c-jun, jun-B, jun-D and fra2 are found in the non-transformed mouse alveolar cell
line C10 (Shukla et al., 2001), but lower levels of junB, c-fos, and fra-1 are found in
malignant transformed HBE cells compared to non tansformed HBE cells (Birrer et
al., 1992). Interestingly it has been reported that neoplastic lung tissue has higher
expression of c-jun in atypical, hyperplastic and metaplastic epithelium, and in the
surrounding normal epithelium expression is low or undetectable (Szabo et al.,
1996). This altered expression of jun and fos proteins may be relevant in my study as
although the lung tissue used appeared macroscopically normal, (away from the site
of the tumour), histological examination of this same area was not performed to
confirm that this area was infact normal. Thus a relationship between AP-1 DNA
binding and airflow obstruction may not exist in this population of patients examined
and the division into groups with and without airflow obstruction may be a false
division by virtue of the majority of the subjects examined having lung malignancy.
In summary a relationship between the DNA binding ofNF-kB and lung function has
been shown, but no such relationship was found with AP-1. Further work is required
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to define whether the relationship of NF-kB DNA binding and airflow obstruction
holds true in all parts of the lung and/or individual cell types, as this is likely to be
pivotal to the understanding ofNF-kB in smoking related lung disease.
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CHAPTER 4
4-HYDROXY-2-NONENAL IN HUMAN LUNG
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4.1 Introduction
Cell membrane lipid peroxidation of polyunsaturated fatty acids generates aldehyde
end-products including malondialdehyde (MDA), 4-Hydroxy-2-nonenal (4-HNE)
and 4-hydroxy-2,3-alkenals. 4-Hydroxy-2-nonenal is a specific product of lipid
peroxidation and the adverse effects of 4-HNE result from its effect on signal
transduction, gene expression, apoptosis, cell proliferation and cellular responses
(Parola et al., 1999). Animal models show elevated levels of 4-HNE in response to
cigarette smoke and in human lung tissue there are increased 4-HNE adducts in
airway epithelial cells of smokers with COPD (Aoshiba et al., 2003, Rahman et al.,
2002). Higher levels ofMDA have been reported in the lung tissue of smokers with a
heavy smoking history compared to non-smokers (Fahn et al., 1998).
The aim of this work was to identify 4-HNE in human lung tissue using the
techniques ofWestern blotting and immunohistochemistry.
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4.2 Methods
4.2.1 Immunohistochemistry for 4-Hydroxy-2-Nonenal in human lung tissue
This work was in collaboration with Dr Pim de Boer. Lung sections from 30 patients
were examined for 4-HNE using the technique of immuohistochemistry. The lung
tissue was obtained from patients who were undergoing resection for suspected
bronchial carcinoma and patients who were undergoing LVRS for severe
emphysema. Ten patients had severe emphysema, 10 patients had airflow obstruction
and ten patients had no airflow obstruction.
Three micron thick lung sections were cut and deparaffinised, rehydrated and
pretreated before the immunohistochemistry was performed. The lung sections were
then refixed. The primary antibody used was a mouse monoclonal antibody specific
for 4-HNE adducts (Japan Institute for the control of aging, Fukuroi City, Shizuoka
Prefecture, Japan) at a dilution of 1:500 and incubated overnight at room temperature
in a humidified chamber. The avidin-biotin-peroxidase complex (ABC) method was
used, and novaRED (Vector Labs, Burlingame, CA) was used as the chromogen, and
the slides were counterstained with haematoxylin. The immunohistochemical
staining of the tissue sections from all thirty subjects was performed in a single
batch.
The negative control consisted of the same procedure as above, but with the omission
of the primary antibody. The positive control was a section of lung tissue from a
patient with adult respiratory distress syndrome.
The staining was assessed semi-quantitatively using a scoring system of 0-3 for cell
types including type I and type II alveolar epithelial cells, alveolar macrophages and
neutrophils. The slides were examined by a single observer (subjective viewing and
non automated) and all areas of the slide were viewed, using a grid which divided the
slide into 8 areas. A score of 0 reflected no staining present, score 1 weak staining,
score 2 moderate staining, and score 3 reflected intense staining.
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Data are expressed as mean ± SEM. 4-HNE staining scores in the three subject
groups were compared using Student's t test.
4.2.2 Western Blot to examine for 4-Hydroxy-2-Nonenal in human lung tissue
My previous work (chapter 2, section 2.3) had failed to demonstrate a relationship
between levels of lipid peroxidation products (MDA) in whole lung and lung
function. An attempt to examine 4-HNE, a specific product of lipid peroxidation was
undertaken in human lung tissue using the technique of Western blotting in which
proteins are separated by movement through a gel containing a denaturing detergent
(SDS/polyacrylamide gel) and then blotted and detected using antibodies. Various
modifications of the basic procedure were undertaken in an attempt to demonstrate 4-
HNE, and are outlined below.
Standard Western Blot
Cytosolic protein was extracted and then used in the Western Blot, and various
modifications of protein extraction, samples and antibodies were carried out, and
these are outlined later in pages 119-125.
General method for Western
A 10% acrylamide separating gel was prepared with an upper stacking layer of 4%
acrylamide. The 10% separating gel was poured and topped up with water-saturated
isobutanol and left to polymerise, following which the isobutanol was removed and
the plates washed with distilled water and dried using filter paper. The 4% stacking
gel was then added to the top of the separating gel, combs inserted and allowed to
polymerise.
The protein lysates were prepared and then denatured by heating with sample loading
buffer for 3 minutes at 95°C. The protein separating gels were prepared and the
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denatured protein was added to the wells (20pl), and molecular markers to the left
hand side well, and the protein and molecular weight standards were electrophoresed
at 200V for 35 - 40 minutes in xl running buffer. The gels were removed from the
glass plates and the protein was then transferred to nitrocelullulose paper (Hibond)
using the transfer apparatus in which a sandwich of gel, nitrocellulose paper (soaked
in transfer buffer) and Whatman paper (soaked in transfer buffer) was formed and
placed in the transfer chamber and electrophoresed at 25 volts for 90 minutes in
transfer buffer. Transfer of protein was confirmed using Ponceau S red dye, and the
protein lanes on the nitrocellulose membrane were marked with pencil, and then
Ponceau red washed off using TBS. Non specific binding was blocked by placing the
membrane in a solution of lg Marvel in 20mls TBS on a rocker at room temperature
for 15 minutes, followed by rinsing in TBS/0.05% Tween. The membrane was
incubated over night using primary antibody 4-HNE Michael adducts (rabbit),
Calbiochem diluted in TBS/Tween. After 3 washes in TBS-Tween the membrane
was incubated with secondary antibody (HRP anti-rabbit IgG Diagnostics Scotland)
diluted 1:10,000 in TBS/Tween with Marvel. Bands were detected using enhanced
chemiluminescence (ECL Western blotting detection system (Amersham Biotech,
Buckinghamshire, UK).
SDS-polyacrylamide gels
10% Separating Gel volume
dEEO 4.05ml
1.5M Tris-HCL, pE18.8 2.5 ml
10% (w/v SDS stock) 100 pi
acrylamide/Bis(30% stock) 3.3 ml




1.5M Tris-HCL, pH8.8 2.5 ml
10% (w/v SDS stock) 100 pi
acrylamide/Bis(30% stock) 1.3 ml




In this preliminary experiment one lung tissue sample from each of the three
previous patient groups (no airflow obstruction, airflow obstruction and severe
airflow obstruction) that had been examined for lipid peroxidation, were used (lung
samples 99, 91, and 83 respectively). The characteristics of the three patients are
shown in table 4.1 in the results section.
la. Total cellular protein was obtained by homogenising 0.5 g lung tissue in 2 mis
1.5% potassium chloride, and quantified using the BCA protein kit as previously
described, and 40 pg protein was made up to 25pi with sample loading buffer and
heated at 98°C for 5 minutes before loading onto the polyacrylamide gel. The
concentration of the primary antibody (4-HNE Michael adducts) was 1:10,000.
lb. The conditions were altered so that the final volume of protein and sample
loading buffer was 20pl and the concentration of primary antibody was increased to
1:1000.
lc. Protein extraction modification: Using the protein extracted in la, which had
been stored at -80°C, a further centrifugation step was performed (13000rpm at 4°C
for 15 minutes) and the supernatant used. Primary antibody was incubated at room
temperature for lhour. The concentration of the primary antibody (4-HNE Michael
adducts) was 1:10,000.
Antiproteases were not used in la-lc.
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Western blot modification 2
The lysis buffer was changed as described below, and antiproteases were added. The
cytosolic extract obtained was used in the immunoprecipitation reaction followed by
Western blotting.
2a. Lysis buffer. The method for the lysis buffer was based on the method by
Cucchiaro (Cucchiaro et a., .1999) and Current protocols in Immunology vol 2, unit
8.3. Frozen lung was homogenised in 1.1 ml of lysis buffer with 20 pi of
antiproteases, followed by centrifugation at 13000 rpm at 4°C for 15 minutes and the
supernatant used. Protein was measured using the BCA method. The lysis buffer
consisted of 10 mM Tris CI pH 7.6, 150 mM NaCl, ImM EDTA, 0.1%
Deoxycholine, 1% TritonX-100 and 46.4 mis dEFO.
2b. Immunoprecipitation
Antibody binds to an antigen or protein complex and this antigen-antibody complex
is precipitated, followed by dissociation of the antigen from the antibody and the
released antigen is then electrophoresed on a gel and a standard Western procedure is
carried out.
To asses whether the technique of immuno-precipitation was working, we chose to
examine for the presence of a protein within a sample that was likely to be positive.
The protein chosen was EIA (early one adenoviral protein), and it was postulated that
cell lysates from hydrogen peroxide treated EIA transfected A549 cells would
demonstrate a protein band using immunoprecipitation and Western blotting.
Immunoprecipitation was performed using stored cell lysates from hydrogen
peroxide treated A549 cells, and A549 cells that had been transfected with EIA, and
was immunoprecipitated using EIA mouse monoclonal IgG2a (Santa Cruz sc-25,
cone 200pg/ml). Lung tissue lysate from a subject with severe airflow obstruction
(sample 129), was immuno precipitated using anti-4-HNE Michael adducts. Non
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immunoprecipitated tissue lysate from lung sample 129 was also included in the
Western.
One hundred pg of cell lysate from:l. A549 cells, 2. hydrogen peroxide treated A549
cells, 3. ElA transfected A549 cells, 4. hydrogen peroxide treated A549 cells, and
500 pg lung sample 29 lysate was incubated with 2pg ElA mouse monoclonal IgG2a
(Santa Cruz sc-25, cone 200pg/ml) at 4°C for 4 hours.
500pg of lung sample 129 lysate was incubated with 10 pi anti-4HNE Michael
adducts (rabbit) at 4°C for 4 hours.
Protein G beads (Sigma) were washed twice in lysis buffer and made into a 50:50
mix with lysis buffer. 50 pi bead slurry mix was added to the protein lysate (500pg
lung tissue lysate and lOOpg for cell lysate) and allowed to incubate with agitation
for 90 minutes. Following which the bead/protein mix was centrifuged at 13000 rpm
at 4°C for 5 minutes and the supernatant discarded and the beads washed x2 in lysis
buffer and the beads boiled in SDS page buffer.
For the non immunoprecipitated protein sample (129), then 40pg and 80 pg were
made up to 20pl using SDS-page buffer and then boiled at 98°C for 5 minutes.
Primary antibody
E1A mouse monoclonal IgG2a 10 pi in lOmls TBS/0.05% Tween
anti-4-HNE Michael adducts 10 pi in lOmls TBS/0.05% Tween
Secondary Antibody
E1A anti-mouse IgG HRP 2 pi in 20mls (1:10,000)
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4-HNE anti-rabbit IgG HRP 2 pi in 20mls (1:10,000)
Western Modification 3
Human and rat lung tissue lysates were used in the immunoprecipitation technique.
Rat lung tissue lysate that had been prepared earlier for a different Western
experiment and stored at -70°C and lung sample lysate (129) that had been stored
from the previous experiment, and 4-HNE-myoglobin adduct were used. The 4-
HNE-myoglobin was used as it was postulated that this may be one of the 4-HNE
protein adducts that is present in the human lung and so if the lung tissue produced a
band at the same level as the 4-HNE-myoglobin, then it would imply that there was a
protein present that was myoglobin or a protein that had the same molecular weight
as myoglobin.
Tissue lysates consisting of 500 pg of human tissue and 100 pg of rat lung tissue and
200 pg of 4-HNE-myoglobin adduct (2mg/ml) were made up to a final volume of
200pl in lysis buffer. Ten pi 4-HNE adduct was added to each protein/lysis mix and
agitated for 4 hours at 4°C. The method for the rest of the immunoprecipitation was
as previously described on page 126. Standard non immunoprecipitated tissue lysates
were also used and made up to a final volume of 20 pi in sample loading buffer and
heated for 5 minutes at 98°C. Twenty pi of the lysate/SDS reducing buffer mix was
added to each well and the Western performed as previously described with the
following modifications
1. Primary antibody 1:500 in TBS/Tween 0.05%/marvel. One hour incubation at
room temperature
2. Addition of streptavidin in a dilution of 1:1500 with TBS/Tween 0.05% alone
(without marvel) was added at the same time that the secondary antibody was
incubated inorder to allow the molecular weight markers to develop.
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Modification to Western procedure 4
It was not clear if cytosolic protein extraction had been achieved and so the method
was altered. The lung tissue samples (127 and 129) which had been stored at -80°C,
underwent cytoslolic and nuclear extractions as per the new protocol which is
described below, and the protein used in the Western.
4.a Method for Extraction of cytosolic protein
Lung tissue was homogenised in 1ml soloution A, and then incubated on ice for 15
minutes, following which 125pl of solution A' was added and mixed by inversion






10 mis buffer A with one antiprotease tablet
Solution A'
10 mis buffer A with 250 pi NP-40
40 pg of cytosolic and nuclear protein used for Western which was performed as per
modification 3 without the immunoprecipitation step.
5. Western Modification 5
The previous Western blot experiments failed to demonstrate 4-HNE in human lung
cytosolic extractions. It was possible that there was no 4-HNE in these samples, but
the other possibility was that the 4-HNE was rapidly lost during the process of
handling the lung tissue. Frozen lung tissue (lung tissue sample 132) was defrosted,
finely chopped and approximately 200 mg was incubated with a 100 mM solution of
4-HNE in PBS (4-HNE 5mg/0.5 ml N-hexane, Alexis cat no. 270-245-M005) at
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37°C, and 200 mg lung tissue incubated in PBS solution alone for lhour at 37°C.
Lung sample 132 was from a 45 year old male, current smoker with no airflow
obstruction, who had undergone a pneumonectomy for squamous cell carcinoma.
Cytosolic extraction was as per modification 4, and the amount of protein included in
the Western was 20 pg and 40 pg. 20 pg myoglobin-4-HNE adduct was also used in
the Western.
Gel 1: 20 pg cytosolic protein, or myoglobin-4-HNE adduct made up to 20 pi with
SDS reducing buffer and heated at 98°C for 8 minutes.
Gel 2: 40 pg cytosolic protein and 20 pg myoglobin-4HNE adduct made up to 20pl
with SDS reducing buffer.
The primary antibody concentration was 1:500, and the secondary antibody
concentration was 1:10,000.
Western Modification 6
Same as modification 5, but increased amounts of the cytosolic protein from human
lung sample 32 (4-HNE incubated and control that had been used in the previous
experiment and stored at -80°C) was used, 20 pg, 40 pg and 100 pg. 4-HNE-
myoglobin adduct was also used as in the previous modification. The primary
antibody concentration was 1:500, and the secondary antibody concentration was
1:10,000.
Modification to Western 7
The product information sheet for the anti-Michael adducts stated that use of more
than 0.01% Tween 20 can interfere with antibody binding in Westerns. Therefore the














1.25 ml 1 M Tris HCL Ph 6.7





Dissolve in 400 ml dH20





Dissolve in 500 ml dH20
Add 200 ml methanol
Make up to IL with dH20
lOx Tris Buffered Saline (TBS)
24.2g Tris base
Dissolve in 800 ml dH20
Adjust pH to 7.4 with HCL and make up to IL with dH20
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4.3 Results
4.3.1 Immunohistochemistry for 4-HNE in lung tissue
4-HNE a specific product of lipid peroxidation was examined in lung tissue in thirty
patients undergoing resection for suspected peripheral bronchial carcinoma or LVRS.
There were ten patients in each patient group consisting of patients with severe airflow
obstruction, moderate airflow obstruction and no airflow obstruction. Table 4.1 shows
the characteristics of the patients included in this study. Staining was assessed semi-
quantitatively using a scoring system of 0-2.5 for cell types including type I and type
II alveolar epithelial cells, alveolar macrophages and neutrophils. Table 4.2 shows the
mean 4-HNE staining scores for the different cell types in the three patient groups.
The histograms in figure 4.1, 4.2 and 4.3 demonstrate 4-HNE staining scores for
bronchial epithelial cells, macrophages and neutrophils. There is a higher mean 4-
HNE staining score in bronchial epithelial cells, macrophages and neutrophils in lung
tissue obtained from subjects with severe airflow obstruction (LVRS), compared to
those with no airflow obstruction.
Normal Lung COPD Severe
Function COPD
n=10 n-10 n=10
Age 61.7(49-74) 57.3(21-72) 54.3 (49-64)
Male:female 5:5 6:4 2:8
Smoking History pack yrs 54.45 (3-168) 50.6 (30-57) 37.5 (25-76)
FEVi litres (±SD) 2.51 ±0.73 1.92 ±0.41 0.66 ± 0.22
FEVi % pred 94.6 62 25.8
FVC litres 3.34 ±0.99 3.38 ± 0.94 2.32 ± 0.89
FEVi/FVC% 75.8 ±6 58.7 ± 8.7 30.28 ±10.17










4-HNE staining score (mean ± SEM)
Bronchial epithelium 0.909 ±0.15 1.071 ±0.13 1,45± 0.15
Alveolar epithelium (type 1) 0.363 ± 0.13 0.389 ±0.13 0.75 ±0.17
Alveolar epithelium (type II) 0.363 ± 0.09 0.667 ±0.14 0.65 ±0.15
Alveolar macrophages 1.227 ±0.12 1.44 ±0.15 1.7 ±0.133
neutrophils 1.05 ±0.19 0.88 ± 0.073 1.8 ±0.133

















No Airflow Severe Airflow
Airflow Obstruction Obstruction
Obstruction (LVRS)
Figure 4.1 shows the 4-HNE staining score in bronchial epithelial cells in lung
sections from patients with no airflow obstruction, airflow obstruction and severe
airflow obstruction (LVRS). The histograms are mean values and the bars represent
SEM. There is a significant increase in 4-HNE staining in the severe airflow




















No Airflow Severe Airflow
Airflow Obstruction Obstruction
(LVRS)
Figure 4.2 shows the 4-HNE staining score in alveolar macrophages in lung sections
from patients with no airflow obstruction, airflow obstruction and severe airflow
obstruction (LVRS). The histograms are mean values and the bars represent SEM.
There is a significant increase in 4-HNE staining in the severe airflow obstruction
















Figure 4.3 shows the 4-HNE staining score in neutrophils in lung sections from
patients with no airflow obstruction, airflow obstruction and severe airflow
obstruction (LVRS). The histograms are mean values and the bars represent SEM.
There is a significant increase in 4-HNE staining in the severe airflow obstruction
group compared to no airflow obstruction p=0.0046.
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4.3.2 Western Blotting for 4-HNE
Lung tissue from three patients was used with patient characteristics shown below in
table 4.3.
Smokers
Normal Lung COPD Severe COPD
Function
n=l n=l n=l
Age (years) 63 69 52
Male/female male female female
Smoking History pack yrs 168 32 not documented
FEVi litres (±SD) 3.0 1.06 0.42
FEV, % pred 85 66 17.5
FVC litres 3.79 2.02 2.1
FEV,/ FVC % 76.9 52.4 20
Table 4.3 Characteristics ofpatients from whom lung tissue was used
The use of a 1.5 % potassium chloride solution lysis buffer to obtain cytosolic
cellular protein failed to demonstrate protein bands on Western blotting. The
introduction of a further centrifugation step also failed to yield anything on Western
blotting of the cytosolic extract, (methods la-lc).
The alteration of the lysis buffer to that outlined on page 120 of the methods section
also failed to yield any protein bands on Western when this protein extract was used.
4.3.3 Immunoprecipitation
The technique of immunoprecipitation was used to examine lung tissue for 4-HNE
and ElA. Lung tissue was examined from a 58 year old woman with severe airflow
obstruction (FEVi of 0.6 L and FEVi/VC ratio of 26%), who had undergone LYRS.
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Figure 4.4 shows a Western blot using immunoprecipitated protein from A549 cells
and human lung tissue, using an El A primary antibody. EIA transfected A549 cells
were examined for EIA protein as these cells should be positive for EIA and would
act as a control to determine if any bands were the result of the immunoprecipitation
process or were truly positive for EIA. If bands were similar in the EIA
immunoprecipitated and 4-HNE Michael adduct immunoprecipitated protein lysates
then it would imply that the bands were the result of the extraction process.






Figure 4.4 Western blot using immunoprecipitated protein and primary antibody to
EIA. Lane 1 represents molecular weight markers, lane 2 cytosolic protein extracted
from A549 cells, lane 3 cytosolic protein from A549 cells transfected with EIA, lane
4 cytosolic protein from A549 cells stimulated with hydrogen peroxide, lane 5
cytosolic protein from A549 cells transfected with EIA stimulated with hydrogen
peroxide, and lane 6 cytosolic protein from human lung. All of the samples
demonstrated two bands (as indicated by the arrows), a higher band in the region of
47 kDa and a lower band in the region of 20-28 kDa. It is unlikely that these bands
represent EIA protein as the same pattern is achieved irrespective of whether the
extract was obtained from EIA transfected A549 cells, or A549 epithelial cells that
were not transfectedwith EIA.
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Figure 4.5 Western blot using primary antibody anti-4-HNE Michael adduct. Lane 1
represents molecular weight markers, lane 2 40pg lung tissue lysate, lane 3 80 pg
lung tissue lysate, and lane 4 immunoprecipitated protein from human lung. Lane 5
represents spill over from lane 4. There is also some spill over into lane 3 from lane
4.
Figures 4.4 and 4.5 show two bands in the immunoprecipitated protein in all cases,
irrespective of which primary antibody was used. The expected weight of ElA is
43,000 kDa. The higher band is at the approximate levels of 40 kDa and the lower
band is between 20 kDa and 28 kDa. It is likely that the upper band represents heavy
chain and that the lower band represents light chains from the immunoprecipitation
reaction. The upper bands cannot represent El A as these bands are present when
E1A and 4-HNE primary antibodies are used. Similarly figure 4.6 shows similar
bands when rat lung protein, human lung and 4-HNE-myoglobin adduct is
immunoprecipitated. In figure 4.6, lane 3 which represents non immunoprecipitated
lung tissue protein has no bands. Lane 5 which represents the 4-HNE-myoglobin
adduct (non immunoprecipitated) shows 2 clear bands approximately at 66 kDa and
45 kDa. It is unclear whether the bands in lane 5 represent 4-HNE protein adduct.
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Figure 4.6 Western blot using a primary antibody to 4-HNE (anti-Michael adducts).
Lane 1 molecular weight markers, lane 2 human lung sample 129
immunoprecipitated, lane 2 human lung cytosolic extract non immunoprecipitated,
lane 4 4-HNE-myoglobin immunoprecipitated, lane, lane 5 4-HNE-myoglobin non
immunopreciptated (with x2 protein bands), lanes 6, 7 and 8 rat lung cytosolic
extract that has been immunoprecipitated. In all the immunoprecipitated samples,
multiple bands are seen with dense bands in the region of45,000 kDa to 66,000 kDa
(see right arrow).
Using the modification 4a to obtain cytosolic extraction failed to yield any bands on
Western blotting using anti 4-HNE-Michael adduct primary antibody.
Lung tissue was incubated with 100 mM solution of 4-HNE in PBS solution for 1
hour and then the cytosolic extract as per methods 4a was obtained and 20 pg and 40
pg used in the standard Western procedure. Twenty micrograms of myoglobin-4-
HNE adduct was used as a control. Figure 4.7 shows the Western blot, and this
shows that the lung samples that were incubated with 4-HNE and PBS all produce
two bands, an upper stronger band at approximately 81 kDa and a weaker lower band










Figure 4.7 Western blot using primary antibody to 4-HNE (anti-Michael adduct).
Lane 1 molecular weight markers, lane 2 and 3 human lung (40 pig), lanes 4 and 5
human lung incubated in 4-HNE (lOOpiM), 40 pig, lane 6 empty, lanes 7 and 8
myoglobin-4HNE (20pig), lane 9 empty. Two faint bands (in the region of 47,000-
81,000 kDa) are demonstrated in lanes 2,3,4 and 5 (human lung incubated with 4-
HNE and control lung in PBS), indicated by the two arrows. No band is
demonstrated in the myoglobin-4-HNE adduct.
Increasing concentrations of cytosolic extract (20 jag, 40 pg, and 100 pg) from 4HNE
incubated lung tissue and control PBS incubated were used in the Western blot to
determine if a more definite band could be identified on the gel using an increased
concentration of cytosolic protein. The polyacrylamide gel in figure 4.8 is a poor
quality gel, but similar bands at 81 kDa and 47 kDa can be seen. These bands
become denser with increasing amounts of protein.
143







Figure 4.8 Western blot using primary antibody to 4-HNE (anti-michael adduct).
Lane molecular weight markers, lanes 2 and 3 20 pg of control lung cytosolic
extraction and 20 pg 4HNE incubated cytosolic extraction respectively, lanes 4 and 5
40 pg 4FINE incubated cytosolic extraction respectively, lanes 6 and 7 100 pg 4HNE
incubated cytosolic extraction respectively, lanes 8 and 9 4-HNE-myoglobin adduct.
Lanes 3, 4, 5, 6, 7 all show two faint bands in the region of 47,000-81,000 kDa (the
bands are indicated by the arrows).
Changing the concentration of the Tween to 0.01% Tween 20 from 0.05% Tween 20
resulted in no bands being seen.
In summary Western blotting using 4-HNE-Micheal antibody and human lung tissue
lysate has demonstrated bands which may represent 4-HNE protein adducts.
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4.4 Discussion 4-hydroxy-2-nonenal in human lung
The lipid peroxidation product 4-HNE is highly reactive and capable of diffusion
away from the original site of production (Esterbauer et al., 1991), and can affect
both intracellular and extracellular biological targets. The mechanism of 4-E1NE lung
related damage is not known, however it is well described that 4-HNE forms
Michael-type nucleophilic protein adducts via amino acid residues of histidine,
lysine, serine and cysteine (Esterbauer et al., 1991).
4-HNE, a specific product of lipid peroxidation was detected and localised in human
lung tissue using immunohistochemistry (IHC). The distribution and levels within
patients with severe, moderate and no airflow obstruction was also examined. The
mean 4-HNE staining score is higher in bronchial epithelial cells, macrophages and
neutrophils in lung tissue sections, in subjects with severe airflow obstruction
compared to those without airflow obstruction.
For the 4-HNE immunohistochemical analysis a manual method of subjective
viewing of the slide was adopted using a single observer. The use of two observers
would have been more accurate. Image analysis systems are increasingly being used
in an attempt to remove observer and intra-observer bias and inaccuracies in
immunohistochemical analysis. Automated image analysis can examine large areas
from multiple biopsies and can also perform densitometry measurements on the
stain. Sont (Sont et al, 2003) have used a fully automated technique for assessing
inflammatory cell counts and cytokine expression in bronchial tissue, and have
compared this technique to a semi-quantitative method and found that it compared
well and that the automated method gave optimal repeatability of the analysis of cell
counts and cytokine expression. One of the weaknesses of using a semi-quantitative
method is that the cell staining will diminish over time and re-analysis at a later time
can be problematic.
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The ability to adequately quantify 4-HNE in tissue is limited using IHC, which best
indicates the localisation of a protein. The technique of Western blotting was used in
an attempt to provide more quantitative 4-HNE-protein adduct data in the tested
human lung tissue. The aim of the 4-HNE Western experiments was to identify 4-
HNE immuno proteins in lung tissue.
We found that combining immunoprecipitation with Western blotting using 4-HNE
Michael antibody yielded several bands when using human and cellular cytosolic
proteins. Non immunoprecipitated 4-HNE-myoglobin adduct produced two discrete
bands on Western blotting and may represent a 4-HNE-protein adduct, however it
was not of the expected molecular weight of 17 kDa. Lung tissue that was incubated
at 37°C, both with and without 4-HNE, produced two faint bands when the tissue
lysates were run on a Western using 4-HNE Michael antibody. Again these bands
may represent 4-HNE immunoprotein.
The major problem with the Western blot experiments was the lack of a true positive
control. We postulated that 4-HNE would form a protein adduct with myoglobin and
created a 4-HNE-myoglobin protein adduct to act as a positive control.
Immunoprecipitated samples gave a dense band at the level of 45-66 kDa that was
likely to represent the IgG carried through from the immunoprecipitation. To confirm
that this band did infact represent IgG, controls of primary antibody alone and
sample buffer alone should have been included in the Western. A limitation of the
immunoprecipitation technique is that immunoreactive proteins of 50-60 kDa, which
have similar molecular weights to IgG cannot be detected. However the presence of
such IgG bands does act as an internal control with regards to protein loading and
successful immunoblotting.
After immunoprecipitation there is an antigen-antibody complex, and this complex is
also complexed to the protein G beads. The addition of the reducing buffer (gel
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loading buffer) to the immunoprecipitated lysate should release the antigen, however
it can also have the effect of releasing the heavy and light chains from the ElA IgG
by virtue of breaking the disulphide bonds of the heavy and light chains. The same
antibody and therefore the same species of antibody had been used for the
immunoprecipitation and the primary antibody for the Western. Ideally different
species antibodies should be used for the immunoprecipitation step and as the
primary antibody.
Optimising the tissue lysis buffer is critical in Western blotting, and may need to be
tailored to the individual protein. Using 1.5% potassium chloride as the lysis buffer
may have released protein as there was evidence of staining with ponceau red on the
membrane, but no bands were detected on Western blotting. The use of antiproteases
is vital and these were not included in the 1.5% potassium chloride lysis buffer. The
lysis buffer was modified to a solution containing nonidet-P, and also a solution
containing 0.1% deoxycholine/1% triton X-100, with both of these lysis buffers
containing antiproteases. Altering the salt concentration in the lysis buffer can affect
the cytosolic protein yield. In this work lysis buffer containing 10 mM potassium
chloride, 1.5 mM magnesium chloride and also 150 mM sodium chloride was used.
Tissue lysates obtained from lung tissue that had been incubated in 4-HNE/control
PBS at 37°C, produced two bands, but the 4-HNE-myoglobin protein adduct that was
run on the same Western did not give any bands. This differed from earlier Westerns
in which two clear bands at 45-66kDa were found for the 4-HNE-myoglobin adduct.
It is possible that the 4-HNE-myoglobin-protein adduct was incorrectly prepared in
these later experiments. However the molecular weight ofmyoglobin is 17 kDa and
so it would not be expected that the 4-HNE-myoglobin adduct would be seen at 45-
66 kDa. It is possible that the 4-HNE-myglobin adduct is very unstable and degrades
quickly and so may be very difficult to measure and impossible to use as a positive
control. Another possibility is that the 4-HNE-myoglobin adduct is not present in
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human lung tissue. As stated earlier we did postulate that myoglobin may be one
such protein, but our data does not support this.
The 4-HNE primary antibody that was used in the Western experiments was a
polyclonal rabbit immunoglobulin which recognised 1:1 cysteine-, histidine- and
lysine-4-HNE 'Michael' adducts, and this differed from that used in the
immunostaining work, which was a monoclonal antibody (Japan; Institute for Ageing
Research).
A 32 kDa protein in human and murine alveolar macrophages in response to ozone
has been identified using a 4-HNE antibody that recognises HNE-Cys, HNE-Lys,
HNE-His adducts (Hamilton et al., 1998, Kirichenko et al., 1996). In our work whole
lung tissue was lysed rather than using a pellet of macrophage cells. Like our work,
Hamilton's group also did not have a 'true' positive. Usatyuk has used a Calbiochem
anti HNE Michael adduct antibody to examine for 4-HNE in bovine lung endothelial
cells by Western blotting and demonstrated several protein bands in the region of 40-
203 kDa (Usatyuk et al., 2004), and this group was similarly unable to identify what
each protein band represented. The Usatyuk group also showed increased 4-1TNE
protein adducts when the endothelial cells were exposed to increasing concentrations
of 4-HNE, and that adduct formation peaked at 45 minutes.
4-HNE- and MDA- adducted proteins have been examined in liver (Paradis et al.,
1997), and it has been postulated that lysine rich epitopes of 4-HNE adducts are less
likely to be formed under physiological conditions, and that 4-HNE under normal
physiological conditions would react most rapidly with sulfhydryl residues of
proteins (Hartley et al., 1997). The functional groups histidine, lysine and glycine
react rapidly with 4-HNE under non physiological conditions of pH 8.8 and 10 mM
concentrations. The experiments contained in this thesis have only examined for the
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lysine, histidine and glycine epitopes of 4-HNE and have not examined for a
sulfhydryl epitope. In studies analysing liver tissue sections by
immunohistochemistry, 4-HNE protein adducts have been successfully detected by
immuno-staining using antibodies against 4-HNE-amine epitopes of lysine-rich LDL
(Houglum et al., 1990; Benedetti et al., 1982), but these antibodies have not been
successful in detecting or identifying cellular protein targets by Western blot.
Similarly Hartley et al (Hartley et al., 1999) has demonstrated immunopositive
proteins of 80, 150, and 205 kDa in liver when using immunoprecipitation
techniques with anti-MDA-amine serum and 4-HNE sufhydryl serum, but not with 4-
HNE amine epitopes. Bedossa et al, (Bedossa et al., 1994) used antibodies directed
to 4-HNE-amine epitopes, and like ourselves, also failed to demonstrate 4-HNE
adducts in liver sections from carbon tetrachloride treated rats.
Formal identification of the protein that corresponded to the protein bands on
Western blotting using the anti 4-HNE Michael adduct antibody should have been
performed. Instead of using a denaturing gel alone which separates the proteins based
on molecular size, a two dimensional gel system separating initially by their
isoelectric point followed by SDS-polyacrylamide gel electrophoresis would yield
the best resolution of the proteins. The bands of interest could be cut from the gel and
the protein treated with either acid hydrolysis, or tryptic digest, or high pressure
liquid chromatography could be used to release the free amino acids and identify the
amino acids in the protein. Determination of the amino acid sequence of the protein
can be performed by mass spectrometry using peptide mass fingerprinting. In the
technique of mass fingerprinting the protein is cleaved into peptides giving a pattern
for the 4-HNE protein adduct and this fingerprint is then compared to a database of
proteins that have been cleaved electronically by computer simulation.
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In summary protein bands in the region of 45 kDa and 66 kDa, and 47-81 kDa have
been demonstrated on Western blotting using anti HNE Michael adduct antibody,
and these may represent 4-HNE protein adducts, although no formal identification of
these proteins has been performed.
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CHAPTER 5
EARLY ONE ADENOVIRAL PROTEIN IN HUMAN LUNG TISSUE FROM




It is unknown why only a proportion of smokers go on to develop chronic
obstructive pulmonary disease (COPD). An environmental factor may be important
in the development of the enhanced inflammation associated with COPD.
Epidemiological studies show that an earlier viral infection confers an increased risk
of respiratory disease from asthma and COPD (Schroeckenstein et al., 1988, Samet
et al., 1983), and it has been suggested that an earlier adenoviral infection may
render the respiratory tract more susceptible to damage in the face of an oxidant
stimulus such as cigarette smoke (Hogg, 1999). After adenoviral infection, the
adenovirus can integrate into the human genome, and a crucial step in this process is
the expression of early DNA proteins, A and B (E1A and E1B). E1A protein may
enhance the inflammatory reaction by modulation of the transcription of
inflammatory mediators (Higashimoto et al., 2002), effects on cell signal
transduction pathways (Shen et al., 1998; Barbeau et al., 1994), and displacement of
transcription factors from the transcription machinery (O'Connnor et al., 1999).
In vitro systems using ElA transfected cell lines (Higashimoto et al., 2002,
Gilmour et al., 2001, Keicho et al., 1997, Keicho et al., 1997) and also animal
models (Vitalis et al., 1996 and 1998) have demonstrated an enhanced inflammatory
reaction in response to stimuli. In a Canadian population, genomic DNA extracted
from resected lung tissue has shown increased amounts of the ElA region of the viral
genome in patients with COPD, (Matsuse et al., 1992), and El A has also been
demonstrated in lung tissue from patients with sarcoidosis (Kuwano et al., 1997).
We therefore wished to establish whether such adenoviral protein DNA
(ElA) was also present in a Scottish population of smokers with COPD. Human lung
tissue was examined for the presence of El A protein using the techniques of
polymerase chain reaction, nested polymerase chain reaction, Southern hybridisation
and immuno-histochemistry. We failed to conclusively demonstrate the presence of
ElA in human lung tissue obtained from a Scottish population, and during the course
of the work experienced problems with adenoviral contamination.
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5.2 Methods E1A
A full summary of the patient characteristics for the lung tissue that was used in this
series ofEl A experiments is shown in the results section 5.3.
5.2.1 Genomic DNA Extraction from human lung tissue
Frozen lung tissue was sliced using a sterile scalpel, and the tissue was lysed
by incubating in lysis buffer (100 mM NaCl, 10 mM Tris-Cl pH 8, 25 mM EDTA pH
8 and 0.5% SDS) and proteinase K, Sigma Aldrich Co Ltd. (Poole, UK) at 55°C. The
volume of lysis buffer and proteinase K was varied depending on the lung weight
(250 mg tissue then 1ml lysis buffer and 5pl of proteinase K (O.lmg proteinase K)
was added). Further proteinase K diluted in lysis buffer was added at 12 and 24 hrs if
the tissue had not lysed. The lysis buffer/tissue mix was mixed with an equal volume
of saturated phenol/chloroform/isoamyl alcohol, vortexed gently and then
centrifuged at 13000 rpm, 4°C. A further phenol chloroform extraction was
performed. The aqueous top layer containing the DNA was transferred to another
eppendorf and the DNA was precipitated using cold 100% alcohol and 3M sodium
acetate solution. The DNA in the alcohol/acetate mix was stored at -20° for 48 hrs, or
longer if not required for use. After storage at -20° the DNA was washed in 500pl of
70% alcohol and left to air dry for 20-30 minutes, and the genomic DNA was
dissolved in lx TE buffer (10 Mm Tris-Cl pH 7.5, 1 mM EDTA). This dissolving
process took several days and often a week, and during this stage the DNA solution
was stored at 4°C. The concentration and purity of the DNA was estimated by
measuring the absorbance at wavelengths 260 nm and 280 nm in a glass cuvette in a
spectrophotometer. A ratio of 260/280 of 1.8 was aimed for.
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5.2.2 Assessment of E1A gene by Reverse transcriptase polymerase chain
reaction using genomic DNA
Aliquots of genomic DNA were PCR amplified using a thermal cycler (Hybaid,
Ashford, UK). Human genomic DNA was added to 50 pi of PCR mixture (a solution
containing 2.5 mM MgCU, lx PCR Buffer (Promega), 0.2 mM dNTPs and lOpl of
each primer) with Taq polymerase (lU/pl), for human glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) and early one adenoviral protein (El A).
Conditions for the PCR:
E1A: 40 cycles of denaturation (93°C for 1 minute), annealing (63°C for 1 minute),
and extension (72°C for 2 minutes), and final extension of 7 minutes.
GAPDH: 35 cycles denaturation (94°C for 45 seconds), annealing (60°C for 45
seconds), and extension (72°C for 90 seconds), and final extension of 10 minutes at
72 °C.
Primers were sequenced by MWG-Biotech (Milton Keynes, UK).
The primers chosen for GAPDH were as per previous published sequences (Maier et
al., 1990) and were as follows (sense 5' -CCA CCC ATG GCA AAT TCC ATG
GCA-3') and (anti-sense 5'-TCT AGA CGG CAG GTC AGG TCA ACC-3')
The primers chosen for ElA were according to Vitalis and Matsuse who had
previously performed PCR for ElA in lung tissue (Vitalis et al., 1998; Matsuse et al.,
1992). The size of the amplified product using Matsue primers was 675 base pairs
and the sequences were as follows (sense 5' -CTC AGG TTC AGA CAC AGG ACC
T-3') and (antisense 5' -CTG CCA CGG AGG TGT TAT TAC C-3').
The size of the amplified product using primers from Vitalis was 486 base pairs and
the sequences were as follows (sense 5'- TCA-GGC-TCA-GGT-TCA-GAC-NCA-
G-3') and (antisense 5' -TAA-TGT-TGG-CGG-TGC-AGG-AAG-G-3').
PCR products were electrophoresed on a 1.5% agarose gel containing ethidium
bromide and the gel was scanned using a white/UV transilluminator (Ultra Violet
Products, Cambridge UK).
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The effect of the concentration of genomic DNA on PCR reaction
Previous reports examining El A in human lung tissue by PCR had demonstrated a
clear band when the PCR products had been electrophoresed on an agarose gel
(Matsuse et al., 1992). Our preliminary work using 10 pi (approximately 5pg) of
genomic DNA in the PCR mix failed to show clear bands on PCR for either the
GAPDH or ElA, however the positive controls demonstrated clear bands in the
expected place. The effect of using 5 pi of 500 ng/pl, and 5 pi of 50 ng/pl of template
genomic DNA in the PCR reaction was therefore examined for both ElA primers
and GAPDH primers. The positive control was genomic DNA extracted from
Graham 293 cells, and this was provided by Dr Shizu Hayashi, Vancouver. Graham
293 (G293) cells are human embryonic kidney cells that have been transformed by
exposing the cells to sheared fragments of adenovirus type 5 DNA (Graham et al.,
1977).
For ElA primers the positive control was 1 pi G293 genomic DNA (concentration 10
pg/500pl in TE buffer; 20 ng), and the negative control was 5 pi dd H2O.
For the GAPDH primers the positive control was 1 pi cDNA obtained from the RNA
ofA549 cells, and the negative control was 5 pi dd H2O.
5.2.3 Dot Blot Southern Hybridisation of genomic DNA from human lung tissue
This technique allows the immobilisation of unfractionated DNA on a nylon
membrane which is then hybridised with a probe.
The nylon membrane (Hybond non charged) was placed in the manifold apparatus.
Five hundred pi of 6 x SSC (0.15 M NaCl, 0.015 M Na3 citrate, pH 7) was applied
to each individual dot chamber, followed by suction to pull the solution through the
nylon. The genomic DNA from 24 human lungs was denatured by heating 20 pi of
DNA with 10 pi 20 X SSC at 100°C for 10 minutes, followed by rapid cooling on
ice. Thirty pi DNA/SSC aliquots were added to each dot chamber, followed by a
further 500 pi 6x SSC and allowed to pass through the membrane. The membrane
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was removed and placed on top of Whatman paper that had been soaked in
denaturing solution (1.5M NaCl/0.5 M NaOH) for 10 minutes, followed by the
membrane being placed on top of neutralising solution (1 M NaCl/0.5M Tris-Cl pH
7) for 10 minutes. The membrane was allowed to dry and the DNA samples were
cross linked by placing the membrane under UV light (high strength) for 3 minutes.
Samples: 24 samples of genomic DNA from human lung tissue (concentrations 0.5
pg/pl, and 0.05 pg/pl). 20 pi of genomic DNA was used for each dot blot well
chamber.
Positive controls: 1. genomic DNA from G293 cells
2. c DNA from El A transfected A549 cells
Negative controls: 1. Water
2. c DNA from A549 cells
Preparation of EIA Probe used in dot blot Southern
The PCR product from an earlier EIA positive control using 675 bp EIA primers
was cut from an agarose gel, and purified using a DNA purification kit (Promega,
Madison, USA). Four pi of this purified DNA was added to 21 pi lx TE buffer and
this mix was heated to 100° C for 3 minutes and then cooled on ice for 2 minutes and
then pulse centrifuged for 15 seconds. The 'ready to go' Pharmacia Biotech
(Buckinghamshire, England) labelling kit ampoule was reconstituted using 20 pi dd
H2O and allowed to stand on ice for 60 minutes. The 25 pi of purified PCR product
mix was added to the ready to go ampoule, together with 5pi a 32P-dCTP (Redivue,
Amersham Pharmacia Biotech UK, Buckinghamshire England)(50pCiu), mixed by
pipetting and then incubated at 37 °C for 15 minutes and then placed on ice until
used.
Hybridisation
The membrane was rolled in nylon mesh and prehybridised in 20 mis preheated
(65°C) Church and Gilberts solution for 2 hours in the hybridisation chamber.
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Hybridisation was achieved by adding the labelled probe to 20 mis fresh pre-heated
(65°C) Church and Gilberts solution and the membrane was incubated overnight at
65°C. The membrane was then rinsed in 10 mis 2x SSC/0.1% SDS (65°C), followed
by 20 minute rinse in fresh 20 mis 2x SSC/0.1% SDS (65°C), then 20 minute wash in
20 mis 0.5x SSC/0.1% SDS (65°C), and then two further washes for 20 minutes in
20 mis O.lx SSC/0.1% SDS (65°C).
The membrane was developed using Kodak film.
Church and Gilberts solution
Na2HP04 2H20 51.34g
NaH2P04H20 29g
Dissolved in 800mls H20
70 g SDS added
Make up to 1L
5.2.4 Nested Polymerase chain reaction
In vitro deoxyribonucleic acid (DNA) amplification by the polymerase chain reaction
allows the detection of rare DNA sequences, and can detect the presence of
infectious agents that are present in low copy numbers. Nested PCR is a two step
amplification process where outer primers, followed by inner primers are used in an
attempt to enhance the sensitivity and specificity of the PCR. Kuwano (Kuwano et
al., 1997) has used nested PCR to detect ElA in the lungs of patients with
sarcoidosis.
The outer primers were those that gave a PCR product at 675 base pairs and were
(sense 5'-CTC AGG TTC AGA CAC AGG ACC T-3') and (antisense 5'-CTG CCA
CGG AGG TGT TAT TAC C-3'). The inner primers were those that gave a PCR
product at 261 base pairs and were (sense 5'-GAA CCA CCT ACC CTT CAC GAA
CTG-3') and (antisense 5'-GTG GCA GGT AAG ATC GAT CAC CTC-3').
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The conditions for the PCR using the outer (675bp) ElA primers were the same as
outlined earlier. Four pi of the PCR product obtained from this PCR reaction using
675 bp primers was used in a second PCR reaction using the outer 261 bp primers.
The reaction solution was the same as for the 675 bp PCR with the exception that the
primers were different. 35 cycles of denaturation (93°C for 1 minute), annealing
(63°C for 1 minute), and extension (72°C for 2 minutes), and final extension of 7
minutes were used.
5.2.5 Southern Hybridisation
Twenty samples of human genomic DNA were used in the PCR using ElA and
GAPDH primers (details of the patient characteristics are detailed in section 5.3).
The concentration of genomic DNA was reduced to 250 ng in 5 pi. The samples were
run in triplicate on each gel. The PCR mixture consisted of 100 pi of lOx PCR
buffer, Promega, 100 pi MgCf 25mM, Promega, 20 pi dNTP mix, Pharmacia
Biotech, 10 pi of each E1A 486 bp primers, MWG-Biotech, and 760 pi dd EEO. The
reaction mixture consisted of 45 pi of PCR mix, with 5 pi lung genomic DNA (250
ng), and 1 pi Taq polymerasere (2.5 units/ pi). The conditions of the PCR for the
E1A primers were hot start at 90"C for 5 minutes, then 40 cycles of denaturation
(93°C for 1 minute), annealing (63°C for 1 minute), and extension (72°C for 1
minute), and final extension of 6 minutes. Positive control was G293 genomic DNA
(3ng), and negative control was PCR mix alone.
For the GAPDE1 PCR, the PCR mix was the same as for the ElA, with the exception
of the primers. The volume of PCR mix was 45 pi, together with 5 pi lung genomic
DNA (250 ng) and 1 pi Taq polymerase (0.5 units/ pi). The conditions of the PCR
for the GAPDH primers were a hot start at 94°C for 10 minutes, then 35 cycles of
denaturation (94°C for 45 seconds), annealing (60°C for 45 seconds), and extension
158
(72°C for 90 seconds), and final extension of 10 minutes. The positive control was 2
pi of cDNA from A 549 cells, and the negative control was PCR mix alone.
The PCR products were run on 1% agarose gels, and then transferred to nylon
membranes, and then probed using the ElA probe, or the GAPDH probe.
E1A Probe
The E1A probe was provided by Dr Shizu Hayashi. The probe consisted of a
fragment of DNA 756 base pairs long. The 742 bp Alu 1 fragment was cut from the
ElA DNA adeno virus 5. This Alu 1 fragment was cloned in the Hinc II site of
pUC13. This DNA was then digested using the restriction enzymes Pst\ and BamYll.
The DNA was run on a 1% agarose gel and the BamHl/Pstl fragment was cut out of
the gel and the DNA purified and 0.5 ng of DNA used for the probe. The probe was
labelled with 5 pi a 32P-dCTP (50p Ciu) using the ready to go labelling kit
(Pharmacia Biotech, Buckinghamshire, England), as previously described.
GAPDH Probe
This was prepared by cutting out the PCR product from an agarose gel in which 5 pi
cDNA from A549 cells had been used in a PCR reaction for GAPDH. This PCR
product was purified using DNA purification kit and then 0.5ng was used as the
probe. The GAPDH probe was labelled with 5pi a 32P d CTP (50p Ciu) using the
ready to go labelling kit (Pharmacia Biotech).
The PCR gels were denatured by soaking twice in 1.5 M NaOH/0.5 M NaOH for 10
minutes, and then neutralised in 1.5 M NaCl/0.5 M Tris-Cl pH 7.2,1 mM EDTA.
The PCR products were transferred to the nylon membrane using a sandwich
consisting of a weight, paper towels, Whatman paper, membrane, gel with PCR
products facing upwards, and Whatman paper, that was placed on top of a wick of
whatman paper that was soaking in lx SSC solution and the transfer was allowed to
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take place overnight. The membrane was allowed to dry at room temperature and the
DNA crosslinked using UV cross linker for 30 seconds.
Prehybridisation Mix
6 x SSC
5 x Denhardts (Sigma D-2532)
0.5% SDS
20 pg/ml salmon sperm DNA (Sigma D-9156)
The membrane was prehybridised for 6 hours in prehybridisation mix at 65°C.
Hybridisation was carried out by adding the labelled probe to 20 mis of
prehybridsation solution and incubating this with the membrane over night at 65°C.
The membrane was then rinsed in 2x SSC/0.1% SDS twice for 10 minutes at 65°C,
followed by two washes in 2x SSC/0.1% SDS at room temperature. The membrane
was then washed in O.lx SSC/0.1% SDS for 30 minutes at 65°C and then rinsed in
2x SSC at 65°C. The membrane was then autoradiographed using Kodak developing
film. The phosphoimager was used for developing and imaging for selected Southern
experiments (Southern hybridisation using positive controls of plasmid El A DNA).
Southern Hybridisation using Positive controls of plasmid E1A DNA and G293
genomic DNA, and a 'positive' lung sample
Dr Hayashi provided a sample of lung genomic DNA from the laboratory in
Vancouver, which she had previously found to be positive for El A. She also
provided further G293 genomic DNA, and a sample of the plasmid DNA (5pg/20pl
water) which the ElA probe had originally been constructed from (vector). Ten
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nanograms of this vector DNA was also used as a further positive control in the PCR
reaction.
Five pg of pUC EIA (plasmid DNA) was dissolved in 20 pi distilled water, and 10 pi
was used in a double digest using 2 pi of Pst\ and BamYll restriction enzymes and
enzyme buffer, Promega (Madison, USA), incubating overnight for 10 hours at
37°C. The cut DNA was run on a 1% agarose gel and then the 0.76 Kb insert was cut
out of the agarose gel, weighed and the concentration of EIA DNA calculated, and
distilled water added to give a concentration of lng/pl. It was heated to 65° for 20
minutes. Twenty five pi (25 ng) of DNA was used for the probe but was first
denatured by heating at 95° C for 20 minutes, followed by 10 minutes at 37 °C, and
room temperature for 10 minutes. The probe was labelled with 5pi a 32P-dCTP (50p
Ciu) using the ready to go labelling kit (Pharmacia Biotech, Buckinghamshire,
England), as previously described.
Template DNA: 7 samples of Scottish lung genomic DNA (5 pg)
1 sample of Vancouver lung genomic DNA (previously found to be
positive in Vancouver) (5 pg)
genomic DNA from G293 cells (which had been in use for 5
months) positive control (3 ng)
genomic DNA from G293 cells (recently brought to UK by Dr
Hayashi) positive control (3ng)
Vector DNA 10 ng
Negative controls were 15 pi dd EEO2.
A volume of 32.5 pi of PCR mix (lx PCR buffer, 2.5 mM MgCl2, 0.2 mM d NTP,
0.5 pM primers), 5 pg genomic DNA in final volume of 15 pi dd FEO, and 5 pi Taq
polymerase 500 units/1 OOpl, Promega (Madison, USA). The EIA primers were 486
bp primers as described earlier, and the GAPDH primers were as described earlier.
The PCR programme for EIA consisted of 35 cycles of denaturation (93°C for 1
minute), annealing (63°C for 1 minute), and extension (72°C for 1 minutes), and
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final extension of 6 minutes, with an initial hot start of 90°C for 5 minutes. GAPDH
PCR programme and conditions as previously described, using 1 pg genomic DNA,
and 50 pi PCR mix.
5.2.6 Restriction enzymes to cut and then probe genomic DNA for E1A DNA
sequences
The PCR amplification reaction may not have been very efficient using total
genomic DNA, and the genomic DNA was cut using restriction enzymes. The
restriction enzymes used were Alu-1, Boehringer Manheim, Pstl and Hind III,
Promega (Madison, USA). The template genomic DNA for these restriction enzymes
was 2.5 pg G293 genomic DNA, and Scottish human lung sample 91 genomic DNA.
Controls ofDNA with buffer but without the restriction enzymes were included. Due
to an error Pst-1 enzyme was added to the controls for the G293 genomic DNA and
lung sample 91, and there were no controls for the Pst-1 enzyme. The DNA, buffer
and enzymes were incubated for 24 hours at 37 ° C, and then were electrophoresed
on a 1% agarose gel. The agarose gel was transferred to a nylon membrane and the
membrane was hybridised using the 756 bp ElA probe as previously described.
5.2.7 Polymerase chain reaction and Southern hybridisation for E1A in
collaboration with Dr Shizu Hayashi
81 samples of fresh frozen human lung tissue from well characterised patients were
taken on dry ice to Vancouver, and genomic DNA extractions were performed in the
laboratory at St Pauls Hospital Vancouver as per the previously documented protocol
above. DNA from human placental tissue that had been stored at -80° in the St Pauls
laboratory freezer was also extracted at the same time. The concentration of genomic
DNA was calculated by measuring the absorbance at 260 nm, and lung and placental
DNA was dissolved in water to a concentration of 0.1 pg/pl. Five pi of genomic
DNA was used in the PCR reaction. Samples were run in duplicate and the PCR
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reaction mix consisted of lx PCR buffer, 2 mM MgCh,, 0.2 mM dNTPs and 10 pi of
each primer (0.5 pM). Forty pi of this mix together with 5 pi of genomic DNA and 5
pi Taq polymerase (2.5 units/5pi) was used in the PCR reaction. A 3 minute hot start
at 94°C was used prior to addition of the Taq polymerase. The size of the amplified
product was 486 base pairs and the sequences were as follows (sense 5'- TCA-
GGC-TCA-GGT-TCA-GAC-NCA-G-3') and (antisense 5' -TAA-TGT-TGG-CGG-
TGC-AGG-AAG-G-3').
The conditions for the PCR were ElA: 40 cycles of denaturation (94°C for 1
minute), annealing (63°C for 1 minute), and extension (72°C for 2 minutes), and
final extension of 7 minutes. The PCR products were allowed to stand overnight at
4°C in the PCR machine. Human genomic DNA of concentration lmg/ml contained
2.7 x 105 copies of ElA per pg genomic DNA. Positive controls of 10, 100 and 1000
copy numbers were included by dissolving G293 in human placental DNA (6 pg/pl,
60 pg/pl, and 600 pg/pl). Negative controls of PCR mix alone, and 5pl of genomic
DNA in the PCR reaction were used. The PCR products were transferred to a nylon
membrane and hybridised as described earlier.
The HLA DQa primers produced an amplified product of 242 base pairs and the
sequences were as follows (sense 5'-GTGCTGCAGGTGTAACTTGTACCAG-3')
and (antisence 3'-GTTGAGATGGCGACGATGGCCTAGGCAC-5'). The conditions
of the PCR reaction were as for the EIA and the programme consisted 40 cycles of 1
minute denaturation at 93°C, 2 minutes at 50°C annealing, and 2 minutes at 72°
extension.
5.2.8 Immunostaining for EIA protein
This work was carried out in collaboration with Shizu Hayashi and Mark Elliot,
UBC, Vancouver. Paraffin embedded sections from a population of Scottish patients
(43) who had undergone LVRS or lung resection for suspected bronchial carcinoma
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were examined. Full details of the patient characteristics are included in the results
section, table 5.3.
Three micron thick paraffin embedded sections were cut and placed on Superfrost
slides. Sections were deparaffinised by two 10 minute soakings in Hemo-DE
solution. The sections were rehydrated using alcohol, initially 100% ethanol for 10
minutes (twice) and then placed in diethyl alcohol ether for 60 seconds, and then
0.4% nitrocellulose solution for 60 seconds, and then allowed to dry. After which the
slides were placed in 70% alcohol for 3 minutes to allow to harden, and then they
were placed in water until ready to use. The slides were autoclaved for 7 minutes in 6
M urea using a plastic Coplin jar and the slides were rinsed in water. The slides were
then incubated with 1 OjlxI TBS and then the immunostaining started. The sections
were incubated with 5% normal rabbit serum for 20 minutes at room temperature,
and then poured off. One hundred pi of primary antibody (mouse monoclonal ElA
Calbiochem DPll-lOOpG diluted 1:100 in 1% bovine serum albumin was incubated
for 30 minutes at room temperature, followed by three 5 minute TBS washes. The
secondary antibody was applied (rabbit antimouse Dako Z0259, 1:40 in TBS/1%
BSA solution pH 7.6) for 30 minutes at room temperature, followed by three 5
minute washes in TBS buffer. 600 pi (APAAP-mouse monoclonal Dako D0651
diluted 1:100) was added to each slide for 30 minutes followed by washing in TBS
buffer. The substrate was prepared fresh and the solutions A and B were mixed and
filtered directly onto the slides.
Solution A
250 pi 4% sodium nitrite solution was placed in an Ehrlenmeyer flask and 100 pi of
5% New Fuschin (in 2M hydrochloric acid) was added and the solutions mixed. 50
pi of TBS buffer pH 8.7 was added to the solution and 50 pi 1 M levamisole was
added.
Solution B
25 ng naphthol-AS-BI-phosphate was added to dimethyl formamide.
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Three batches of lung sections were examined for El A by immunohistochemistry.
After the first batch, the positive control consisting of sections of HA 35-1 cells was
changed to A549 cells infected with adenovirus, as this gave a better positive result.
Positive controls: Batch 1 HA 35 -I (Human bronchial epithelial cell line which has
been transfected with ElA)
Negative control: HA-35-II
Run 2 and 3: Positive controls:A549 cells infected with adenovirus
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5.3 Early One Adenoviral Results
5.3.1 Amplification of genomic DNA using PCR
Standard amplification of 500 ng and 50 ng of template human genomic DNA from
24 patients who had undergone lung resection was performed using PCR with 675 bp
and 486 bp El A primers, and GAPDH primers. Nine patients had normal lung
function (mean FEVi 2.5 ± 0.77 litres), thirteen patients had airflow obstruction
(mean FEVi 1.8 ± 0.35 litres) and 2 patients had severe airflow obstruction having
undergone LVRS (mean FEVi 0.45 ± 0.21 litres). All patients were either current or
ex-smokers except for three patients who had never smoked. Two patients who had
never smoked were included in the airflow obstruction group, one of which had mild
airflow obstruction with a percent predicted FEVi of 68%, and the other non smoker
had a tumour that was acting as a ball and valve and resulting in airflow obstruction.
One never smoker was included in the normal lung function group. The
characteristics of the patients included in these PCR experiments are shown in table
5.1.








Age years(mean & range) 62.9 (58-72)
Male: female 4:5
Smoking History (pack yrs) 52.75+33.4
FEV, (litres) 2.5+0.77
FEVi % pred 96.2+10.3
FVC (litres) 3.2+1.1
FEVi/FVC% 77.2+3.65
Data expressed as mean ± SD
* p< 0.05 versus normal lung function group
















The use of ElA primers and 500 ng of template DNA failed to show any single
bands in the expected area when PCR products were electrophoresed on an ethidium
bromide stained agarose gel and smears were observed. Reduction in the quantity of
genomic DNA lead to multiple bands, but the strongest band was above the level of
the positive control template DNA, figure 5.1. Similarly GAPDH primers produced
smears when using 500 ng of genomic DNA but using 50 ng produced single clean
bands on the ethidium bromide stained agarose gel. Figure 5.1 shows representative
ethidium bromide stained gel of the PCR products using 486 bp primers and GAPDH
primers with 50 ng genomic DNA from lung tissue.
DNA
Ladder x5 human lung x5 human lung
1Kb cont buffer cont buffer
600bp GAPDH primers 486bp E1A primers
Figure 5.1 The amplification ofgenomic DNA from human lung tissue using GAPDH
primers and 486 bp ElA primers. Lane 1 1Kb DNA ladder, lane 2 cDNA from A549
cells used as positive control, lane 3 buffer with no template DNA, lanes 4 8 human
lung genomic DNA as template DNA. Lane 9 template DNA positive control genomic
DNA from G293 cells, lane 10 buffer with no template DNA and lanes 11-15 human
lung genomic DNA as template DNA.
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5.3.2 Dot Blot Southern Hybridisation using 675bp Probe
PCR with ElA primers and electrophoresis on agarose gel had failed to demonstrate
single bands in the expected area. The technique of dot blot Southern which allows
unfractionated DNA to be immobilised on a nylon membrane, followed by
hybridisation was used in an attempt to identify El A in non amplified DNA.
Genomic DNA from 24 human lungs was used in the dot blot. The patient
characteristics are shown in table 5.1, and DNA is from the same group as that used
in section 5.3.1. The probe used was the positive control PCR product from the PCR
reaction using 675 bp primers which had been run on agarose gel and cut out and
^9
purified and labelled with a "P dCTP. The positive controls included G293 genomic
DNA and cDNA from A549 cells transfected with El A. No lung genomic DNA was
positive on dot blotting, and only the cDNA from ElA transfected cells was positive.
The G293 cell genomic DNA was negative on dot blotting. This is shown in figure
5.2.
Figure 5.2 Dot blot Southern hybridisation of genomic DNA from 24 human lung
samples. The three round dots, indicated by the arrow arc the positive control ofElA
transfected cell cDNA. No human lung genomic DNA was positive and nor was the
genomic DNA from G293 cells. The probe consisted of the labelled positive control
(G293 genomic DNA) PCR product (675bp) that was cut out ofan agarose gel.
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5.3.3 Nested PCR
Nested PCR with 675 bp outer primers and 261 bp inner primers for ElA was used
to examine for the presence of ElA protein in 30 samples of human lung genomic
DNA. The characteristics of the 30 patients are shown in table 5.2.




Age (mean ± SD) 63.3±7.2 62.9± 7.5 54.8±8
Male:female 5:4 11:6 1:3
Smoking History (pack yrs) 59.2±42.2 44.6± 22.6 32.7±17.5
FEVi 2.41±0.73 1.93±0.47 0.6210.23**
FEVi % pred 91.419.7 65.41 8.1** 23.718.1**
FVC 3.211 3.210.85 2.2910.93
FEVi/FVC% 75.813.15 61110.49** 27.3+6.1
Data expressed as mean ± SD
** p< 0.001 versus normal lung function group
**
Table 5.2 Patient characteristics
On one occasion a positive result was obtained for lung sample number 64 (figure
5.3.). We were unable to reproduce this result. There were repeated problems with
contamination in the experiments using nested PCR that followed this positive result
and so it is highly likely that this positive result was the result of contamination.
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Figure 5.3. An ethidium bromide stained agarose gel with 1Kb DNA ladders
demonstrated in lanes 1, 6 and 13. Lane 2 G293 genomic DNA PCR product using
outer primers, 675bp. Lane 3 is a negative control with PCR mix alone. Lane 4 is a
positive control for the nested PCR using inner and outer primers. Lanes 7-12
represent PCR products from human lung tissue genomic DNA which have
undergone nested PCR using 675bp and 261bp primers. A faint positive band is
present in lane 11, see arrow.
5.3.4 Southern Hybridisation
Genomic DNA from 20 human lung samples was amplified using ElA 486 bp
primers and also using 600 bp GAPDH primers. These samples were obtained from
patients with the characteristics outlined in table 5.3. Lung function was classified as
obstructed if the percent predicted FEVi was less than 80 %. There were six subjects
with normal lung function (mean percent predicted FEVi 91.9), eight with airflow
obstruction with mean percent predicted FEVi 73.1, and six with severe airflow
obstruction who had undergone lung volume reduction surgery for severe
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emphysema, with percent predicted FEVi 24.9. Two samples in the severe airflow
obstruction group were from the same patient but were from different lobes of the
lung. The airflow obstruction group included in this work contained patients with
very mild disease rather than in previous experiments were subjects had more severe
disease. Only the severe obstruction group had complete smoking histories recorded,
and within the normal and airflow obstruction groups smoking history data was
incomplete in 5 patients.
The PCR products were transferred to a membrane and probed with ElA probes and
GAPDH probes. These 20 samples were all negative for ElA. All samples however
were positive on agarose gel for GAPDH and also on probing using GAPDH probe.




Age years (mean & range) 63.8 (43-75) 67 (57-77) 62 (42-59)
Male:female 4:2 6:2 4:2
Smoking History (pack yrs) 90.25(22-168) 41.1(26-51.75) 61.1(25-184)
FEVi (litres) 2.57+0.59 2.18+0.56 0.75+0.2 *
FEVi % pred 91.9+7.4 73.14+ 8.4* 24.9+7.44*
FVC (litres) 3.53+1.1 3.19+0.98 2.67+0.95
FEV,/ FVC % 73.5+3.65 69.5+12.01 29.3+5.4 *
Data expressed as mean ± SD
* p< 0.001 versus normal lung function group
Table 5.3. Patient characteristics
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
486 bp
Figure 5.4.a
Lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
600 bp
Figure 5.4. b
Figure 5.4. a is a representative ethidium bromide stained agarose gel ofhuman lung
genomic DNA amplified using 486 bp primers (in triplicate) lanes 4-15. Lane 1, 1Kb
DNA ladder, lane 2 positive control ofG293 genomic DNA, and negative control in
lane 3 consisting of PCR mix alone. Amplification of lung genomic DNA gives
multiple bands as previously shown in figure 5.1.
Figure 5.4.b is an ethidium bromide stained agarose gel of the same lung sample
genomic DNA (lanes 4-15) as in figure 5.4a using GAPDHprimers for amplification
and the positive control ofA549 cell cDNA. A single clean band is demonstratedfor
the GAPDH at 600bp.
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To determine if any of the PCR product bands represented the 486 bp DNA of the
ElA region, Southern blots of these agarose gels were probed using a DNA probe
corresponding to the ElA region of the adenovirus genome. The human lung PCR
amplification products obtained using El A primers were negative on probing, but
clear positives were obtained on probing the G293 positive controls, figures 5.4.a and
5.5. The human lung PCR amplification products obtained using GAPDH 600 bp
primers were all positive on probing, and clear positives were obtained on probing
the cDNA positive controls (figures 5.6 and 5.4.b).
lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 5.5. is the Southern transfer of the agarose gel in figure 5.4. a (ethidium
bromide stained agarose gel of human lung genomic DNA amplified using 486 bp
primers (in triplicate) lanes 4-12. Lane 1, 1KB DNA ladder, lane 2 positive control
(template ofG293 genomic DNA), and negative control in lane 3 consisting ofPCR
mix alone, which has been probed using E1A DNA probe. The previously noted
amplification gave multiple bands in the lung DNA, but no signal is demonstrated on
probing the Southern transfer of the gel and PCR products.
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Lanes 1 2 3 45 6 7 8 9 10 11 12 13 14 15
Figure 5.6. is an autoradiograph of the Southern transfer of the agarose gel in figure
5.4.b which has been probed using GAPDH DNA probe. All of the 12 lung samples
lanes 4-15 (4 different genomic DNA performed in triplicate) demonstrate a similar
signal on the autoradiograph. Lane 1 1Kb DNA ladder, lane 2 positive control of c
DNA, and lane 3 negative control ofPGR mix alone.
5.3.5 Southern Hybridisation using Positive controls of plasmid E1A DNA and
G293 genomic DNA, and 'positive' lung sample from Vancouver
PCR amplification with 486 bp primers was carried out using 5 pg lung genomic
DNA {from 8 lung samples including lung sample 64 (lane 9) which had a single
unrepeatable positive using nested PCR, and 'positive' Vancouver lung sample (lane
10)} in the reaction mixture and plasmid DNA as control together with G293
genomic DNA. The PCR products were transferred to a nylon membrane and probed
using the pUC El A which had been cut using restriction enzymes BamUl and Pst\.
The lung samples were all negative on PCR amplification and similarly they were all
negative on probing (figure 5.7). No positive signal was found in lane 10 which
represents the PCR product from genomic DNA that had been found to be positive in
Vancouver, and no positive signal was found in lane 9 which had been found to be
positive on one occasion using nested PCR. The nylon membrane was cut inorder to
hybridise the positive samples (G293 PCR products) separately to the lung samples
to ensure that the 'positive controls' were not preferentially binding the probe.
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Figure 5.7 shows the Southern hybridisation of the transferred PCR products that
have been probed using ElA probe. Lane 1 DNA ladder, lane 2 negative control with
PCR mix alone, lanes 3-9 templates ofScottish lung genomic DNA, lane 10 template
of Vancouver 'positive' lung genomic DNA, lane 11 G293 PCR products, lane 12
G293 PCR products, lanel3 empty, and lane 14 Vector E1A DNA. Binding of the
probe to the DNA ladder is also noted in lane 1. There is no positive signal in the
area of lane 10, which is the genomic DNA from Vancouver which was reportedly
positive on testing in Vancouverfor ElA.
5.3.6 Restriction enzymes to cut and then probe genomic DNA for E1A DNA
sequences
The PCR amplification reaction may not have been very efficient using total
genomic DNA as unwanted DNA is included in the PCR reaction.
Genomic DNA from human lung and G293 cells was cut using the restriction
enzymes Alul, Pstl and Hind III, electrophoresed on an agarose gel and then probed
using the same El A probe as in the previous experiments. Alul failed to cut human
lung genomic DNA, as did Hind III, but Pstl cut both human lung genomic DNA
and G293 genomic DNA. Probing of these cut DNA sequences failed to yield any
positive signals even for the cut G293 using DNA 756 bp ElA probe.
175
506 bp
Figure 5.8. This shows an agarose gel with genomic DNA that has been cut using the
restriction enzymes Alu-1, Pst-1 and Hind-III, which has been electrophoresed. Lane
1 1 Kb DNA ladder, lane 2 G293 genomic DNA cut with Alu-1, lane 3 G293 no
enzyme control, lanes 4 and 5 human lung genomic DNA with Alu-1, lane 6 human
lung genomic DNA no enzyme, lanes 7 and 8 G293 genomic DNA cut with Pst-1,
lanes 9 and 10 human lung genomic DNA cut with Pst-1, lane 11 G293 genomic
DNA cut with Hind-Ill, lane 12 G293 genomic DNA without enzyme, lane 13 human
lung genomic DNA cut with Hind-III, and lane 14 with no enzyme.
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5.3.7 Results from work carried out in collaboration with Vancouver laboratory
81 lung samples were taken on dry ice to the laboratory in Vancouver where
genomic DNA extractions were undertaken, and PCR amplification of duplicate
samples using 486 bp ElA primers and the PCR products were transferred to nylon
membranes and probed using 756 bp E1A probe. The duplicate PCR samples were
electrophoresed on separate agarose gels, giving a total of ten agarose gels.
Table 5.4 shows the patient characteristics for the 75 genomic DNA samples
obtained from lung tissue that were included in the final analysis for the presence of
ElA by Southern hybridisation. Six samples were excluded from the final analysis as
they were negative for HLA DQa. DNA was obtained from 29 smokers with no
airflow obstruction, 31 patients with mild to moderate airflow obstruction (FEVi <
70% predicted FEVi/FVC ratio <70%), and 15 patients with severe emphysema who
had undergone lung volume reduction surgery for emphysema.
Normal Lung COPD Severe COPD
Function
n=29 n=31 n=15
Age (range) 63.9(37-75) 63.2 (21-73) 55.7 (42-66)
Male:female 9:20 7:24 3:12
Smoking History (pack yrs) 43.4 ±7.6 43.4 ±5.1 47.7 ± 6.8
FEVi litres (± SD) 2.3 ± 0.13 1.9 ± 0.08 0.63 ± 0.05
FEVi%pred 93.9 ±3.61 61.1 ± 1.8 25.5 ±1.4
FVC litres 3.1 ±0.18 3.3 ±0.13 2.2 ±0.21
FEV,/FVC% 72.7 ±.3 59 ± 1.78 3 0.9 ± 3
ElA positivity % patients 44.8 45.2 66.7
Data expressed as mean ± SD
Table 5.4 Characteristics of the 75 patients included in the final analysis for ElA by
Southern hybridisation
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Increased copy numbers of ElA in the positive controls clearly show an increase in





Figure 5.9 Autoradiograph of the Southern transfer of the two positive control areas
from 2 separate gels. The upper autoradiograph shows increasing copy numbers of
ElA (increasing concentrations ofG293 dissolved in placental DNA) with increasing
signal following hybridisation using E1A probe. In the lower autoradiograph the
same copy numbers ofElA are present (102), but the stronger signal comes from a
template of G293 dissolved in water and the weaker signal from G293 template
dissolved in human placental DNA.
A representative agarose gel containing samples from 15 patients is shown in Figure
figure 5.10a, and the corresponding autoradiograph of the transferred PCR products
that has been probed using the radiolabelled El A probe is shown in figure 5.10b.
Lanes 1 -2 represent negative controls in the form of PCR mix with distilled water
and PCR mix with human placental genomic DNA respectively. Lanes 3 to 17 show
the resolved PCR products from 15 patients (includes samples from patients both
with and without airflow obstruction). Lane 18 is a 1Kb DNA ladder and lanes 19, 20
and 21 are resolved PCR products using increasing concentrations of G293 genomic
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DNA diluted in human placental DNA. The level of the expected ElA bands on the
autoradiograph is indicated by the arrow. The autoradiograph shows two bands an
upper (predicted for El A) and a lower band in 10 of the cases, a lower band alone in
4 cases and no bands in 3 cases. Samples in lanes 2, 3, 4, 7, 10, 12, 14, 15 and 17 are
positive for El A, however the negative control (human placental genomic DNA) is
also positive for ElA, figure 5.10b.
Southern hybridisation of the PGR products from the ten gels (x5 that had been run
in duplicate) showed that the negative control of human placental DNA was positive
on at least one of each of the duplicate gels. The other negative using dd H2O was
consistently negative for ElA on probing. No PCR product from human lung
genomic DNA gave a single band on ethidium bromide staining and all gave multiple
bands similar to earlier work see figure 5.1. The positive controls for ElA that
consisted of G293 dissolved in genomic DNA gave multiple bands on the ethidium
bromide stained gel, where as those dissolved in water gave a single band.
Although human lung samples appear to be positive in a proportion of cases, the




lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Figure 5.10b
lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
f
4
Figure 5.10a Polymerase chain reaction amplification of adenovirus DNA using
genomic DNA from human lung tissue. Figure 5.10a represents the ethidium bromide
stained agarose gel with the PCR products. The template DNA used in the
polymerase chain reactions were as follows. lane 1 PCR mix alone, lane 2 human
placental genomic DNA, lanes 3-17 genomic DNA from frozen human lung tissue.
Lanes 18, 20, 22 empty, lane 19 lkB DNA ladder, lanes 21, 23 and 24 increasing
concentrations ofG293 template DNA.
Figure 5.10b is the autoradiograph of the transferred PCR products of the gel in a
above probed with E1A DNA. In this case the positive controls have been cut from
the membrane and have been hybridised separately.
? ?
-486 bp
5.3.8 Diluting G293 genomic DNA in human lung genomic DNA
To test if it was easy to contaminate human lung genomic DNA with G293 genomic
DNA, and also to assess whether contamination produced a single clean band on
ethidium bromide stained agarose gel electrophoresis, G293 genomic DNA was
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diluted in human lung genomic DNA and PCR amplification performed. The agarose
gel is shown in figure 5.10, and dilution of G293 genomic DNA in water up to
0.0002 pg/pl gave a single clean band. No single clean bands were obtained when
G293 genomic DNA was diluted in human lung genomic DNA, however smears and
two bands were seen using a concentration up to 20pg/pl, figure 5.12. Dilutions
below this concentration failed to show any bands.
1Kb DNA G293 water y 2 0.2 0.02y y 2 0 2 0.02 j lkb DNA
ladder (negative) Y Y ladder
(0.02gg/gl) ng/u| water pg/fo.1 water
Figure 5.11 An ethidium bromide stained agarose gel with the PCR products from a
PCR using various concentrations ofG293 dissolved in water, in the PCR mix and
486 bp primers. A faint band is visible down to a concentration of 0.02ng ofG293
genomic DNA/pi.
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1Kb DNA 0.02pg water 2 0.2 0.02 2 0.2 0.02 0.002
ladder G293/pl (nesative) V y J v ^ J
ng G293/pl human pg G293/pl human
lung DNA lung DNA
Figure 5.12 shows an agarose gel in which PCR products from a PCR reaction using
486 bp primers and using reducing concentrations ofG293 genomic DNA diluted in
human lung genomic DNA from lung sample 101 in the PCR mix. With reducing
concentrations smears ofDNA are no longer present. Of note, however is the fact
that single clean bands are never produced when G293 genomic DNA is diluted in
human lung DNA and used in the PCR.
G293 genomic DNA that is diluted in water and then used in the PCR reaction
produces a single clean band in the expected area, however G293 genomic DNA that
is diluted in lung genomic DNA and then used in the PCR reaction produces a smear
and several faint multiple bands, none of which correspond to the expected 486 bp
area.
182
5.3.9 Immuohistochemical Staining for E1A protein in human lung tissue
The PCR work for ElA had been complicated by contamination problems and we
were unable to confirm the presence of El A DNA sequences in human lung by this
method and so immunohistochemistry for ElA was carried out. Forty three patients
were included in the final analysis. The characteristics of the fourty three patients are
shown in table 5.5.
Smokers
Never Smokers Normal Lung COPD Severe COPD
Function
n=4 n=18 n=13 n=8
Age years(range) 55.5 (21-70)
Male:female 0:4


































Data expressed as mean ± SD
Table 5.5 Characteristics ofpatients
Only one section was positive for El A by immunostaining. This positive section was
from an exsmoker, with no airflow obstruction.
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5.4 Discussion Early One Adenoviral Protein (E1A)
It is well described that smokers develop lung inflammation (Neiwoehner et al.,
1974). However the mechanism of the enhanced inflammatory response in the lungs
of susceptible smokers who develop COPD is unknown. It has been postulated that
the persistence of the adenoviral genome even without viral replication (latent
infection), and the subsequent expression of the protein ElA in lung cells renders the
cells susceptible to the effects of cigarette smoke (Matsuse et al., 1992; Hogg, 2001).
After human adenoviral infection, expression of part of the adenoviral genome can
take place, and such expression occurs first with the Early Region 1 A, and this is a
crucial step for the integration of the adeno viral DNA into the human genome.
ElA protein has been implicated in enhancing lung inflammation by virtue of its
inhibitory effect on the TGF-p signalling pathway (Tarakanova and Wold, 2003),
modulation of inflammatory mediators including ICAM-1 and IL-8 (Keicho et al.,
1997; Higashimoto et al., 1999, Gilmour et al., 2001; Keicho et al., 1997), its ability
to subvert cellular processes by displacing cellular transcription factors from CBP
and related p300 proteins (O'Connnor et al., 1999; Lundblad et al., 1995; Arany et
al., 1995) and the subsequent over expression of host inflammatory genes. El A also
exerts oncogene effects by the binding and inactivation of tumour supressor gene
product Rb (Whyte et al., 1988).
The presence of ElA has been demonstrated in human lung tissue using PCR
(Kuwano et al., 1997; Vitalis et al., 1998), and its presence has been associated with
the development of COPD in a Canadian population of patients undergoing lung
resection. The aim of this part of the thesis was to assess for the presence of ElA
DNA sequences in lung tissue, and ElA viral protein expression by immuno
histochemistry in another population.
We found that in our patient population (in work carried out in UK), standard PCR
using lung genomic DNA as template DNA produced smears and multiple bands,
and Southern hybridisation failed to demonstrate the presence of ElA DNA
sequences in human lung tissue. The use of lung tissue genomic DNA as template
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DNA for the PCR for GAPDH demonstrated bands and similarly the Southern
showed good signals for all the samples examined. Using nested PCR, bands
suggestive of El A were demonstrated on one occasion, but this could not be
repeated. PCR performed in Vancouver for El A produced multiple bands and
Southern hybridisation demonstrated signals suggestive of positive ElA DNA
sequences, however there were problems with the negative samples also showing
these signals on Southern, suggesting contamination had occurred in the
experiments.
It is likely that GAPDH primers worked well because greater copy numbers of the
GAPDH nucleic acid sequence were present, unlike El A in which the copy number
is likely to be low. It is surprising that single bands were not obtained using the 486
and 675 bp primers as Matsuse and Vitalis (Matsuse et al., 1992; Vitalis et al., 1998)
demonstrated single clean bands in their papers when genomic DNA from human
lung tissue and rats had been used. Our work differed from that of Vitalis as we
extracted genomic DNA from fresh frozen tissue and the Vitalis group extracted the
DNA from paraffin embedded sections and lung tissue that had been inflated with
Optimal cutting agent (OCT).
On one occasion, using the technique of nested PCR, a single band corresponding to
the expected band was found in a lung sample from a patient with small cell lung
carcinoma. Despite repeated attempts we failed to demonstrate this again, and
following on from this initial positive there were problems with contamination as
various lung samples and negative controls were intermittently positive. However
once these contamination problems were rectified, then no further lung tissue
genomic DNA samples were found to be positive for ElA. Kuwano (Kuwano et al.,
1997) who used the same nested PCR primers, examined lung tissue from patients
with lung cancer and reported 30% of those with small cell lung cancer had ElA but
was unable to detect ElA sequences in the non small cell group. Again our work
differed from that of Kuwano (Kuwano et al., 1997) who extracted DNA from
paraffin embedded samples where as we used frozen lung tissue for the extraction.
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In case there was a problem with my technique, I took 81 human lung samples on dry
ice to the laboratory in Vancouver and carried out genomic DNA extractions, PCR,
and Southern hybridisation under the supervision ofDr Hayashi and Ted Sedgewick.
Genomic DNA from the Graham 293 cell line was used as the positive control, and
there were two positive controls run on each gel consisting of G293 diluted in water,
and also G293 diluted in human placental DNA. Once again no single bands were
found on electrophoresis of the PCR products from human lungs. Southern
hybridisation of the PCR products with the ElA probe did yield positives, however
the results from the duplicate samples were not always consistent. Also, one of each
of the duplicate PCR products' negative controls (human placental DNA) was
positive on Southern hybridisation. This suggests that there was a contamination
problem and the likely source was the placental DNA or the extraction process rather
than the PCR mix, as the negative that consisted of water was consistently negative.
In Matsuse's original report clear bands were demonstrated on electrophoresis of the
PCR products from human lung (Matsuse et al., 1992), however as stated earlier we
were unable to show clear bands. Also Matsuse did not use human placental DNA in
which to dilute the G293 genomic DNA positives in. The human placental DNA had
been stored in the -80° C freezer in Vancouver. Another possibility is that human
placental DNA contains ElA. It is possible that the lack of consistency with regard to
positive signals on Southern hybridisation results from the low copy number of the
ElA virus.
Due to the ubiquitous nature of the adenovirus, contamination is a well described
problem with this type of work. In fact Fernandez-Soria had to discard tissue from
sixty out of a total of ninety lymphoma samples being examined for ElA as there
was a contamination problem (Fernandez-Soria et al., 2002). Extractions, PCR and
Southern were performed on the bench top in the ELEGI laboratory, but this
laboratory had not previously been involved in ElA work. In Canada even though
we tried to minimise the risk of contamination by performing the DNA extractions
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and the running of the agarose gels in different laboratories, our results suggested
that there was a contamination problem.
Contamination is a well described problem in PCR work, and sources of
contamination within the laboratory include the PCR product and the target template.
To minimise contamination then pre and post PCR events should be performed in
separate laboratory areas using separate equipment. As stated previously the pre and
post PCR work performed in Vancouver was performed in separate laboratories,
although this was not the case in Scotland. The generation of aerosols of PCR
amplicons can be minimised by the use of barrier tipped pipettes. Barrier tipped
pipettes were not used routinely used for the PCR work performed in Edinburgh.
Chemical methods such as UV photolinking can be used on the PCR equipment to
inactivate amplicons by virtue of the pyrimidines on DNA strands being cross linked
by UV light at 254 nm. We did not use this technique in the laboratory in Vancouver.
Real time PCR systems can provide direct measurement of amplicon accumulation
during the reaction without the need to handle the sample/open the sealed tubes, and
this method would have been a good way to minimise contamination.
Contamination is one explanation as to why the PCR and Southern experiments
performed in the laboratory in Scotland failed to yield positives, where as those
performed in Vancouver did. However it could be argued that the smaller number of
genomic lung DNA samples used in Scotland (20 compared to 81) were truly
negative and that if a larger sample had been used, then positives would have been
identified. This seems unlikely as 10 samples were common to both sets of
experiments.
We were given a sample of lung genomic DNA that had been found to be positive on
PCR testing in Vancouver, however when this was included in a PCR in Scotland, no
positive bands were identified either on the agarose gel or by Southern hybridisation.
It is possible that a low copy number DNA may not be present in every aliquot of
genomic DNA sampled and this may explain the inconsistency in the results.
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It is possible that the probe used in the ElA Southern hybridisation was not detecting
the E1A DNA sequence. This seems unlikely as the positive controls for E1A (G293
cells) were always positive. We did see faint signals in the DNA ladder when the
Southerns were performed in the UK, although this was not found in the Southerns in
Vancouver.
To confirm that contamination from the G293 positive was possible, serial dilutions
of G293 genomic DNA in water, and also serial dilutions of G293 genomic DNA in
the genomic DNA from human lung sample 101 were performed. This showed that
concentrations below 0.0002 pg/pl in water failed to give a band and that G293
genomic DNA diluted in the genomic DNA from human lung sample 101 gave
smears and two bands up to G293 concentration of 20pg/pl. These PCR gels were
not transferred or probed using the El A probe. These findings suggest that human
lung genomic DNA interferes with the amplification process for 675bp and 486bp
primers, as a single band is repeatedly found when G293 genomic DNA is diluted in
water, but not when it is dissolved in human genomic DNA.
As stated previously the striking feature of all the PCR experiments performed using
lung genomic DNA and the positive controls of G293 dissolved in human placental
DNA was the presence of smears of DNA, without a single clear positive band. One
explanation for this could be failure of the PCR to work. This question could have
been addressed by performing PCR using templates consisting of G293 genomic
DNA alone, G293 genomic DNA diluted in placental DNA, genomic DNA from a
positive lung sample by Southern, and an apparent negative lung sample on
Southern, using PCR mixes with and without primers. If the later three templates all
gave the same appearance (using mixes with and without primers) of smears without
clear single bands then the implication would be that the PCR has not worked.
The fact that G293 genomic DNA can be diluted in lung genomic DNA without the
production of a clean single band on PCR amplification suggests that examination
using PCR products on agarose ethidium bromide gels is not a very sensitive test for
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ElA. The other alternative explanation is that the presence of lung genomic DNA
with G293 genomic DNA adversely affects the PCR reaction.
The probe used for Southern hybridisation was a 756 bp probe and the DNA
sequence being sought was actually smaller than the probe at 486 bp.This
combination is less efficient than using a small probe to seek a larger sequence. Also
a large probe may lead to problems with non-specific binding. It may have been
better to cut the genomic DNA using restriction enzymes and probe the cut fragments
with a new smaller probe. To confirm that the bands noted on the agarose gel after
running the PCR products (for the G293 positive controls), are the ElA sequence of
interest, then the G293 genomic DNA could be cut using restriction enzymes that cut
through the probe sequence, and also cut using restriction enzymes that cut around
the ElA sequence. If the DNA enzyme mix from the restriction enzyme that cuts
through the ElA sequence is run on an agarose gel and produces a band, then this
would suggest that the band seen on the agarose gels is not ElA.
The dot blot technique using genomic DNA and positive controls consisting of
cDNA from ElA transfected cells and genomic DNA from G293 cells, and genomic
DNA from 24 lung samples gave a surprising result in that the only positive was the
cDNA from ElA transfected cells. The G293 genomic DNA was negative, as were
all of the lung genomic DNA samples. This result is surprising as the genomic DNA
from G293 should have been positive on dot blot. The likely explanation for this is
that the probe will bind more easily to single stranded DNA, compared to genomic
DNA. Fernandez-Soria (Fernandez-Soria et al., 2002) also attempted to use dot blot
Southern using genomic DNA from lymphoma tissue samples and they were unable
to detect ElA sequence by this method.
Imuunohistochemistry showed only one lung sample to stain positively for ElA
protein, and this was localised to a macrophage. The positive controls used were cell
lines rather than lung tissue from ElA transfected or adeno viral infected animals. It
is thus possible that the technique was not optimised for lung tissue.
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Our data have merely confirmed the great difficulty in performing experimental work
identifying adenoviral related protein and DNA as contamination in the laboratory is
an enormous problem. Although we have been unable to confirm the presence of
ElA by PCR in a Scottish population, there is supporting in-vitro data to suggest that
the presence ofEl A leads to increased inflammation (Keicho et al., 1997, Gilmour et
al., 2001). Animal models have also been used to mimic the ElA situation within the
lung (Vitalis et al., 1996; Vitalis et al., 1998; Yang et al., 2002). However, in vitro
work using El A transfected cell models have high copy numbers of EIA gene and
protein, and although they provide an insight into how the inflammatory process may
be altered in the presence of ElA, it is difficult to extrapolate this to the human lung
where it is postulated that there is a low copy number.
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Summary and future studies
The aims of this thesis were to investigate in vivo the protective glutathione
antioxidant system and measure local and systemic oxidative stress in the lungs of
smokers with airflow obstruction. The DNA binding of the redox sensitive
transcription factors AP-1 and NF-kB was also measured, and human lung was
assessed for the presence ofEl A protein.
Glutathione synthesis has been shown to be sensitive to cigarette smoke in vitro and
this may be important in the human lung with regard to the development of smoking
related chronic obstructive pulmonary disease. Alterations in the glutathione enzyme
system may render the lungs more susceptible to the effects of oxidants, with
resultant inflammation and damage to airways. The present study has shown that the
level of total glutathione is the same in the lungs of patients with severe airflow
obstruction and those with no airflow obstruction. However, the activity of y-GCS
(GCL), the rate limiting enzyme in the synthesis of glutathione was found to
correlate with lung function, and we found that the activity of y-GCS (GCL) is
significantly lower in the lungs of smokers with airflow obstruction and those with
severe emphysema who have undergone lung volume reduction surgery, compared to
those with normal lung function.
Cells expressing y-GCS-HS were identified using in situ hybridisation, and the
predominant cell types that expressed y-GCS-HS in the lung were epithelial cells,
including bronchial, type I and II alveolar cells, irrespective of the presence of
airflow obstruction.
The finding in our study that y-GCS activity is reduced in the lungs of subjects with
severe airflow obstruction was unexpected, and given that there was no difference in
total GSH in the groups with and without airflow obstruction, suggests that there
may be post translational modification of y-GCS. However before exploring post
translational modification of y-GCS, the measurement of GSH and y-GCS activity
within lung homogenate should be repeated to confirm this finding. Multiple areas of
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the lung should also be included to ensure that the y-GCS activity data was not a
spurious finding. Also the measurement of GSH related enzyme levels and y-GCS
(GCL) message in primary culture of epithelial cells obtained from the different
subject groups, including a group with potentially early disease would help clarify if
the alveolar epithelial cell is a source of altered GSH homeostasis.
In the studies presented here, the emphasis and grouping of patients has been on the
basis of the presence/degree of airflow obstruction. This may not have been ideal as
cigarette smoking is the major risk factor for the development of COPD. In future
studies it would be better to group subjects in terms of smoking history and airflow
obstruction, such as smokers with and without airflow obstruction, non smokers, and
ex-smokers with and without airflow obstruction. Grouping in this way will produce
better characterised and more specific groups. In future work a detailed drug history
including oral theophyllines and oral corticosteroids should be obtained as drugs
such as these can affect histone acetylation. Lung tissue sampling needs to be more
homogeneous across the subject groups, rather than using a non-specified area that
was dependent on the pathologist. Similarly sampling from more than one area of the
lung is needed to ensure that the results obtained are not just a reflection of the area
of the lung sampled. A weakness of my studies has been the lack of any true
'normal' lung tissue, and the use of an animal model would allow the examination of
the mechanisms of lung inflammation in normal and damaged lung tissue. Future
studies would require a power calculation and determination of sample size, and the
data presented in this thesis could be used to help determine the power of any future
studies.
My work has examined total NF-kB DNA binding in lung tissue and has shown that
the DNA binding of NF-kB in human lung tissue is inversely correlated with the
degree of airflow obstruction, and the subunits p65 and p50 were identified using
Supershift. No such correlation with lung function was found for AP-1 DNA
binding. The DNA binding of NF-kB to specific genes/promoters, and examination
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of these processes in specific cell types was not performed in my studies. Primary
cell culture to isolate macrophages and type I and II bronchial epithelial cells from
lung tissue from well characterised patients would allow DNA binding of NF-kB to
be examined in a broad array of cells to determine ifmore subtle changes are present
in individual cells.
The mode of activation of NF-kB in human lung needs to be characterised further.
The investigation of pathways other than the IkB dependent NF-kB activation should
be undertaken as these may be important in smoking related lung inflammation.
Activation of the p38 MAPK pathway in-vitro by oxidative stress leads to activation
ofNF-kB. Using the techniques ofWestern blotting, levels of IkB and p38 could be
measured in lung tissue. This work could be expanded to determine if there are cell
specific differences in the p38 and IkB pathways of NF-kB activation by the use of
immunohistochemistry.
Histone acetylation and deacetylation are important in allowing access of genes to
the transcription machinery and subsequent gene transcription and repression.
Understanding the role of these processes in lung inflammation is critical. Certainly
recent work performed in the ELEGI laboratory has attempted to clarify histone
acetylation and deacetylation in smokers with COPD, with the findings that there
was decreased IkB-a levels in healthy smokers and current and ex smokers with
COPD compared with non smokers, and that an increase in acetylated H4 was found
in current smokers. Future work should include a group of healthy exsmokers, ie
patients without evidence of airflow obstruction as this group may show the presence
of a protective mechanism that prevents the development of symptomatic COPD.
The use of an animal model may provide further insight into the mechanism of
inflammation and GSH regulation in the lung, as the molecular assessment of human
lung tissues obtained at surgery is limited by the presence of only a single time point.
In smoking related lung disease, examination of a single time point may not be
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relevant as the disease often follows a long and initially clinically asymptomatic
course.
The three major model types used to investigate COPD include an inhalation model
(of noxious stimuli), a model based on the intracheal instillation of tissue degrading
enzymes to induce emphysema like lesions within the lung, and gene targeting
approaches which employ gene modifying techniques such as gene depletion and
over-expression. There are limitations to animal models as such models do not
necessarily mimic the entire COPD phenotype, or the different disease stages found
in COPD, and the systemic effects of COPD are difficult to replicate in animal
models. Most animal models tend to have the morphological features of COPD, but
are lacking in the mucus hyper-secretion element of COPD disease. Also in the case
ofNF-kB it is recognised that there are both cell specific and species specific effects.
In animal models it can be difficult to reproduce the small airways pathology present
in COPD. It can also be difficult to obtain measurements of lung function in small
animals such as mice. Ex-vivo precision cut lung slices combined with
videomorphometry can be used in animal models re lung function assessment. The
advantages of an animal model system include an abundant source of material,
repeatability of the work, and experiments are not restricted to a single time point.
Lung inflammation is the result of increased pro-inflammatory mediators and
cytokine production, and NF-kB regulates the expression ofmany pro-inflammatory
cyokines and adhesion molecules, including IL-8 and IL-ip. Similarly the promoters
ofmany inflammatory response genes have AP-1 binding sites. The DNA binding of
the transcription factor NF-kB in human lung tissue was found to inversely correlate
with the degree of airflow obstruction, and the subunits p65 and p50 were identified
using Supershift. No such correlation with lung function was found for AP-1 DNA
binding. Identification of AP-1 subunits using Supershift and antibodies to c-jun and
c-fos failed, however a band suggestive of c-jun was identified by Western blotting.
Further work is required to identify if the negative correlation of NF-kB DNA
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binding with lung function is present in all areas of the lung and whether a particular
cell or group of cells is responsible for this finding in lung tissue homogenate. There
is also evidence to suggest that expression of jun and fos proteins is dependent on the
cell type and the presence or absence of malignant transformation, and extending this
work to include other AP-1 subunits would be useful.
Systemic and local oxidative stress as measured by trolox equivalent antioxidant
capacity and lung MDA, were not related to lung function. The lipid peroxidation
product 4-hydroxy-2-nonenal was identified in human lung using
immunohistochemistry, with increased 4-HNE staining scores in bronchial epithelial
cells, macrophages and neutrophils in lung tissue obtained from smokers with severe
airflow obstruction compared to those with no airflow obstruction. The use of
Western blotting to identify 4-HNE protein adducts yielded protein bands, however
we were unable to confirm if these bands represented 4-HNE protein adducts. The
antibody used in this work recognised cystine, histidine and lysine 4-HNE adducts,
and a different antibody may yield better results. Future work to identify the protein
bands identified by Western should be undertaken. This could be achieved by using a
two dimensional gel system electrophoresis to resolve the proteins, followed by a
tryptic digest or high pressure liquid chromatography, and then the use of mass
spectrometry to determine the amino acid sequence.
Susceptibility to the effects of cigarette smoke is central to understanding the
pathogenesis of COPD. In vitro there is a heightened inflammatory response in ElA
transfected cells in response to inflammatory stimuli. Amplification of genomic
DNA using polymerase chain reaction and Southern blotting was used to identify
early one adenoviral protein in the lung. Work carried out in Scotland failed to
identify E1A in human lung tissue. Using similar techniques in Vancouver, bands
suggestive of ElA were identified on Southern, however the negative controls also
showed bands suggesting contamination had occurred.
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COPD is asymptomatic in the early stages of the disease, and study of the initial
disease process in vivo is very difficult. Whole lung tissue contains multiple cell
types, and potential significant results in individual cell types may be masked in
whole lung tissue. In addition some of the techniques used in this thesis may require
refining.
In conclusion the work presented in this thesis has examined in vivo glutathione and
y-GCS, NF-kB and AP-1 transcription factor binding, systemic and local oxidative
stress and the relationship with airflow obstruction, and assessed for the presence of
EIA. The activity of y-GCS is reduced in the lung tissue of patients with airflow
obstruction compared to those with no airflow obstruction.
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